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Abstract 
The primary aim of this study was to investigate the potential of an aroA mutant 
of Pasteurella multocida B:2 (vaccine strain JRMT12) as a candidate for DNA 
vaccine delivery (bactofection). First, the invasive property of the vaccine strain 
was assessed for its interaction with different mammalian cell lines. Next, a 
eukaryotic expression plasmid that could be maintained in Pasteurella was 
modified to contain a prokaryotic reporter gene to help in determining the 
location and viability of the bacteria when moving from the extracellular 
environment into the intracellular compartment of the mammalian cells. This 
plasmid was further developed to function with a dual prokaryotic and 
eukaryotic reporter system in order to demonstrate expression of the plasmid 
DNA in the mammalian cells. 
During interaction of strain JRMT12 with mammalian cell lines, the ability of the 
bacterium to adhere, invade and survive intracellularly was monitored and 
assessed. Three mammalian cell lines were used: a mouse macrophage-like cell 
line, J774.2; a bovine-lymphoma cell line, BL-3; and an embryonic bovine lung 
cell line, EBL. The JRMT12 strain was compared with strains of the wild-type P. 
multocida B:2 (85020), bovine P. multocida A:3, Mannheimia haemolytica A:1 
and Escherichia coli XL-1 BLUE. Both P. multocida B:2 strains were capable of 
adhering to and invading J774.2, BL-3 and EBL cells. All of the Pasteurella and 
Mannheimia strains tested were able to adhere to EBL cells but only B:2 strains 
were taken up intracellularly in significant numbers. The vaccine strain, JRMT12 
was found to survive intracellularly in EBL cells for at least 7 h although a steady 
decline in the number of viable intracellular bacteria was noted with time. In an 
invasion inhibition assay, the use of the microfilament formation inhibitor 
cytochalasin D suggested that the entry into mammalian cells was by an actin-
dependent process. Cell viability assessment by trypan blue staining indicated 
that none of the bacterial strains was toxic for the mammalian cells. Upon entry 
into the mammalian cells the JRMT12 strain resided in a vacuolar compartment, 
as demonstrated by transmission electron microscopy. However, P. multocida 
A:3 and M. haemolytica A:1 were only found loosely adhering to the cell surface 
of EBL cells and were not detected intracellularly. Further morphological 
assessment by TEM showed that only a low percentage of mammalian cells 
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appeared to contain one or more JRMT12, suggesting that only certain cells in 
the population were capable of being invaded by, or taking up, the bacteria. 
Attempts were made to construct a Pasteurella eukaryotic expression plasmid 
using a gene sequence from the Pasteurella shuttle plasmid pAKA16, developed 
previously in this laboratory, and the commercial eukaryotic expression plasmid 
pCMV-sCRIPT, but these were only partially successful. The origin of replication 
gene (oriP) in the Pasteurella shuttle plasmid was isolated and sequenced. 
Analysis of oriP showed sequence similarity with the known origins of replication 
in other Pasteurella plasmids. The E. coli plasmid origin of replication (oriE) was 
removed from pCMV-sCRIPT and the oriP gene was ligated into the oriE-free 
pCMV-sCRIPT but attempts to transform the resulting plasmid into P. multocida 
B:2 were not successful. An alternative approach to plasmid development was 
made using another commercial eukaryotic expression vector, pEGFP-N1. This 
plasmid has the same properties as pCMV-sCRIPT but has an additional, 
fluorescent reporter gene under the control of a eukaryotic promoter. It was 
found to be able to replicate in P. multocida B:2 but positive transformants were 
only recovered after prolonged incubation after electroporation. The plasmid 
was stably maintained in strain JRMT12 for at least 14 days with or without 
antibiotic selection. It was also successfully transfected into EBL cells, as shown 
by expression of green fluorescent protein (GFP) in individual cells. The P. 
multocida vaccine strain JRMT12 was also able to deliver the plasmid into EBL 
cells, although the number of EBL cells expressing GFP after bacterial delivery 
was lower than by direct transfection of the plasmid. 
Next, plasmid pMK-Express, a Pasteurellaceae prokaryotic expression vector with 
a gfp reporter gene, was used. When this was electroporated into the vaccine 
strain, the strain was shown to express GFP maximally as measured by 
fluorimetry, during the early exponential phase of bacterial growth. The 
DsRed.M1 gene coding for red fluorescent protein (RFP) from plasmid pDsRed-
Monomer was then used to replace the gfp gene in pMK-Express to make the 
construct pMK-RED. After electroporation of pMK-RED into the JRMT12, RFP 
expression was detected maximally during the early exponential phase of 
bacterial growth. The same strain expressing RFP could also be detected in the 
intracellular compartment of the EBL cells by fluorescence microscopy at 3 h 
post-invasion. 
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Finally, plasmid pSRG, our so-called “traffic light” plasmid with a dual reporter 
system was constructed. This was made from plasmid pEGFP-N1 (with its existing 
eukaryotic expression system for GFP expression) and the sodRED fragment (with 
a Pasteurella promoter controlling the DsRED.M1 gene for RFP expression) 
isolated from plasmid pMK-RED. This plasmid was stable in strain JRMT12 with or 
without antibiotic selection for 14 passages. RFP expression from JRMT12 was 
detected maximally during the early exponential phase of bacterial growth. 
Transfection of pSRG into EBL cells gave individual cells expressing GFP. Invasion 
assays with EBL cells and P. multocida B:2 JRMT12 pSRG+ showed that RFP-
expressing bacteria could be detected intracellularly at 3 h post-invasion. At this 
stage, some EBL cells harbouring RFP-expressing bacteria were observed to 
express GFP simultaneously. At 5 h post-invasion, some of the EBL cells were still 
harbouring RFP-expressing bacteria and at the same time expressing GFP 
themselves. Concurrently, some Pasteurella free-EBL cells were shown to 
express GFP. These experiments proved the functionality of the pSRG dual 
reporter system and the potential of P. multocida B:2 JRMT12 for bactofection 
and delivery of a DNA vaccine. 
An apparent immunosuppressive effect of P. multocida B:2 on the proliferative 
response to concanavalin A (ConA) of peripheral blood mononuclear cells (PBMC) 
had been reported by Ataei (2007). The PBMC had been taken from calves 
infected with P. multocida B:2 or from normal calves and treated in vitro with 
extracts of P. multocida B:2. In the present study, in vitro assays with PBMC 
from normal calves were undertaken in an attempt to confirm these findings. A 
cell-free extract (CFE) of the vaccine strain JRMT12 was found to suppress the 
subsequent proliferation of PBMC in response to ConA in a dose-dependent 
manner. However, the results were not consistently reproducible and the same 
effect could not be demonstrated with CFE from the wild-type strain 85020. 
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1.0 INTRODUCTION 
 1.1 History and taxonomy of the family Pasteurellaceae 
Members of the bacterial family Pasteurellaceae are small (0.2-2.0 µm), Gram-
negative, chemoorganotrophic, non-motile, facultatively anaerobic coccobacilli 
or rods. Organisms belonging to the Pasteurellaceae can colonize mucosal 
surfaces of the respiratory, alimentary and genital tracts and cause diseases in 
different mammals, birds and reptiles (Jacques & Mikael, 2002). For years it was 
believed that the family consisted only of three genera: Pasteurella described by 
Trevisan in 1887, Actinobaccillus by Brumpt in 1910 and Haemophilus by Winslow 
et al., in 1917, but several other groups of organisms that exhibit complex 
phenotypic and genotypic relationships with these genera were also included 
(Boot & Bisgaard, 1995; De Alwis, 1999). After the designation of the organisms 
Bisgaardia hudsonensis (Foster et al., 2011) into the new genus Bisgaardia in 
2011, Pasteurellaceae now have 16 genera in the family. Other genera are 
Mannheimia (Angen et al., 1999), Gallibacterium (Christensen et al., 2003; 
2004), Actinobacillus (Christensen & Bisgaard, 2006), Volucribacter (Christensen 
et al., 2004b), Nicoletella (Kuhnert et al., 2004) Avibacterium (Blackall et al., 
2005), Pasteurella, Haemophilus, Lonepinella, Phocoenobacter, 
Aggregatibacter, Bibersteinia, Basfia, Chelanobacter and Histophilus. The 
Pasteurellaceae family consisted of 62 species. 
1.2 The genus Pasteurella 
The phylogeny of the genus Pasteurella has been investigated by 16S rRNA 
sequence comparison and rRNA-DNA hybridization (De Ley et al., 1990; Dewhirst 
et al., 1992; Dewhirst et al., 1993). The phylogenetic position of members of 
Pasteurella is shown by analysis of the 16S rRNA sequences of well-characterized 
strains. On the basis of this method, Pasteurella includes nine named species (P. 
multocida, P. canis, P. stomatis, P. dagmatis, P. gallinarum, P. avium, P. 
volantium, P. langaa and P. anatis) and two unnamed taxa (Pasteurella species 
A and species B). The type species of the genus P. multocida has been separated 
into three subspecies, P. multocida subsp. multocida, P. multocida subsp. 
gallicida and P. multocida subsp. septica. In addition, the exclusion of seven 
species: [P.] aerogenes, [P.] pneumotropica, [P.] trehalosi, [P.] caballi, [P.] 
  Introduction 
 
2 
mairii, [P.] bettyae and [P.] testudinis from Pasteurella has been suggested. 
However, their names have not been formally changed and the genus name of 
these species is consequently denoted in brackets.  
Pasteurella species exist as normal upper respiratory and gastrointestinal flora 
of dogs, cats, and other domestic and wild animals (Carter, 1967; Jones et al., 
1973; Francis et al., 1975; as cited by De Alwis, 1999). These organisms are 
known to be widespread veterinary pathogens (Hubbert et al., 1970; Jones et 
al., 1973; Furie et al., 1980) and some are being recognized as important human 
zoonotic pathogens (Hubbert et al., 1970; Jones et al., 1973; Johnson et al., 
1977; Furie et al., 1980). Pasteur first isolated the causative agent of fowl 
cholera, P. multocida, in 1880 (Robinson, 1944). Thereafter, bacteria with the 
same growth characteristics were implicated in haemorrhagic septicaemia of 
cattle, in swine plague, and in rabbit septicaemia (Jones et al., 1973). Isolates 
from all sources with common biochemical and morphological features were 
grouped together as ‘‘P. septica’’ in 1929 and P. multocida in 1939 (Weber, 
1984). The organisms do not grow on MacConkey’s agar and they are non-
haemolytic on blood agar. On nutrient agar they produce fine, translucent 
colonies with a characteristic musty odour.  
1.3 Pasteurella multocida 
1.3.1 The organism 
Members of the bacterial genus Pasteurella usually are regarded as 
opportunistic, secondary invaders in vertebrates. P. multocida is the only 
representative of the genus regarded as a major pathogen, causing a clinical 
disease called pasteurellosis. It has been recognized as an important veterinary 
pathogen for over a century, and its importance as a human pathogen has been 
increasingly recognized in the last 50 years. The organism can occur as a 
commensal in the naso-pharyngeal region of apparently healthy animals and it 
can act as a primary or secondary pathogen in disease processes of a variety of 
domestic and feral mammals and birds (section 1.3.3). 
The name ‘multocida’ originated from the words multus; (many) and cida: 
(killing) which means “many killing” (Carter, 1984). According to Rimler and 
Rhodes (1989), the organism was first isolated in 1879 by Toussiant. It had many 
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names (according to Frederiksen, 1989), beginning with Micrococcus gallicidus, 
which was given by Burril in 1883, Bacterium multocidum (Lehmann and 
Neumann, 1899) and in 1925 Buchanan suggested Pasteurella gallicida. However 
after several disagreements, the name Pasteurella multocida was finally 
proposed by Rosenbusch and Merchant (1939) and is now widely used. 
1.3.1.1 Cell morphology and staining 
Pasteurella multocida is a non-motile, non-spore forming, coccobacillus or short 
rod of 0.2-0.4 by 0.6-2.5 µm in size. The coccobacillus occurs either singly or in 
pairs and occasionally as chains or filaments. It is a Gram-negative organism and, 
as quoted by Adamson (1993), in tissue exudates and in recently isolated 
cultures will show bipolar staining with Giemsa or Wright’s stain.  
1.3.1.2 Colonial morphology 
Isolates of P. multocida from the respiratory tract of ruminants, pigs and rabbits 
may form large, watery, mucoid colonies, which may collapse after 48 hours of 
incubation. Rough colonies of P. multocida are formed from filamentous, non-
capsulated cells (Rimler and Rhoades, 1989). Growth in broth usually causes 
turbidity, but granular growth may occur (Mutters et al., 1985). 
1.3.1.3 Biochemical properties 
P. multocida organisms are oxidase, catalase and indole positive. They ferment 
sugars such as glucose, sucrose, sorbitol and mannitol with acid, but with no gas 
production. Lactose, maltose and salicin are not fermented, while variable 
fermentation results are obtained with arabinose, trehalose and xylose. Gelatin 
is not liquefied (Holt, 1994). 
1.3.2 Typing 
Typing methods are used for detailed characterization to investigate the 
diversity of taxa of Pasteurella and for the study of pathogenicity and 
epidemiology. 
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1.3.2.1 Serotyping 
Serotype designations of the P. multocida strains are based on capsular antigen-
somatic antigen combinations (capsular antigens A to F and somatic antigens 1 to 
16). Using a serotype designations system which is a combination of Carter 
(1955) capsular typing and Heddleston (1972) somatic typing, the Asian and 
African serotypes causing haemorrhagic septicaemia are designated B:2 and E:2 
respectively. 
1.3.2.2 Advanced typing methods 
1.3.2.2.1 Identification by PCR 
P. multocida can be detected at the species level by a PCR targeting the rrl 
gene that codes for 23S rRNA. This PCR assay correctly identified all 144 isolates 
of P. multocida tested, including type strains of the three subspecies as well as 
the reference strains for the Heddleston and Carter typing schemes (Miflin & 
Blackall, 2001). In addition, the bacteria can also be detected using two sets of 
primers designed from P. multocida 6B; KTT72, KTSP61 and KMT1T7, KMT1SP6 
(Townsend et al., 1998). The first set of primers specifically amplified a DNA 
fragment from types B:2, B:5, and B:2,5 P. multocida and the second set of 
primers produced an amplification product unique to all P. multocida isolates. 
When PCR amplification was performed directly on bacterial colonies or 
cultures, it proved to be a rapid and sensitive method of P. multocida 
identification. Another PCR described by Kasten et al. (1997) was based on the 
gene for an outer-membrane protein known as the P6-like (PSL) protein (Kasten 
et al., 1995) which shares significant similarities with the P6 protein of 
Haemophilus influenzae. The PSL P.multocida PCR has been shown to detect 
each reference strain of the 16 Heddleston somatic serovars, one field isolate of 
P. multocida and one live vaccine strain (Kasten et al., 1997). 
1.3.2.2.2 In situ hybridization 
An in situ hybridization test for P. multocida has been developed based on the 
recognition of a specific part of the 16S rRNA sequence and the presence of P. 
multocida was detected in sections of infected chicken and pig lungs (Mbuthia et 
al., 2001). The test was recommended for verification of pure cultures of P. 
multocida on smears as well as for histopathological detection of P. multocida 
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within infected tissues. Similar to the PCR tests described for P. multocida, the 
in situ hybridization test also detects biovar 2 strains of P. avium and P. canis, 
which are routinely misclassified and should be reclassified with P. multocida 
(Christensen et al., 2002). 
Other advanced typing methods have also been developed for identification of P. 
multocida. Restriction endonuclease analysis (REA) was used in epidemiological 
studies of porcine pasteurellosis and fowl cholera caused by P. multocida 
(Christensen et al., 1998; Blackall et al., 2000). The high genotypic resolution of 
random amplified polymorphic DNA (RAPD) represents the method of choice for 
fast screening of many isolates (Christensen & Bisgaard, 2006). Additionally, 
Gunawardana et al. (2000) has used Pulsed-Field Gel Electrophoresis (PFGE) to 
differentiate between P. multocida isolates from different outbreaks and thus 
produced another method that has been of great value for typing of P. 
multocida. Amplified Fragment Length Polymorphism (AFLP) has also been used 
to characterize the molecular epidemiology of avian isolates of P. multocida 
involved in fowl cholera (Amonsin et al., 2002). 
Briefly, as concluded by Christensen et al. (2006), identification and typing of P. 
multocida has been dominated by molecular-based techniques. The PCR-based 
tests are used for species identification and also for PCR- based ‘serotyping’ 
which are both capable of detecting the presence of the organism. REA, PFGE 
and other techniques have been refined to discriminate between closely-related 
isolates.  
1.3.3 Diseases causes by P. multocida B:2 and other serotypes 
The numerous serotypes of P. multocida are associated with a variety of disease 
syndromes in a wide range of agricultural, domestic and feral animal species (De 
Alwis, 1992). In many occurrences, Pasteurella plays a secondary role in the 
pathogenesis of the disease or acts in combination with other agents. 
Pasteurella multocida serotypes B:2 and E:2 are associated with haemorrhagic 
septicaemia of cattle, water buffaloes, and occasionally other species, resulting 
in major economic losses, mainly in South East Asia (Carter and De Alwis, 1989; 
De Alwis, 1995). Capsule type A, serotypes 1, 3 and 4, are recognized as the 
primary cause of fowl cholera in poultry and wild birds (Rhodes and Rimler, 
1989; Christensen & Bisgaard, 1997). Fowl cholera may appear as an acute 
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septicaemia characterized by disseminated intravascular coagulation, petecchial 
or ecchymotic haemorrhages, multifocal necroses and fibrinous pneumonia. 
Chronic infections may involve a variety of types and local infections 
(Christensen & Bisgaard, 1997). Respiratory diseases in cattle, including 
bronchopneumonia in feedlot cattle and enzootic pneumonia of calves less than 
6 months old, are mainly associated with capsule type A (Frank, 1989). 
Outbreaks of septicaemia in fallow deer have also been reported (Eriksen et al., 
1999). Infections of major economic importance in pigs include atrophic rhinitis 
and bronchopneumonia (Chanter and Rutter, 1989; Gardner et al., 1994; Nagai 
et al., 1994). Severe cases of atrophic rhinitis are mainly associated with capsule 
type D. Pulmonary lesions may result in blood-borne dissemination to the 
kidneys in pigs (Buttenschøn and Rosendal, 1990). P. multocida D was also 
proposed to be associated with porcine dermatitis and nephropathy syndrome 
(Lainson et al., 2002). Atrophic rhinitis caused by P. multocida A:12, A:3 and 
other A and D serotypes has also been reported in goats and rabbits (Baalsrud, 
1987; DiGiacomo et al., 1989). In addition to major diseases in production 
animals, P. multocida has been recovered from a wide range of sporadic 
infections in many other species, including laboratory animals (Manning et al., 
1989), dogs and cats (Mohan et al., 1997) and other mammals (DiGiacomo et al., 
1989). 
1.3.4 Virulence factors 
Several factors that may be important for the virulence of P. multocida are 
lipopolysaccharide (LPS) (Rimler et al., 1984), capsule (Tsuji et al., 1989), 
outer-membrane proteins, fimbriae (Glorioso et al., 1982), invasins and 
adhesins, toxins, plasmids and resistance to complement-mediated bacteriolysis. 
Many studies have been undertaken to determine the properties of each 
virulence factor and to investigate the correlation between antibiotic resistance 
profiles (Hirsh et al., 1989; 1985), virulence attributes (Lee & Wooley, 1995) and 
the presence of plasmids.  
1.3.4.1 Capsule and lipopolysaccharides 
There is general agreement in the literature that the capsule or outer layer of 
the cell is believed to be responsible for the serogroup specificity. It is 
composed of acidic polysaccharides and a variety of proteins. Both LPS and 
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polysaccharides can be adsorbed onto erythrocytes and are believed to play a 
role in passive haemagglutination. It was mentioned that LPS structure 
expressed by P. multocida has two main glycoforms, A and B (Harper et al., 
2011). Both glycoforms share the same outer core structure but differ in their 
inner core. Another study mentioned a low expression of a third LPS glycoform 
termed glycoform C found in the serovar 1 strain (Boyce et al., 2009). The 
structure of glycoform C is similar to the one found in the LPS of Haemophilus 
influenzae and Neisseria meningitidis. It was suggested that the expression of 
glycoform C by these bacteria may allow the bacteria to avoid innate immune 
detection through molecular mimicry of the host carbohydrate (Harper et al., 
2011). In a recent review, it was suggested that LPS is an important virulence 
factor and minor changes in its structure could greatly affect the ability of P. 
multocida to cause disease (Harper et al., 2011).  A mutation in a gene hptD, 
encoding a heptosyltransferase (HptD) on a fowl cholera strain, P. multocida A:1 
showed that this mutant was fully attenuated in chickens. HptD is required for 
the addition of heptose III to the tri-heptose side chain in the LPS inner core 
structures of glycoform A and B (Harper et al., 2003). However, when the 
mutant strain was screened for attenuation in mice, it was not highly 
attenuated, indicating that the role of LPS in disease is host specific (Harper et 
al., 2003). 
The B serotype that causes HS does not possess the capsular hyaluronic acid 
responsible for the mucoid colonial character of the type A strain. The specific 
capsular substances were shown to be polysaccharide in nature by their capacity 
to adsorb to unmodified red blood cells. Knox & Bain (1960) recovered a fraction 
from serotype B:2 which contained protein, some polysaccharide and 
lipopolysaccharide (LPS). Bain & Knox (1961) found that phenol-extracted LPS of 
serotype B:2 yielded galactose, glucose, glucosamine and a heptose sugar. The 
LPS was toxic for rabbits and adsorbable to red blood cells. Rebers et al. (1967) 
isolated a LPS-protein complex from a B:2 strain and found that it had many of 
the properties of an endotoxin. It was immunogenic and immunologically specific 
in mice. The properties of the capsular antigens recovered from B:2 and E:2 
strains by Penn and Nagy (1976) suggested that they were high molecular weight 
acidic polysaccharides. They were immunogenic for cattle but only weakly so for 
rabbits. Nagy and Penn (1974) had previously found that the purified capsular 
  Introduction 
 
8 
antigens, presumably polysaccharides of types B and E HS strains, elicited 
antibodies in cattle that were protective, as tested by challenge. 
1.3.4.2 Outer-membrane proteins 
This group of molecules includes components of importance for virulence, e.g., 
a 37.5-kDa porin of P. multocida affecting bovine neutrophils (Galdiero et al., 
1998). Outer-membrane proteins (OMPs) also include molecules with specific 
antigenic properties. In P. multocida serotype B:2,5, the presence of transferrin-
binding proteins was discovered along with the pathways involved in iron 
regulation which are essential for bacterial growth and replication, as well as for 
establishment and progression of infection. P. multocida serogroup B bovine 
strain has been shown to produce transferrin binding proteins Tbp1 and Tbp2 
(Veken et al., 1994). Many of these OMPs are powerful antigens and some of 
them have been used in protection experiments against bacterial pathogens 
(Ratledge & Dover, 2000). A strain of P. multocida serotype A has been reported 
to excrete a siderophore called multocidin (Hu et al., 1986).  There is also 
agreement in the literature indicating that OMPs of P. multocida B:2 have the 
ability to immunize animals and to resist phagocytosis by murine peritoneal 
macrophages and are important contributors to the pathogenic process (De Alwis 
et al., 1990; Srivastava, 1998; Basagoudanavar et al., 2006). Further findings 
particularly in relation to the generation of immune response in cattle as well as 
in buffaloes reported that Montanide-adjuvanted OMPs derived from P. 
multocida type B grown in either iron-depleted or iron-sufficient medium could 
act as acellular vaccines against HS (Basagoudanavar et al., 2006).   
1.3.4.3 Fimbriae 
Glorioso et al. (1982) demonstrated fimbriae by electron microscopy on rabbit 
type A strains and found that the fimbriae were capable of adhering to rabbit 
pharyngeal cells. In addition, two types of fimbriae were identified on serogroup 
D strains, the first one similar to the type A fimbriae and the second were 
morphologically similar to the type 1 fimbriae of E. coli (Ruffolo et al., 1997). 
Some fimbriae-like filamentous appendages have also been observed on the 
surface of HS-causing P. multocida B:2 (Tomer et al., 2004). Strains belonging to 
other serotypes without fimbriae showed much less adhesive capacity to the 
host cell and suggested that fimbriae were involved in attachment of the 
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bacteria to their respective host. The attachment of P. multocida B:2 to the host 
cell could be inhibited by N-acetyl-D-glucosamine, which may suggest that this 
amino sugar could be the animal cell receptor to which the fimbriae adhere. 
Adhesiveness is reduced following treatment of the organism with pronase, heat 
or homogenisation, all of which would reasonably affect fimbrial function. 
Nevertheless, there is a poor correlation between possession of fimbriae and 
virulence in experimental models of disease. Indeed, toxigenic strains of P. 
multocida may have no detectable fimbriae or flagella and yet can colonize the 
porcine tonsil and respiratory tract both alone or concurrently with 
Streptococcus suis (Ackermann et al., 1991).  
1.3.4.4 Plasmids and transposons 
Various sizes of plasmids between 1.3 and 100 kbp have been found in P. 
multocida from different serotypes (Hunt et al., 2000). These plasmids have 
been found related to resistance to streptomycin, sulfonamides, tetracycline, 
penicillins, kanamycin and chloramphenicol (Rimler & Rhoades, 1989; Hunt et 
al., 2000). The distribution of identical non-conjugative R plasmids of P. 
multocida did not follow the clonal population structure (Ikeda & Hirsh, 1990). 
The only transposable element identified in P. multocida is transposon Tn5706 
(Hunt et al., 2000). 
1.3.4.5 Toxins 
Strains of P. multocida serogroup D, which cause atrophic rhinitis, produce a 
dermonecrotic toxin (PMT, for P. multocida toxin). It is the principle virulence 
factor in atrophic rhinitis and induces localised osteolysis in the nasal turbinates, 
primarily through increased osteoclastic bone resorption (Kock et al., 1995). PMT 
is a potent mitogen and induces many cellular effects especially in the 
rearrangement of the actin cytoskeleton. It shares significant homology with the 
cytotoxic necrotizing factors (CNF1 and CNF2) of E. coli (Pei et al., 2001). The 
homology is highest in an N-terminal region of PMT (residues 250–530). In CNF1, 
this region functions as a translocation-domain (Pei et al., 2001) and is flanked 
by an N-terminal receptor binding domain and a C-terminal catalytic domain 
(Lemichez et al., 1997). Similarly, it has been shown that the receptor binding 
and catalytic domains of PMT are also located at the N- and C-termini, 
respectively, of the toxin (Baldwin et al., 2004). Although toxin-related 
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sequences have occasionally been found in other serotypes, the synthesis of PMT 
is usually restricted to serogroup D. Recombinant toxin derivatives have been 
used as vaccine candidates (Nielsen et al., 1991; Petersen et al., 1991). Vaccine 
components for protection against atrophic rhinitis in pigs were developed by 
deletion mutagenesis of the gene encoding the PMT. Four purified toxin 
derivatives lacking different and widely separated regions in the amino acid 
sequence were characterized by a lack of toxic activity. One such component 
was shown to induce efficient protection of vaccinated female mice and their 
offspring against challenge with purified PMT. 
The toxic effects of P. multocida serotype B:2,5 on macrophages in vitro and in 
vivo have been tested. HS-associated strains of P. multocida are reported to 
reproduce a vacuolating cytotoxin (Shah et al., 1996). Mice were injected 
intraperitoneally with 102 cells of P. multocida B:2,5. Observation of peritoneal 
macrophages with electron microscopy after 6 h revealed strong induction of 
cytoplasmic vacuolation, macrophage lysis and death. When the HS-associated 
strains of P. multocida were then incubated with mouse macrophage cell line 
(RAW 264.7) at a ratio of 10:1 (bacteria:cell), vacuolation of macrophages were 
observed at 30 min post-invasion (Shah et al., 1996).  
1.4 Haemorrhagic septicaemia (HS) 
1.4.1 The disease 
Haemorrhagic septicaemia (HS) is an acute, fatal, septicaemic disease of cattle 
and buffaloes caused by the bacterium Pasteurella multocida serotypes B:2 or 
E:2. It is also a primary pasteurellosis and is reproducible in susceptible host 
species using pure cultures of the causative organism alone (De Alwis, 1999). 
It has been shown that HS occurs most commonly in cattle and buffaloes. 
According to Carter (1991), buffaloes are more susceptible than cattle and the 
disease occurs more frequently in poor husbandry conditions. Clinical symptoms 
are often not observed but high temperature, loss of appetite, nasal discharge, 
increased salivation, and laboured breathing, with swelling in the submandibular 
region have been recorded. Moreover, Carter (1989) also stated that death 
usually occurs quickly and mortality is almost 100% in infected animals. True 
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recovery from clinical disease occurs only if the animal is treated in the very 
early stages, which is often impossible under prevailing field conditions. 
1.4.1 Global distribution 
Haemorrhagic septicaemia has been recorded in almost all parts of the world 
except for the UK and Oceania, including Australia, where it has never occurred 
(De Alwis, 1999). The disease is of great economic importance in Asia where 
cattle and buffaloes are abundant and are vital for draught power and milk 
production. In Malaysia, the disease was first reported as early as the 1880s 
(Bain, 1963). In the Peninsula of Malaysia, the disease is enzootic in Kelantan, 
Terengganu, Kedah, Perak, Pahang and Negeri Sembilan due to the high 
population of cattle and buffaloes (Chandrasekaran et al., 1981).  
1.4.3 Epidemiological cycle 
Explosive outbreaks of HS may occur when it is first introduced to areas that 
have previously been free of the disease, or when it occurs as sporadic outbreaks 
in non-endemic areas. Previous studies have found that in endemic areas, large 
numbers of animals that survive after an outbreak of disease become latent 
carriers (Carter, 1989). They intermittently shed the organisms but, since the 
herd immunity is also high, there are no fresh clinical cases. A new outbreak 
occurs when a shedder come into contact with a susceptible animal, which may 
be one born after the previous outbreak or one introduced into the herd from 
elsewhere. According to De Alwis (1999), the chance of a fresh outbreak 
increases with time and with increase in size of the susceptible population. 
1.4.4 Progression of the disease 
In West Malaysia, Saharee and Salim (1991) have done a field observation of five 
outbreaks of disease involving 37 buffaloes and 7 cattle. They recorded a clinical 
course of 4-12 hours in per acute cases and 2-3 days in acute and sub-acute 
cases. On a herd basis, the outbreaks usually occur very fast and do not persist 
for long. Their observations indicated that 75% of outbreaks lasted for less than 
15 days within a herd. 
As recorded by De Alwis (1999), the clinical syndrome of HS may broadly be 
divided into three phases; phase one is dominated by increased temperature, 
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loss of appetite, general apathy and also depression. If closely monitored, a rise 
in rectal temperature to 40-41ºC is recorded, which lasts throughout the course, 
dropping to subnormal levels during the terminal phase, a few hours before 
death. Phase two is dominated by a respiratory syndrome. There will be 
increased respiration rate (40/50 minute), laboured breathing, clear nasal 
discharge and salivation. Submandibular oedema may also begin to show during 
this phase. As the disease progresses, the nasal discharge becomes opaque and 
mucopurulent. Lastly, phase 3 is dominated by recumbency. The respiratory 
distress becomes more acute, the animal lies down, terminal septicaemia sets in 
and death follows; the case fatality is nearly 100%.  
An earlier study by Graydon et al. (1993) stated that the disease is more acute 
and has a shorter course in buffaloes than in cattle. He also observed that upon 
experimental subcutaneous inoculation, buffaloes died 24-31 hours after 
inoculation, whereas the time of death for cattle was around 60 hours. 
1.4.5 Treatment 
As HS is a primary bacterial disease with no other biological agents involved, 
treatment may appear simple, using the wide range of antibiotics currently 
available. In spite of this, in reality, treatment is constrained by a host of 
practical considerations. It has been found in practice that animals can only be 
cured if they are treated at the very early stage of the disease (Carter, 1989).  
1.5 Vaccination against HS 
Several types of vaccines have been used for prevention and control of the 
disease. Countries where the disease is endemic resort to routine prophylactic 
vaccination. Nonetheless, several disadvantages with the current vaccines have 
provoked scientists all over the world to try to develop an improved vaccine to 
overcome the weaknesses with the current vaccines.  
1.5.1 History and current status 
In 1907, Baldrey discovered the first vaccine for HS by preparing a killed vaccine 
(0.25% lysol-inactivated broth culture) (De Alwis, 1999). This vaccine conferred 
immunity against the disease for only 6 weeks. Later, in 1938, Delpy and 
Rastegar (as cited by De Alwis, 1999) prepared a vaccine that consisted of a 
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suspension of bacteria lysed in 5% saponin. It was then followed in 1959 by 
Dhana attempting to develop a vaccine from a capsular extract of the organism 
(De Alwis, 1999). The aim to produce better vaccines for HS continued and it 
was thought that a live vaccine might be an ideal vaccine to confine and control 
the disease more efficiently. Thus, an early development of live vaccine started 
with a streptomycin-dependent (StrD) mutant of P. multocida by Chengappa et 
al. (1979). This work progressed to use different serotypes of the pathogen to 
discover whether they can be cross-protective; Myint et al. (1987) first used a 
strain isolated from deer to be used as a live vaccine. There was then a debate 
on precautions, procedure and safety measures as to whether the live vaccine 
might confer the disease or in some other way generate an outbreak of HS by 
itself. Meanwhile, other scientists were considering other types of vaccine for 
HS, such as subunit vaccines. Sabri et al.(2000) used an OMP preparation from 
the pathogen as a subunit vaccine. However, the vaccine failed to contain the 
disease. To mimic the ability of the pathogen to infect the host without causing 
the disease has always been seen as an ideal way to confer protection against 
the disease. Consequently another live-attenuated vaccine was developed by 
Tabatabaei et al. (2002) by mutating a housekeeping gene, aroA, in order to 
develop an attenuated live P. multocida strain. The live vaccine strain proved to 
be very highly attenuated yet protective in mice and in cattle (Hodgson et al., 
2005; Dagleish et al., 2007). The different types of HS vaccine are described 
below. 
1.5.1.1 Plain bacterin 
 One of the simplest vaccines comprised of killed whole-bacterial cells as the 
bacterin. Generally, bacterins need repeated vaccination in order to provide 
sufficient immunity. The most common type of bacterin is an inactivated broth 
culture. However, it triggers antibody poorly and it provides immunity for only 
about six weeks (OIE, 2004). An earlier study by Verma & Jaiswal (1997) which 
used another form of bacterin, an agar-wash formalin-killed vaccine shown to 
provide immunity for up to 4 months but later was found to cause a certain level 
of shock when administered to animals. 
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1.5.1.2 Alum-precipitated vaccines (APV) 
This type of vaccine is the most widely used vaccine in Asia and Africa. It 
consists of a bacterin to which potash alum has been added to give a final 
concentration of 1%. If derived from aerated culture, the density of the bacterin 
should be adjusted to approximately 0.75 mg dry weight per ml, so that a 3 ml 
dose will contain a minimum of 2.0 mg bacteria (OIE, 2004). 
The disadvantages of this type of vaccine are that it provides reliable immunity 
only for three to four months and shock reactions can also occur (Verma & 
Jaiswal, 1998). It is important to thoroughly mix the contents of the bottle 
before use because precipitation with alum causes the cells to settle at the 
bottom. If this precaution is not taken, animals receiving vaccines from the 
bottom of the bottle will receive a large dose of bacteria, and the chances of 
shock will be increased. Adding to that, in some countries where HS is endemic, 
the administration of the vaccine is also difficult because of poor husbandry 
condition with semi-wild buffaloes. 
1.5.1.3 Aluminium hydroxide gel vaccines 
This vaccine has common properties with the APV. The antigen solution is added 
to preformed aluminium hydroxide, aluminium phosphate, mixed aluminium 
hydroxide plus phosphate or gamma aluminium oxide (Edelman, 1980). According 
to Verma & Jaiswal (1998), this type of vaccine has been used extensively in 
Thailand and Laos and it has been able to produce immunity for up to 6 months, 
demanding twice-a-year vaccination. However, further vaccination did not 
confer a substantial immunity of more than 90 days even when used with 
immunomodulators such as vitamin E and levamisole (Verma & Jaiswal, 1998). 
1.5.1.4 Oil-adjuvant vaccines 
Oil-adjuvant vaccine is an alternative vaccine to overcome the disadvantages of 
alum precipitated vaccines such as short-term immunity. This vaccine can 
provide longer immunity for the host. In addition to that, this vaccine, which has 
been described in detail by Bain et al. (1982), is the most potent of the available 
vaccines. It consists of a dense bacterial suspension emulsified with a light 
mineral oil using various emulsifying agents (e.g., lanolin). The emulsion is of 
the water-in-oil type, and must contain approximately equal volumes of the 
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internal and the external phases. A well-made oil-adjuvant vaccine is white in 
colour and adheres evenly to clean glass. It is reported to confer immunity for 
six to nine months on primary vaccination of young animals, and up to one year 
with a booster (Thomas, 1970; De Alwis et al., 1978). 
When oil-adjuvant vaccines are injected, a vaccine depot is formed at the site of 
inoculation. This depot serves as a prolonged source of antigen. There is little 
production of antibody around the depot, the main sites of production being the 
local lymphatic chain and ultimately the reticulo-endothelial system. Talmage 
and Dixon (1953) showed that the antibody response to the protein antigen in 
this form remained constant for over 300 days. This contrasted with the antibody 
response to the same antigen in aqueous solution or alum precipitated, which 
declined after 10 days. 
Although it is an alternative to the alum-precipitated vaccines, it also has some 
major set-backs. The disadvantages of this vaccine are that it has the added 
complexity of high viscosity, which make it quite unpopular even though 
improved oil-adjuvant vaccines with lower viscosities have been described. In 
addition, it also requires a high number of inactivated bacteria (1010 to 1011 
cells) which is not economical for production and is potentially reactogenic 
(Verma & Jaiswal, 1998). A summary of current vaccination practices against HS 
in Asia is shown in Table 1. 
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Table 1. Haemorrhagic septicaemia vaccination practices in Asia.  
Country Type of vaccine Dose Route Duration of 
immunity 
Cambodia Alum-adjuvant vaccine; 
given twice a year 
2 ml s.c. 3-6 months 
India Alum-precipitated 
vaccine 
3 ml s.c. 4-6 months 
Indonesia Oil-adjuvant vaccine 3 ml i.m. up to 1 year 
Iran Alum-precipitated 
vaccine combined with 
Black leg vaccine; given 
twice a year 
2-3 
ml 
s.c. 4-6 months 
Malaysia Alum-precipitated 
vaccine 
Oil-adjuvant vaccine 
5 ml  
3 ml 
s.c.  
i.m. 
4-6 months 
up to 1 year 
Myanmar Live vaccine; contains 
107 cfu/dose of P. 
multocida serotype 
B:3,4 
2 ml i.n. 1 year 
Nepal Alum-precipitated 
vaccine 
5 ml s.c. 6 months 
Philippines Killed alum adjuvant 
vaccine; booster every 6 
months 
5 ml s.c. 4-6 months 
Sri Lanka Oil-adjuvant vaccine; 
given at 4-6 months, 
booster 3-6 months 
later, followed by annual 
vaccination 
3 ml i.m. up to 1 year 
Thailand Aluminium hydroxide 
gel, contains 3x1010 
cfu/dose of P. multocida 
serotype B:2 
3 ml s.c. 3-4 months 
Vietnam Alum-precipitated 
vaccine; two injections 
per year 
2 ml s.c. 4-6 months 
Table cited from Tabatabaei (2000) based on Verma and Jaiswal (1998) review. (s.c., 
subcutaneous and i.m., intramuscular) 
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1.5.2 Deficiencies of available vaccines 
Since the current vaccines have notable defects, most countries in which HS is 
endemic have put a considerable amount of research to develop an improved 
vaccine. In addition to that, it is widely recognized that an ideal vaccine should 
posses certain characteristics, such as: easy and economical to produce, with 
sustainable production technology in the endemic countries; stable for use in the 
tropics; easy to handle in the field with a consistency that make it easy to 
administer; no adverse reactions, high level of immunity with a minimum delay 
after vaccination and lasting for at least one year. From De Alwis’s (1999) 
suggestions on attempts to produce better HS vaccines, they can be classified 
into several groups, which are: use of other adjuvants; production of oil-
adjuvant vaccines of low viscosity; production of vaccines based on purified 
extracts of the organism and on the identification of the protective antigens; 
and the use of live-attenuated vaccines.  
Vaccination failure against HS is frequent in many countries. This is due to 
several factors. In some countries like Malaysia, vaccination campaigns are 
directed against several cattle diseases such as foot-and-mouth disease and HS. 
More than one vaccine is thus administered simultaneously. According to Joseph 
and Hedger (1984), there was no adverse effect towards simultaneous 
vaccination, hence indicating that cattle may be safely and effectively 
vaccinated simultaneously. However, another problem is the timing and the 
frequency of the vaccination. Failure to vaccinate at the critical time, such as 
prior to the stressful monsoon season, leads to disease outbreaks (Yeo & 
Mokhtar, 1993). Nevertheless, the major problem associated with vaccination 
failure is the low vaccination coverage, which has been reported in Malaysia, the 
Philippines and Indonesia (Syamsudin, 1993; Yeo & Mokhtar, 1993). Vaccination 
coverage of less than 80% may lead to the recurrence of disease outbreaks (Bain 
et al., 1982). After several epidemiological studies, it was concluded that 
vaccination coverage of 70% leads to sporadic occurrence of HS while coverage 
of more than 80% will be able to significantly reduce the incidence of the 
disease (Syamsudin, 1993). 
As well as having a vaccine that can eventually control HS, the mode of vaccine 
delivery to the animal is a major consideration (Sarah et al., 2006). Injectable 
vaccines, such as oil-adjuvant vaccines, have been shown to stimulate immunity. 
  Introduction 
 
18 
However, livestock production systems in many developing countries use either 
extensive or semi-extensive types of management with little animal handling 
(Zamri-Saad, 2005). This leads to difficulties in gathering animals for vaccine 
injection, thus most vaccination coverage, for example in Malaysia, is as low as 
17% (Saharee and Salim, 1993). Disease outbreaks are often reported in the 
unvaccinated animals. 
1.5.3 Live-attenuated vaccines 
The advantages of a live-attenuated vaccine are (i), it mimics the early stages of 
a natural infection and (ii), use of the natural route of entry into the host might 
be expected to confer more solid and long-term protective immunity, 
particularly if it is amenable to oral or intra-nasal administration that would 
favour induction of mucosal immunity in a way similar to the natural infection. 
Not only would the live vaccine stimulate mucosal immunity of the exposed host, 
it might also transmit the attenuated organism to in-contact hosts and 
eventually stimulate the mucosal immunity of these animals. This was proven in 
a trial of live vaccine using low doses of P. multocida B:2 and challenge with a 
high doses of the same organism, when 100% of the non-exposed animals that 
were kept together with the intranasally-exposed group showed similar 
stimulation of the bronchus-associated lymphoid tissue (Zamri-Saad et al., 
2006). Concurrently, 60% of the in-contact animals carried the live P. multocida 
B:2 vaccine strain for a period of between 1 and 2 weeks after exposure to the 
exposed group (Zamri-Saad et al., 2006). This is an important finding since there 
is a possibility of intranasal vaccination with live vaccine leading to self-
vaccination of the in-contact animals. 
De Alwis (1999) has suggested several characteristics for an ideal live vaccine: it 
must have all or at least most of the protective antigens present in the field 
strains; it must grow readily in ordinary culture media; it should be avirulent for 
cattle and buffaloes or have reduced virulence, i.e. the lethal dose must be 
much higher than the immunising dose; and it should be able to multiply 
sufficiently in vivo following vaccination, producing a full complement of the 
important immunogens, thereby stimulating an adequate immune response. The 
different types of live-attenuated vaccines used against HS are described in the 
next sections. 
  Introduction 
 
19 
1.5.3.1 Streptomycin-dependent mutant 
In this vaccine, Pasteurella multocida B:2 was mutagenised using N-methyl-N-
nitrosoguanidine to produce a streptomycin-dependent mutant. After a single 
vaccination by the intranasal route using the rabbit as an animal model, it was 
shown to be fully protective against homologous challenge at 21 days post-
vaccination (Wei & Carter, 1978). However, the vaccine needed a large number 
(3.75 x 109 organism per dose) of the mutant strain in order to produce a 
protective response and the inability of the organism to multiply in the absence 
of streptomycin was another disadvantage of the vaccine (Alwis et al., 1980; 
Chengappa et al., 1979). Yet, the development of this vaccine was a milestone 
in proving that a live strain of the pathogen could be used for vaccination. 
1.5.3.2 Deer strain live vaccine 
Jones & Hussaini (1982) isolated a P. multocida serotype B:3,4 from a fallow 
deer (Dama dama) in England after an outbreak of septicaemia. It was then used 
in experimental infection of cattle and buffaloes and succeeded in protecting 
calves for up to 9 months after they had been vaccinated subcutaneously or 
intradermally and later challenge subcutaneously with serotype B:2 (Myint et 
al., 1987). Moreover the vaccine was reported to have a low virulence for cattle, 
possibly due to the lack of transferrin-binding proteins (Veken et al., 1996). 
Myint and Carter have continued to investigate the vaccine, to prove its 
efficacy. By administering the vaccine intranasally as an aerosol spray, they have 
obtained encouraging results when applied to a population of cattle and 
buffaloes over six months of age in Myanmar (Myint et al., 2005). They reported 
that the live B:3,4 organisms were able to induce efficient cross-protecting 
immunity by a single immunisation at a relatively small dose of 2 x 107 viable 
organisms. 
Yet the safety of the vaccine has been questioned. One study of isolates from 
the palatine tonsils of healthy fallow deer from an HS outbreak area in Denmark 
showed a 27% carrier rate of P. multocida B:3,4. The carrier isolates had 
identical ribotyping and pulse-field gel electrophoresis profiles to those of the 
strain used as the live vaccine for cattle and buffaloes in Asia (Aalbaek et al., 
1999). Thus here it was shown that the deer vaccine strain is a potential 
pathogen and vaccination of cattle and buffaloes would have to be done under 
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strictly controlled conditions. The question is how to prevent the spread of the 
organism if it is being administered to semi-wild cattle and buffaloes? 
1.5.3.3 Acapsular mutants 
The search for an ideal live-attenuated vaccine continued when a cexA (gene 
involved in the export of capsule) mutant of P. multocida serotype B:2 was 
constructed by allelic exchange (Boyce & Adler, 2000). Immunisation (i.p.) with 
the vaccine conferred significant protection against wild-type challenge (i.p.) in 
a mouse model but only with high doses (e.g. >8 x 105) of the mutant (Boyce & 
Adler, 2001). 
Boyce and Adler (2001) developed another acapsular mutant by constructing an 
inactivation of the bcbH gene (a gene predicted to be involved in polysaccharide 
biosynthesis) from the same organism. Immunisation with this mutant was able 
to confer significant protection against wild-type challenge in a mouse model, 
while immunisation with similar doses of either killed wild-type or killed mutant 
failed to confer protection (Boyce & Adler, 2001). There are no subsequent 
reports of the use of this vaccine in cattle or buffaloes. 
1.5.3.4 aroA mutant vaccines 
Homchampa et al. (1992, 1994) first developed this particular type of vaccine 
against Pasteurella strains. They constructed aroA mutants of P. multocida 
serogroup A:1 and P. haemolytica biotype A:1 using recombinant DNA 
techniques. The mutants contained a KmR cassette inserted into the aroA gene 
via a suicide vector approach. The mutants were shown to be attenuated in a 
mouse model when injected i.p. and protected the mice against wild-type 
challenge (i.p.). Further study by Homchampa et al. (1997) reported the cross-
protective immunity conferred by a marker-free aroA mutant of P. multocida 
serotype A:1. They found that this new strain was highly attenuated in the 
mouse model. In addition, they also showed that with one or two doses of 
vaccine, this mutant strain could confer protective immunity against homologous 
and heterologous (serotype A:3 strain) challenge, but not against challenge by 
other biotypes. When tested further, the mutant was also able to protect 
chickens against intratracheal challenge with the wild type (Scott et al., 1999). 
  Introduction 
 
21 
The vaccine strain was also capable of providing cross-protection against 
heterologous challenge with strain serotype A:4. 
Subsequently an aroA mutant derivative of P. multocida B:2 was developed by 
Tabatabaei et al. (2002). The mutant was constructed by allelic exchange and 
confirmed to be highly attenuated when tested in a mouse model of HS. 
Vaccination of the aroA strain (107-109 cfu/mouse) either i.p. or i.n. completely 
protected mouse against challenge with a high dose (>1,000 x LD50) of the wild-
type B:2 strain. It was further tested in cattle to confirm its attenuation and 
protection. When administered intramuscularly (i.m.) at 108 cfu/animal in two 
doses four weeks apart, it appeared to give the best combination of high 
immune response, safety and protection against challenge with 107 cfu/animal 
of the wild-type strain give by the i.m. route (Dagleish et al., 2007). Whether 
this vaccine has overcome all the disadvantages of other types of HS vaccines is 
still too early to decide. More field trials are needed, especially in the countries 
where HS is endemic.  
1.6 DNA vaccines 
The historical basis for DNA vaccines rests on the observation that direct in vitro 
and in vivo gene transfer of recombinant DNA into mammalian cells by a variety 
of techniques resulted in expression of protein. Multiple approaches have been 
used in order to achieve this expression, such as using formulations of DNA with 
liposomes or proteoliposomes (Nicolau et al., 1983; Mannino & Gould-Fogerite, 
1988; Kaneda et al., 1989), calcium phosphate-coprecipitated DNA (Benvenisty & 
Reshef, 1986), and a polylysine-glycoprotein carrier complex (Wu & Wu, 1987). It 
was shown in a land mark study by Wolff et al. (1990) that direct inoculation of 
plasmid DNA encoding several different promoter genes could induce protein 
expression within muscle cells when “plasmid” or “naked” DNA vaccination was 
done in vivo (Wolff et al., 1990). The finding provided a strong basis that 
purified recombinant nucleic acids (‘‘naked DNA’’) can be delivered in vivo and 
can direct protein expression. These observations were further extended in a 
study by Tang et al. (1992) who injected mice with plasmid DNA encoding hGH 
(human growth hormone) and were able to elicit antigen-specific antibody 
responses. Subsequently, demonstrations by Ulmer et al. (1993) and Robinson et 
al. (1993) that DNA vaccines could protect mice or chickens, respectively, from 
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influenza infection provided a notable example of how DNA vaccination could 
mediate protective immunity. In further mouse experiments, it was proven that 
both antibody and CD8+ cytotoxic T-lymphocyte (CTL) responses were elicited 
(Ulmer et al., 1993), consistent with DNA vaccines stimulating both humoral and 
cellular immunity. 
As shown above, plasmid DNA is a crucial tool in shuttling antigen genes in vivo, 
which results in the in situ production of antigen (for vaccines). Since expression 
is required in the mammalian host cells, a eukaryotic expression plasmid is 
necessary. Thus, several vital elements (listed in the next section) are needed 
when constructing this type of plasmid DNA for DNA vaccines, in order to 
increase the efficiency of antigen delivery.     
1.6.1 Eukaryotic expression plasmids 
1.6.1.2 Properties of eukaryotic expression plasmids 
For optimal expression of antigen in eukaryotic cells, there are certain 
requirements of the plasmid DNA, depending on the initial bacterial host and the 
targeted cells. An expression plasmid for a DNA vaccine needs: an origin of 
replication allowing for growth in bacteria (for easy in vitro manipulation); a 
bacterial antibiotic resistance gene (to aid in selection); a powerful promoter for 
optimal expression in mammalian cells; and stabilization of the mRNA transcript, 
achieved by incorporation of polyadenylation sequences such as those found in 
bovine growth hormone (BGH) or simian virus 40 genes (Gurunathan et al., 2000; 
Grillot-Courvalin et al., 2002).  
It is generally believed that the level of gene expression in vivo obtained after 
DNA vaccination correlates with the immune response generated. Therefore, 
several laboratories have sought to improve gene expression and immune 
responses after plasmid DNA vaccination. These approaches have included 
optimizing gene regulatory elements within the plasmid backbone or modifying 
the plasmid backbone itself to enhance gene expression (Gurunathan et al., 
2000). One of the most important elements from the list above is the type of 
promoter used to express encoded protein. Viruses have a highly evolved 
structure and mechanism in order to transfect mammalian cells to transfer 
expressible genetic materials (Liu, 2003). An early study on DNA vaccines 
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demonstrated an expression plasmid expressing antigens from a eukaryotic viral 
promoter (Sizemore et al., 1997). This work was followed by Darji et al. (2000) 
who had developed a DNA vaccine by manipulating plasmid pAH97, which also 
employs a cytomegalovirus promoter (PCMV) for expression of the encoded 
protein. Similar findings were demonstrated with a different type of expression 
plasmid with the same cytomegalovirus promoter (PCMV) for protein expression 
in vivo (Cossart & Lecuit, 1998; Grillot-Courvalin et al., 2002). To date, 
commercial eukaryotic expression vectors mostly have employed a viral 
promoter from cytomegalovirus which had been proven to maximize protein 
expression especially when combined with the immediate early (IE) gene which 
is known to assist in augmentation of expression efficiency (Thomsen et al., 
1984). 
1.6.2 Mode of delivery 
Introducing the expression plasmid into eukaryotic cells requires an extensively 
appropriate delivery system in order to optimize DNA vaccines or even to make 
the vaccine work. There are multiple carrier-mediated approaches in order to 
deliver DNA vaccine into targeted cells. 
1.6.2.1 Gene gun 
          
Figure 1. Example of gene guns. 
Left: Helios Gene Gun (BioRad), a hand-held device for direct transfection of plasmid 
DNA into eukaryotic cells. Right: It uses an adjustable low-pressure helium pulse to 
sweep DNA-coated gold microcarriers from the inner wall of a small plastic cartridge 
directly into the target.              (Pictures from BioRad, USA) 
 
Gene gun technology as shown in Figure 1, uses a gas-driven biolistic 
bombardment device that propels gold particles coated with plasmid DNA 
directly into the tissues (Yang et al., 1990; Williams et al., 1991; Tang et al., 
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1992; Fynan et al., 1993). These gold particles are propelled directly into the 
cytosol of target cells, resulting in transgene expression levels higher than those 
obtained by comparable doses of injected ‘‘naked DNA’’. As proved by Tang et 
al. (1992) plasmids coated onto gold beads resulted in foreign gene expression 
and the induction of an antibody response to the foreign gene product in mice. 
They used genetic immunisation as a means of generating a humoral immune 
response to a gene product, in this case the human growth hormone, by 
injecting plasmid DNA encoding the foreign gene into a host. This mode of 
immunization has been shown to elicit protective immunity in several animal 
models (Watts & Kennedy, 1999). For example, one study has reported that gold 
particles containing as little as 0.4 µg of DNA can induce protective immunity in 
mice when compared with hundreds of microgram of DNA in saline administered 
without a gene gun (Fynan et al., 1993). Yoshida et al. (2000) indicated that a 
gene gun system developed in their study was highly reproducible and reliable to 
induce cytokine-T-lymphocyte (CTL) and specific antibodies in animal models 
when compared to intramuscular injection of plasmid DNA. However, this 
technique is not as cost-effective as other delivery methods and is one of the 
main reasons of the slow development of this technique (Donate et al., 2011).   
1.6.2.2 Liposomes 
  
Figure 2. Liposomes for delivery of DNA vaccine. 
Left: Image showing cross-section of the liposome bilayer structure. DNA or 
protein is carried in the aqueous core of the liposome (cited from 
http://lyposphericnutrients.co.uk). Right: An electron micrograph of liposomes 
during mammalian cell transfection (cited from http://bioteach.ubc.ca/Bio-
industry). 
 
Liposomes are bilayered membranes consisting of amphipathic molecules such as 
phospholipids, forming unilayered or multilayered (lamellar) vesicles (Figure 2). 
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Unilamellar vesicles have a single bilayer membrane surrounding an aqueous 
core and are characterized by either being small or large unilamellar vesicles. 
Multilayered vesicles have several lipid bilayers separated by a thin aqueous 
phase. Locally-injected liposomes are known to be taken up avidly by antigen-
presenting cells infiltrating the site of injection or in the lymphatics, an event 
that has been implicated in their immunoadjuvant activity (Gregoriadis, 1990).  
Liposomes would also protect their DNA content from deoxyribonuclease attack 
(Gregoriadis et al., 1996). Because liposomes can be prepared with significant 
structural versatility based on vesicle surface charge, size, lipid content, and 
coentrapment of adjuvants, they offer considerable flexibility for vaccine 
optimization (Jain et al., 2011). The full scope of the use of liposomes to 
increase the effect of DNA vaccines is currently an active area of investigation. 
Intramuscular injection of plasmid DNA incorporating hepatitis B surface antigen 
entrapped in liposomes elicited 100-fold increased antibody titers and increased 
levels of both interferon-c (IFN-c) and interleukin-4 (IL-4) when compared with 
those in animals injected with ‘‘naked DNA’’ (Gregoriadis et al., 1997). A similar 
result on antibody augmentation was seen when DNA/liposome complexes were 
administered intranasally (Klavinskis et al., 1997). However, liposome potency 
depends on the composition of the lipid, bilayer fluidity number of lipid layers, 
size and physico-chemical characteristics as the modulation of these features 
bring about changes in immune responses to the associated antigens (Jain et al., 
2011). In a recent review, it was shown that using cationic liposomes alone is not 
sufficiently immunostimulatory. The need for combination of liposomes with 
immunostimulating ligands in order to enable the adjuvant system to work is 
considered as an additional task for further advancement of this technique 
(Christensen et al., 2011).   
1.6.2.3 Cochleates  
Developments from earlier structures of liposomes proved that lipid matrix-
based subunit vaccines can be used to produce custom-designed vaccines. 
Cochleates are rigid, calcium-induced, spiral bilayers of anionic phosolipids. 
They have a unique structure that is different from that of liposomes. They are 
relatively stable after lyophilization or in harsh environments (Gurunathan et 
al., 2000).  
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In oral delivery systems, cochleates have the advantage of preventing internal 
rapid degradation of naked DNA or protein and employing tools (such as pH and 
temperature) for target degradation of cochleate at specific sites such as organ, 
tissue or muscle; such tool could help in site-specific release of DNA or antigenic 
protein (Landry & Heilman, 2005). Upon contact with a lipid bilayer of a target 
cell, the cochleate vector structure delivers one or more of the nucleotide 
sequences with one or more proteins to the interior of the target cell. It is 
believed that, on contact with target cell membrane, a fusion event occurs 
between the membrane and the outer layer of the cochleate leading to delivery 
of the contents of the cochleate into the cytosol. Upon entry into the cell, the 
proteins, such as the surface glycoproteins of enveloped viruses, facilitate the 
integration of the nucleotide sequence into the genome of the host cell. It has 
been reported that DNA/cochleate formulations were able to induce strong CTL 
and antibody responses after parenteral or oral administration (Gould-Fogerite & 
Mannino, 1996; Gould-Fogerite et al., 1998).  
1.6.2.4 Microparticle encapsulation  
 
Figure 3. Compact microparticle encapsulation. 
Illustration of compact microparticle encapsulation with embedded 
degradable polymer in its core for plasmid DNA packaging. (Re-
drawn diagram is based on image from gizmodo.com)  
 
Another potentially exciting means of DNA delivery is the use of biodegradable 
polymeric microparticles. Plasmid DNA trapped in these biodegradable 
microparticles, composed of polymers such as poly(lactic-co-glycolic acid) or 
chitosan (Figure 3), can be administered orally and has been shown to induce 
both mucosal and systemic immune responses (Herrmann et al., 1999). The use 
of poly(lactic-co-glycolic acid)–entrapped DNA vaccines to induce protective 
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immune responses to rotavirus challenge after oral administration was 
demonstrated in two separate studies (Chen et al., 1998; Herrmann et al., 
1999). The ability of polymer–entrapped DNA vaccines to induce systemic and 
mucosal immune responses after oral or intraperitoneal administration is similar 
to vaccine administration using cochleates. Most recent studies have 
manipulated this system for slow release of drugs at targeted sites in vivo. A 
PEG-PLA (polyethylene glycol-polylactic acid) microparticle preparation was 
shown to deliver proteins in cell culture at 1 h of transfection and to persist in 
vivo in retinal cells for at least 9 weeks with no observed toxicity (Rafat et al., 
2010). Another study reported that an encapsulated poly (L-lactide) 
microparticle formulation for sustained intravitreal delivery of TG-0054, a highly 
water-soluble anti-angiogenic drug, was able to persist for 3 months in vivo and 
for 6 months in vitro in retina cell. This continuous choroidal delivery of 
thyroglobulin, TG-0054 has useful in treating choroid neovascularization in the 
retina (Shelke et al., 2010).  
 
Figure 4. Comparison of nanoparticle and microparticle. 
Image shows size comparison between plasmid DNA (red) in 
microparticle encapsulation (right) and plasmid DNA packaged in 
nanoparticles compartment (left). 
 
Further developments of this method have adapted nanotechnology approaches 
to develop nano-scaled drug delivery vehicles termed as nanoparticles (1-2 nm).  
This vehicle has been developed to deliver naked DNA entrapped in its polymeric 
compartment. This system was shown to give more antigen production when 
compared with microparticle encapsulation (10-50 µm) (Figure 4) (Nandedkar, 
2009). A possible explanation would be that smaller molecules are more likely to 
be taken up by antigen-presenting cells (APCs) at higher frequency which in 
turn, will increase the chances of DNA being delivered intracellularly (Foged et 
al., 2005).  
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Figure 5. Nanoparticles in mammalian cells. 
Fluorescence microscopy image above shows cytosolic 
accumulation through receptor (green) mediated endocytosis of 
targeted nanoparticles (pink) specifically targeted to a cell-
surface antigen. (Image adapted from www.bindbio.com) 
 
Nanoparticles also have the advantage of simplicity of preparation when 
compared to microparticles (Wendorf et al., 2006). So far, this system has 
provided a novel delivery tool for naked DNA and an efficient antigen delivery 
and adjuvant system in the development of DNA and protein-based vaccines 
(Figure 5) (Akagi et al., 2005). However, there is still the need to understand the 
role it plays after delivery, host-toxicity effects and also on its efficiency to 
trigger host-immune responses. 
1.6.2.5 Microneedles 
 
  Figure 6. Microneedle vaccine patch. 
 Dissolvable microneedles of 650 microns in length 
and assembled into an array of 36 needles. 
(http://gtresearchnews.gatech.edu/) 
 
The development of microneedles is mostly to address the pain caused by fine 
gauge needles used for intradermal administration of antigens (reviewed by Jain 
et al., 2011) but they have also been used for DNA delivery (Chabri et al., 2004; 
Gill & Prausnitz, 2007). It is a simple and cost-effective approach which employs 
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the microelectronics industry for inexpensive mass production. Microneedles 
typically measure hundreds of microns in lengths and are used as multi-needle 
arrays to pierce the skin in order to deposit antigen or DNA within the skin 
(Figure 6). It is a recent technology incorporating biodegradable polymer 
microneedles. Chabri et al. (2004) and Lee et al. (2008) have applied this 
method for transdermal DNA and protein delivery. Such microneedles have been 
shown to dissolve within the skin for bolus or prolonged delivery without leaving 
any biohazardous sharp medical waste. Other studies have focused on developing 
more versatile structures of the needle for greater future utilization (Wu et al., 
2007; Bal et al., 2010). Although the system shows much promise, especially in 
the ease of vaccine administration, research is needed, especially on its 
efficiency to elicit acquired immunity in the host. 
1.6.2.6 Viral vectors 
Development of a variety of expression strategies has made it possible to deliver 
foreign genes in vivo using viral vectors. Alphaviruses are arthropod-borne 
togaviruses with a positive-polarity and single-stranded RNA genome that can 
replicate in a large number of animal hosts. They have been reported to induce 
cellular immunity. For example, an attenuated Venezuelan equine encephalitis 
virus, a member of the alphavirus family, has been used to deliver and express 
the matrix/capsid (MA/CA) coding region of the HIV-1 gag gene into baby 
hamster kidney cells (Caley et al., 1997). The virus managed to replicate rapidly 
in vitro and massive expression of the MA/CA protein was detected. When 
injected subcutaneously into BALB/c mice, it was observed to stimulate a 
comprehensive humoral and cellular immune response (Caley et al., 1997). 
However, in another study using another family of alphavirus, Sindbis virus, as 
the vector to deliver DNA into mammalian cell lines, only short-term transgene 
expression was obtained (Lundstrom, 1997). Alphaviruses were also reported to 
induce apoptosis and had a cytotoxic effect in infected cells (reviewed in 
Lundstrom, 2005). In another study, a replicating attenuated adenovirus vector 
has been shown to generate strong immune responses against encoded 
heterologous antigens (Guroff, 2007). However, its rapid replicating nature in 
the host has raised general concerns about its safety. This and other factors such 
as their instability, cost and difficulty in production has slowed down the 
practicality of viruses as DNA delivery vectors (Seow & Wood, 2009). Further 
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studies are needed to engineer an attenuated viral vector with controllable 
replication and mutation to disable expression of potentially deleterious 
proteins. 
1.6.2.7 Bactofection  
Bactofection is the technique of using bacteria for direct gene transfer into 
target organisms, organs or tissues. It has been the most studied method of 
delivery of DNA vaccines since the first breakthrough 30 years ago by Schaffner 
(1980). This bacteria-mediated transfer of plasmid DNA (bactofection) into 
mammalian cells is a potent approach to expressing plasmid-encoded 
heterologous proteins in a large set of different cell types, including phagocytic 
and non-phagocytic mammalian cells. Transfected bacterial strains deliver 
antigenic genes localized on plasmids into the cells, where these genes can be 
expressed intracellularly (Liu, 2011).  
Some of the problem of using viral vectors could be overcome by using 
attenuated intracellular bacteria.  Besides being much more stable (controlled 
attenuation), intracellular bacteria carrying the DNA undergo phagocytosis by 
APCs (antigen presenting cells) as during normal infection. Plasmid DNA is 
delivered into the host cell phagosome or cytosol. The released DNA is then 
transcribed, resulting in expression of encoded antigens which will induce host-
adaptive immunity (reviewed by Weiss & Chakraborty, 2001). Table 2 below 
shows some example of bactofection models with attenuated strains of 
pathogenic bacteria that have been reported in recent years. 
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Table 2. Bactofection using attenuated strains of pathogenic bacteria. 
Vector Target gene Disease Model Reference 
Listeria 
monocytogenes 
IL-12 L. major-infection House mouse 
(Mus musculus) 
Shen et al., 
2004 
Salmonella 
typhimurium 
CD40L B-cell lymphoma Mus musculus Urashima et 
al., 2000 
S. typhimurium VEGFR-2 (FLK-1) Various 
carcinomas 
Mus musculus Niethammer 
et al., 2002 
L. 
monocytogenes 
CFTR Cystic fibrosis CHO-K1 cells Krusch et 
al., 2002 
S. typhimurium IFN-γ Immunodeficiency Mus musculus Paglia et al., 
2000 
Salmonella 
choleraesuis 
Thrombospondin-
1 
Melanoma Mus musculus Lee et al., 
2005 
Table based on Pálffy et al. (2006). 
 
1.6.2.7.1 Adhesion, invasion and intracellular survival 
One vital criterion for use of attenuated bacteria as a live-mobile carrier is their 
ability to adhere and to invade targeted mammalian cells in order to deliver 
plasmid DNA intracellularly. There is added value when the strains manage to 
survive or even replicate intracellularly and are able to control the release of 
the plasmid DNA at the appropriate time or place in order for the immunogenic 
protein to be expressed accordingly.  
Various studies have shown attenuated strains of invasive bacteria such as 
Shigella flexneri (Sizemore et al., 1995; Sizemore et al., 1997), Salmonella 
typhimurium (Darji et al., 1997; Paglia et al., 1998), and Listeria 
monocytogenes (Dietrich et al., 1998) being used for the delivery of plasmid 
DNA. For S. typhimurium, the bacteria are lysed within the phagosome, 
releasing plasmid DNA from this compartment into the cytoplasm via an unknown 
mechanism. Vaccination of mice with attenuated S. typhimurium transformed 
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with plasmid DNA encoding listeriolysin (a virulence factor of L. monocytogenes) 
induced specific antibody as well as T-cell responses to listeriolysin (Darji et al., 
1997). In a separate study, fluorescent dendritic cells (DC) were demonstrated 
after oral administration of S. typhimurium harboring plasmid DNA encoding 
green fluorescent protein. These data provided evidence that this delivery 
system could target relevant immune cells, leading to efficient induction of an 
immune response (Paglia et al., 1998). For Shigella infection, after phagocytosis 
and lysis within host cells, antigenic material encoded by a eukaryotic 
expression plasmid is released directly into the cytoplasm. Immunization using 
attenuated S. flexneri transformed with a bacterial plasmid encoding β-gal led 
to induction of a strong antigen-specific humoral and cellular response (Sizemore 
et al., 1997). In a separate study, it was shown that mice vaccinated with 
attenuated Shigella vaccine harbouring measles virus genes induced a vigorous 
measles virus antigen-specific response (Fennelly et al., 1999). An attenuated L. 
monocytogenes has also been used for delivery of eukaryotic expression vectors 
to the cytoplasm of murine macrophage cell lines (Dietrich et al., 1998). 
Whereas immunization with naked DNA has not been reported to lead to genomic 
integration with a significant frequency, delivery of DNA by L. monocytogenes 
can be a trigger for chromosomal integration in mammalian cells raising safety 
concerns with this system (Dietrich et al., 1998; Courvalin et al., 1995).  
There seem to be agreement in the literature on the basic mechanism of the 
bactofection model system for the delivery of DNA vaccine, as illustrated in 
Figure 7 (Grillot-Courvalin et al., 2002; Loessner et al., 2008). Bactofection can 
be modelled with, for example, Salmonella or Listeria. After infecting the host, 
bacteria are normally taken up by the antigen presenting cells (APCs) via 
phagocytosis. However, in the case of L. monocytogenes, some of them can 
escape from the phagosome by the action of pore-forming listeriolysin O whereas 
Salmonella is still trapped in the phagosome. L. monocytogenes proliferates in 
the cell cytosol and proteins secreted by the bacteria are degraded by the 
proteosomes, enter the endoplasmic reticulum and are presented to the immune 
system preferentially by MHC class I molecules. Cytosolic L. monocytogenes 
causes polymerization of actin filaments which mediate its intracellular 
movement and direct transfer to neighboring host cells without exiting the cells 
(Figure 7). A portion of the L. monocytogenes population remains in the 
phagosome and shares the life-cycle of Salmonella, which proliferates in the 
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phagosome. Proteins secreted by the phagosomal bacteria are trapped and 
degraded in this compartment and presented on the APC cell surface by MHC 
class II molecules. At the same time, plasmid DNA carried by both bacteria are 
delivered into the cytoplasm after bacterial cell lysis in the phagosomal 
compartment. The plasmid is then transferred to the nucleus and processed for 
antigen expression. The mechanism of plasmid DNA delivery from the vacuoles 
to the nucleus, however, is still unknown (Becker & Guzmán, 2008).    
 
Figure 7. Bactofection pathway for DNA vaccine delivery. 
Schematic representation of bacteria-cell delivery process e.g. by Salmonella (green) and 
Listeria (red). After cell internalization and phagolysosome fusion, the escape of the bacteria 
or of their plasmid DNA content from the vacuole into the cytosol results in the transfer of the 
plasmid (yellow) to the cell nucleus. (Adapted from Grillot-Courvalin & Goussard, 2011). 
 
1.6.2.7.2 Invasion by P. multocida 
P. multocida may also have the potential as a DNA vaccine delivery vector as it 
has been found intracellularly within a variety of eukaryotic cells. In one study, 
the pathogen was reported as multiplying intracellularly in liver and spleens of 
experimentally-infected turkeys in the early stages of infection, before 
spreading into the blood (Pabs-Garnon & Soltys, 1971). This report was 
supported by histological observations of liver and spleen from infected chickens 
and embryos (Ibrahim et al., 2000). Another study showed that two serotype A 
3,4 strains of P. multocida from turkeys that differed in virulence were able to 
invade epithelial cell monolayers grown in tissue culture. Both organisms were 
comparably adherent to turkey kidney cells (Lee et al., 1994). The virulent 
strain was also able to invade porcine epithelial cells and feline epithelial cells 
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in cell culture. However, neither strain invaded rabbit epithelial cells (Lee et 
al., 1994). More recently, the capsule of serotype A strains was found to be the 
adhesion factor for avian strain A:3 and A:1. These strains are capable of 
invading and multiplying in chicken embryo fibroblast cells (Al-haj Ali et al., 
2004). Association with and invasion of bovine aortic epithelial cell by P. 
multocida serotype B have also been demonstrated (Galdiero et al., 2001). 
Rabier et al. (1997) demonstrated that a group A strain of P. multocida was 
capable of adhering to polarized epithelial MDCK cells and it was present on the 
apical cell surface and inside the cells near the apical border when analysed by 
confocal microscopy. Other studies have demonstrated that P. multocida 
serotype A was able to invade HeLa cells (Esslinger et al., 1993, Esslinger et al., 
1994, Pruimboom et al., 1996) and uptake of P. multocida B:2 into mouse a 
macrophage cell line has also been reported (Tabatabaei, 2000). In his study, an 
aroA mutant of P. multocida B:2 and the wild-type strain were taken up into the 
mouse macrophage-like cell line and were shown to survive intracellularly for at 
least 2 h after invasion. 
1.6.3 Advantages and disadvantages of DNA vaccines  
There are several reasons why DNA vaccination might provide important 
advantages over current vaccines: DNA vaccines mimic the effects of live 
attenuated vaccines in their ability to induce major histocompatibility complex 
(MHC) class I-restricted CD8+ T-cell responses important for cell-mediated 
immune response. This may be advantageous compared with conventional 
protein-based vaccines, while removing some of the safety concerns associated 
with live vaccines; DNA vaccines can be manufactured in a relatively cost-
effective manner and stored with relative ease, eliminating the need for a cold 
chain to maintain the stability of a vaccine during its distribution.  
Concurrently, DNA vaccines do have some possible disadvantages. One concern is 
that there is a potential for integration of the delivered DNA into the host 
chromosome. Plasmid DNA-based vectors sometimes contain nucleic acid 
sequences from oncogenic viruses, and the possibility for chromosomal 
integration exists. A second concern of DNA vaccination is the possibility of 
generating antibodies to DNA. Immune responses to DNA occur in autoimmune 
diseases, such as systemic lupus erythematosus, and the potential exists that 
infection of bacterial DNA could induce an immune response that might cross-
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react with host DNA (Watts & Kennedy, 1999). It has been reported that 
antibodies to DNA have been observed following immunisation of mice with 
bacterial DNA (Gilkeson et al., 1993; Griffiths, 1995). However, this still 
represents a theoretical possibility that requires more attention. A third concern 
is the effect that long-term expression of injected DNA in muscle cells may have 
on immune responses to subsequent vaccination with a different DNA, and 
whether the immune responses to protective epitopes associated with this 
second immunisation will be compromised. It has also been reported that DNA 
vaccination strategies for non-protein based antigens, such as bacterial 
polysaccharides and lipids have been unsuccessful (Watts & Kennedy, 1999). 
1.7 Immunosuppression by Pasteurella multocida B:2 
Hornef et al. (2002) reported that different types of bacterial pathogens have 
adopted different strategies to interfere with host innate and adaptive immune 
mechanisms. Different bacterial components and products play different roles in 
modulating host immune reactions, most of them stimulatory but a minority are 
inhibitory (Schwab, 1975). To study the modulatory effects of bacterial 
pathogens on immune response, one can execute in vitro experiments such as a 
lymphocyte stimulation assay (also called antigen-stimulated lymphocyte 
proliferation or lymphoblastogenesis assays). The assay will assist in investigating 
stimulation and proliferation responses of mononuclear cells after treatment 
with different components of the bacteria. In the body, stimulation of primed 
(activated) lymphocytes occurs in lymphoid tissues in response to antigen 
presented to them. Yet, the ability of isolated lymphocytes (such as peripheral 
blood mononuclear cells, PBMC) to be stimulated (expressed as proliferation 
and/or cytokine secretion) when cultured in the presence of the antigen has 
been exploited as a tool to assess cellular responses in vitro. 
The proliferative response of activated PBMC to antigen has been extensively 
used to study cellular immunity, as PBMC from infected or immune hosts will 
proliferate in response to antigen obtained from the organism that they have 
been exposed too. In a study on HS- and shipping fever-related Pasteurella, it 
was reported that PBMC from HS-immunised cattle exhibited a higher 
stimulation index when incubated with antigen preparations from homologous 
strains than with those from a heterologous, shipping fever strain. In contrast, 
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PBMC from cattle immunised with the shipping fever strain of P. multocida 
exhibited a higher stimulation index when incubated with an antigen preparation 
from the homologous strain than with antigen preparation from heterologous HS 
strains (Maheswaran & Thies, 1979).  
Previous study by Ataei (2007) observed that P. multocida B:2 appeared to 
suppress proliferation of the lymphocyte population in vivo and in vitro. His 
initial observation on P. multocida B:2 suppression of lymphocyte proliferation in 
response to concanavalin A (ConA) was shown when PBMC were sampled from 
vaccinated (i.n.) (with a live-attenuated aroA- P. multocida strain) and non-
vaccinated calves that had subsequently been challenged i.m. with a wild-type, 
virulent P. multocida B:2 strain. Figure 8 below shows a bar graph, adapted from 
his thesis, demonstrating in vivo suppression of lymphocyte proliferation in 
response to ConA.  
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Figure 8.  Observation from infected calves (Ataei, 2007). 
Proliferative in vitro response to ConA of lymphocytes obtained from calves 
after challenge with P. multocida B:2 85020 (wild-type).  
PBMC (2 x 105 cells/well) were prepared from vaccinated and non-vaccinated groups of calves on 
the day of challenge and at different times after challenge with virulent P. multocida B:2 85020. In 
vaccinated group, calves were vaccinated once with 108 cfu of P. multocida B:2 JRMT12 and all 
of the animals were challenged after 28 days. 1 µg/well of concanavalin A (ConA) was added to 
the cells. All of the treated cells along with untreated cells as controls were incubated at 37 ºC. 
On the 3rd day, cells were pulsed with [methyl-3H] thymidine and incubated for 18 h and the 
amount of incorporated thymidine was measured by scintillation. Proliferation of cells was 
detected by the level of thymidine incorporation and is shown as bars, which represent the 
stimulation index (SI). SI is the ratio of treated (ConA added) compared to untreated cells. 
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P. multocida B:2 suppression of lymphocyte proliferation ex vivo in response to 
ConA was clearly demonstrated from 12 hours post-challenge and suppression 
continued until at least day 3 post-challenge. At this time, there was little 
difference in proliferation levels when comparing vaccinated and non-vaccinated 
animals. Immunosuppression by P. multocida B:2 was still observed after 7 days 
post-challenge in PBMC from vaccinated animals while suppression was no longer 
evident in PBMC from non-vaccinated animals. The study was continued to 
further assess this immunosuppressive effect of a cell-free extract (CFE) of P. 
multocida B:2 or PBMC in vitro. Figure 9 (Ataei, 2007) shows that the 
proliferative response of calf PBMC to ConA was markedly suppressed when the 
cells were incubated with the optimal concentration (10 µg/well) of P. 
multocida B:2 CFE for one hour before adding the ConA. Incubation of PBMC with 
CFE alone (10 µg/well) showed no stimulatory effect on lymphocyte 
proliferation. The concentration of CFE and the 1 µg/well concentration of 
ConA, together with incubation of PBMC for 1 h with extract before addition of 
ConA, were optimal conditions to demonstrate this suppressive effect. 
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Figure 9.  Immunosuppressive effect of P. multocida B:2 cell-free 
extract on PBMC in vitro (Ataei, 2007). 
The effect of CFE of P. multocida B:2 on PBMC were obtained from normal 
calves and their proliferative response to ConA, was determined.  
Bars represent the proliferative response of normal calf PBMC (2 x 105 cells/well) after 
incubation for 1 h with 10 µg/well CFE before addition of 1 µg/well ConA. Proliferation was 
detected by measurement of thymidine incorporation and expressed as stimulation index, 
which shows the ratio of incorporation in treated (CFE was added) compared to untreated 
cells. 
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The study was then continued to analyze the suppressive effect caused by 
different component of P. multocida B:2. It was determined that the active part 
of the suppressive agent was likely to be protein, because an outer membrane 
protein preparation of the bacteria markedly suppressed the proliferative 
response of PBMC to ConA. The investigation was extended using fluorescence-
activated cell sorter (FACS) analysis to assess the specific effect of suppression 
of proliferation, on the different populations in the PBMC: B cell and T cell sub-
populations (CD4+, CD8+ and γδ+). In his conclusion, Ataei (2007) suggested that 
the in vitro experiments demonstrated that P. multocida B:2 contains a 
component(s) with the potential to inhibit the proliferative response of CD4+ and 
CD8+ -T cells. This observation is of concern and therefore, was subjected to 
further investigation in parallel with the development of P. multocida B:2 as a 
delivery vehicle for DNA vaccines. 
1.8 Objectives of research and experimental plan 
The long-term goal of the laboratory was to further characterize and develop 
the attenuated P. multocida B:2 aroA derivative created by Tabatabaei et al. 
(Tabatabaei, 2000; Tabatabaei et al., 2002), to determine if it can, in addition 
to raising a protective immune response against P. multocida challenge, also 
raise an immune response to heterologous antigens expressed from a plasmid via 
a eukaryotic promoter. In order to achieve this eventual goal, several 
understandings need to be developed. These have been structured in the current 
study which aims;   
a) To compare the capacity of the wild-type and vaccine strain of P. 
multocida to invade and survive within the mammalian cells lines. 
b) To develop a suitable Pasteurella dual-expression plasmid that enables 
protein expression in both prokaryote and eukaryote. 
c) To demonstrate a bactofection model system of Pasteurella for infection 
of mammalian cells. 
d) To confirm and extend the observations concerned with the possible 
immunosuppressive effects of P. multocida.  
    
 
2. MATERIALS AND METHODS 
2.1 General bacteriological procedures 
2.1.1 Sources of bacteria 
Bacterial strains used in this study are listed in Table 3. All bacterial strains 
were available from culture collections within the Division of Infection and 
Immunity, University of Glasgow or were available commercially. 
2.1.2 Plasmids 
Plasmids used in this study are listed in Table 4. 
2.1.3 Bacterial growth and storage media 
The compositions of the following media are given in Appendix 1. Luria Bertani 
(LB) broth, Luria Bertani (LB) agar, Brain Heart Infusion (BHI) broth, BHI Agar, 
SOC, Terrific broth and Terrific agar. All media were sterilised by autoclaving at 
15 p.s.i. (121°C) for 15 min except where stated. Heat-labile ingredients such as 
antibiotics were sterilised by filtration through a sterile 0.22 µm filter (Sartorius, 
UK). Glassware was sterilised by heating to 160°C for 2 h. All strains were stored 
frozen in 50% (v/v) glycerol at -80°C in BHI broth for Pasteurella strains or LB 
broth for Escherichia coli strains.  
2.1.4 Growth of E. coli 
E. coli strains were subcultured on LB agar medium and  incubated at 37°C 
overnight. Liquid cultures of the strains were grown in LB broth media in 
Universal containers overnight on an orbital shaker at 180-200 rpm at 37°C. 
When required, antibiotic-resistant strains were grown on agar or in liquid media 
containing the appropriate antibiotic concentration. 
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Table 3.  List of bacterial strains used in this study. 
Strain Relevant strain 
characteristics 
Source 
 
Pasteurella  multocida  
serotype B:2 85020 
 
Wild-type, isolated from a 
case of bovine haemorrhagic 
septicaemia in Sri Lanka 
 
Institute of Infection, 
Immunity & 
Inflammation, 
University of Glasgow 
(Prof. John G. Coote) 
 
P.  multocida  
serotype B:2 JRMT12 
AroA- derivative of 85020 
strain 
Institute of Infection, 
Immunity & 
Inflammation, 
University of Glasgow 
(Prof. John G. Coote) 
 
Mannheimia haemolytica 
serotype A1  
Wild-type, isolated from a 
case of bovine pneumonia in 
Glasgow 
Institute of Infection, 
Immunity & 
Inflammation, 
University of Glasgow 
(Dr. Robert L. Davies) 
 
P.  multocida  
serotype A3 (MRI, 671/90) 
Wild-type, isolated from 
bovine pneumonia in Scotland 
Moredun Research 
Institute, Edinburgh 
(Dr. J. Christopher 
Hodgson) 
 
P.  multocida  
serotype B:2 JRMT12 Smr 
 
Spontaneous streptomycin 
resistant (Smr) derivative of 
JRMT12 strain 
 
This study 
E. coli XL-1 BLUE MRF’ 
(Minus Restriction)  
[ restriction minus (McrA–, 
McrCB–, McrF–, Mrr–, HsdR–) 
derivative of the XL1-Blue 
strain] 
 
∆(mcrA)183 ∆(mcrCB-hsdSMR-
mrr)173 endA1 supE44 thi-1 
recA1 gyrA96 relA1 lac [F  
proAB lacIqZ∆M15 Tn10 (Tcr)] 
Stratagene, Amersham 
Biosciences, UK 
E. coli DH5α F’/endA1 hsdR17 (rk
-mk
-) 
supE44 thi-1 recA1 gyrA (Nalr) 
relA1 ∆(laclZYA-argF)U169 
deoR (F80dlacD(lacZ)M15) 
 
Invitrogen, UK 
E. coli SM10 λpir recA::RP4-2-Tc::Mu, λpir, R6K, 
thi, thr, leu, tonA, lacY, supE 
Institute of Infection, 
Immunity & 
Inflammation, 
University of Glasgow 
(Prof. John G. Coote) 
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Table 4.  List of plasmids used in this study. 
Plasmid Relevant characteristics Origin 
pAKA16 P. multocida shuttle vector (ApR) Azad et 
al.(1994) 
pAKA19 P. multocida  suicide vector (ApR) Azad et al. 
(1994) 
pGEM-T-EASY E. coli cloning vector (ApR) Promega, UK 
pCMV-Script E. coli eukaryotic expression vector 
(KmR) 
Stratagene, UK 
pEGFP-N1 Eukaryotic expression vector with green 
fluorescent protein (GFP) reporter gene 
(KmR) 
CLONTECH 
Laboratories 
Inc., USA 
pMK-Express Pasteurellaceae prokaryotic expression 
vector with GFP reporter gene (KmR) 
Bossé et al. 
(2009) 
pMC-Express Pasteurellaceae expression vector with 
GFP reporter gene (CmR) 
Bossé et al. 
(2009) 
pDsRed-
Monomer 
E. coli expression vector with red 
fluorescent protein (RFP) gene (ApR)  
CLONTECH 
Laboratories 
Inc., USA 
pMK-Red pMK-Express with GFP gene  replaced by 
RFP gene from pDsRed-Monomer vector 
This study 
pSRG Dual expression vector modified from 
pEGFP-N1. Containing RFP gene directed 
by a prokaryotic promoter and GFP gene 
directed by a eukaryotic promoter. 
This study 
ApR : Ampicillin resistance   KmR : Kanamycin resistance 
CmR : Chloramphenicol resistance 
Materials & Methods 
 
42 
2.1.5 Growth of Pasteurella species 
P. multocida B:2, P. multocida A:3 and M.(Pasteurella) haemolytica A:1 strains 
from the frozen glycerol stocks were subcultured routinely on BHI agar medium. 
Liquid cultures of the strains were grown in the BHI broth medium in Universal 
containers overnight on an orbital shaker at 180-200 rpm at 37°C. Where 
necessary, antibiotic-resistant strains were grown on agar or in liquid media 
containing the appropriate antibiotic concentration. 
2.1.6 Isolation of spontaneous streptomycin-resistant strains 
P. multocida 85020 and JRMT12 were grown overnight (to approx. 1012 cells/ml) 
in BHI broth with shaking at 37°C. A 100 µl portion of each culture was spread on 
BHI agar supplemented with streptomycin (100 µg/ml). The seeded plates were 
allowed to dry and then incubated at 37°C for 48-72 h. Streptomycin resistant 
colonies were picked, and their phenotype confirmed by overnight subculture on 
agar medium containing the same concentration of streptomycin.  
2.2 Antibiotics 
Antibiotics used in this study were: ampicillin (Ap), chloramphenicol (Cm), 
kanamycin (Km), streptomycin (Sm), gentamicin (Gm) polymyxin B (Pm) and 
neomycin (Nm). All antibiotics were obtained from Sigma, UK. 
Sterile antibiotic solution was added to broth or agar media after the media had 
been autoclaved and then cooled to 50°C. The concentrations of the antibiotics 
used in selective media were (µg/ml): Ap (50), Cm (3.5, 12.5), Km (50), Sm 
(100), Gm (50-350), Pm (50-350) and Nm (50). 
2.3 Plasmid DNA extraction 
Plasmid DNA was isolated according to the QIAprep® Miniprep Purification System 
(Qiagen) (Appendix 3) procedure, based on alkaline lysis of bacterial cells 
followed by selective adsorption of plasmid DNA onto a silica gel membrane in 
high-salt buffer and subsequent elution in low-salt buffer. This procedure is a 
modification of the alkaline lysis method of Birnboim & Doly (1979). Bacteria are 
lysed under alkaline conditions, and the lysate is subsequently neutralised and 
adjusted to high-salt binding conditions in one step, and the lysate cleared by 
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centrifugation. The plasmid DNA, from the resulting supernatant is adsorbed on 
to the silica-gel membrane of QIAprep columns and RNA, cellular proteins and 
metabolites are not retained on the membrane upon washing but are found in 
the flow-through. After washing with washing buffer to remove salts, high-
quality plasmid DNA is then eluted from the QIAprep column with distilled 
water. The purified plasmid DNA is stored at -20°C. 
2.4 Restriction endonuclease digestion of DNA 
All restriction endonuclease enzymes were purchased from Promega or New 
England Biolabs (NEB, UK) and used according to manufacturer’s instructions. 
Restriction enzyme digestion was routinely performed in a 20 µl volume 
containing approximately 2 µg of DNA, 8 to 20 units of enzyme (2 µl) and 
reaction buffer diluted to 1 fold. Sterile distilled water, reaction buffer (10x), 
DNA solution and restriction enzyme were added sequentially to a sterile 
centrifuge tube placed on ice and mixed gently by tapping the tube. The 
reaction mixtures were incubated at 37°C for 4 h to 24 h and analyzed by gel 
electrophoresis in 0.7% (w/v) agarose. 
2.5 Agarose gel electrophoresis 
2.5.1 Sample preparation 
The sample DNA (5-30 µl) was mixed with 6x loading buffer (Appendix 2) in a 
ratio 5:1 prior to loading into the wells. The mixture was centrifuged briefly to 
remove bubbles before loading onto the gel. Two different DNA ladders were 
used, depending on the topological forms and the fragment sizes of DNA. For 
sizing the digested or linearised DNA fragments above 1 kb, 1 kb DNA Ladder 
(NEB, UK) was used and for linearised DNA fragments below 1 kb, 100 bp DNA 
Ladder (NEB, UK) was used (Appendix 2). 
2.5.2 Gel preparation 
Agarose (Roche, UK) was suspended in 1x Tris-borate-EDTA (TBE) buffer 
(Appendix 2) at a suitable concentration and heated until the agarose was 
completely dissolved. The solution was allowed to cool and SybrSafe (Invitrogen, 
UK) was added to a final concentration of 0.1 µg/ml. A gel tray was prepared 
and the gel was cast to the desired thickness. Upon setting, the gel was 
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immersed in 1x TBE buffer in a horizontal multi-sub midi-electrophoresis tank 
(Wolf Laboratories Limited, UK). 
2.5.3 Electrophoresis 
Electrophoresis was carried out at 80 V for 75 min using a Power Pac Basic (Bio-
Rad, UK) that is able to provide constant voltage throughout the running time. 
2.5.4 Visualisation of DNA 
An UV transilluminator (UVIpro, UVItec) was used to visualise the SybrSafe-
stained DNA. Images were stored electronically using the provided software, 
UVtec (UVItec). Images were printed using a video graphic printer (UP-860, Sony, 
Japan). Electronic images were edited using Adobe Photosuite CS (Adobe Suite, 
USA). 
2.5.5 Purification of DNA from agarose gels 
QIAquick Gel Extraction kit (Qiagen, UK) (Appendix 3) was used according to the 
manufacturer’s instructions. The DNA band of interest was excised from a 
SybrSafe-stained agarose gel with a sharp scalpel under long-wave UV light. The 
size of the gel slice was minimised by ensuring there was little extra agarose 
around a band. The gel slice was weighed in a colourless tube and 3 volumes of 
buffer QG were added to 1 volume of gel (100 mg ≈ 100 µl). The tubes were 
incubated at 50°C for 10 min or until the gel slice was completely dissolved. The 
tubes were mixed by vortexing every 2-3 min during the incubation to help the 
gel to dissolve. The colour of the mixture should be yellow (similar to the buffer 
QG without dissolved agarose) after the gel slice was completely dissolved. If 
the colour of the mixture was violet, 10 µl of 3M-sodium acetate, pH 5.0 was 
added and then the colour turned to yellow. The yellow colour indicates a pH 
≤7.5 where the adsorption of DNA to the QIAquick membrane in a later step is 
most efficient. 
The dissolved gel samples, maximum volumes of 800 µl, were applied to the 
QIAquick column to bind DNA and then centrifuged at 13 000 x g in a 1.5 ml 
centrifuge tube using a tabletop microcentrifuge (Biofuge, Heraeus, Germany) 
for 1 min. Sample volumes of more than 800 µl were simply loaded in 800 µl 
batches and recentrifuged. The flow-through was discarded and the QIAquick 
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column placed back in the same collection tube. To remove all traces of 
agarose, 0.5 ml of buffer QG was added to QIAquick column and centrifuged at 
13 000 x g for 1 min. To wash the column, 0.75 ml of buffer PE was added to 
QIAquick column and then centrifuged at 13 000 x g for 1 min. The flow-through 
was discarded and, to remove completely the residual ethanol from buffer PE, 
the QIAquick column was centrifuged for an additional 1 min at 13 000 x g. The 
QIAquick column was then placed into a clean 1.5 ml centrifuge tube and 50 µl 
buffer EB added to the centre of the QIAquick membrane followed by 
centrifugation at 13 000 x g for 1 min to elute DNA. The average eluate volume 
was 48 µl from 50 µl elution buffer volume, and the maximum elution efficiency 
was achieved between pH 7.0 and 8.5.  
2.6 Estimation of DNA concentration 
DNA concentration was measured using NanoDrop™ 1000 (Thermo Scientific, UK). 
A 1-2 µl volume was placed at the measuring point before the DNA concentration 
was estimated by measuring the absorbance at 260 nm. The software was then 
used to calculate the DNA concentration using the Beer-Lambert equation which 
is modified to use an extinction coefficient with units of ng-cm/µl. This 
extinction coefficient gives a manipulated equation: 
c = (A * e)/b  
Where c is the nucleic acid concentration in ng/µl, A is the absorbance in AU, e 
is the wavelength-dependent extinction coefficient in ng-cm/µl and b is the path 
length in cm. The generally accepted extinction coefficients for DNA are 50 ng-
cm/µl for double-stranded DNA and 33 ng-cm/µl for single-stranded DNA. 
Alternatively, the approximate concentration of DNA fragments was determined 
visually on agarose gel, by comparison of their staining intensities with those of 
known quantities of marker DNA of a similar size. 
2.7 Concentration of DNA 
DNA that had gone through the gel extraction procedure was cleaned and 
concentrated before further manipulation. Qiagen Min-Elute (Appendix 3) kit 
with a pre-chilled collection column was used in this case. A three-fold volume 
of binding buffer (ER) was mixed with the sample before addition to the silica-
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gel column followed by centrifugation at 13 000 x g for 1 min. The column was 
then washed with wash buffer (PB) and DNA was eluted out with an elution 
buffer (EB) at a lower volume to increase the DNA concentration. 
2.8 Polymerase chain reaction (PCR) 
The PCR conditions were optimised, where necessary, according to the 
orthogonal array method described by Cobb & Clarkson (1994). The annealing 
and elongation thermal parameters were then adjusted to obtain optimal 
conditions. A Hybaid thermal cycler was used for all reactions. The products of 
the PCR were stored at –20°C or used immediately. 
2.8.1 PCR primers 
All primers were designed manually and assessed by online software such as 
Primer 3. During primer design, care was taken to avoid potential internal 
secondary structure and where possible a GC clamp was engineered at the 3’ 
end of the primer. Additionally, primers were also checked for sequence 
overlapping, possible dimerisation and compatibility of melting temperature 
(Tm) between paired primers. Tm values were calculated according to the 
equation: 
Tm (°C) = 4 (G+C) + 2 (A+T) – 5°C 
Primers (50 nmol, desalted) were obtained from Invitrogen (UK) and resuspended 
in sterile distilled water to give final concentrations of 100 pmol/µl or 25 
pmol/µl for PCR. Table 5 shows the primers used in this study. 
2.8.2 Components of PCR 
The reaction mixture (50 µl) contained (final concentration) 10 mM Tris-HCl (pH 
8.4), 50 mM KCl, 3.0 mM MgCl2, 0.2 mM of each deoxynucleoside triphosphate 
(dNTPs) (NEB, UK), 20 µM each primer, 1.0 U of Taq DNA polymerase (NEB,UK) 
and 1-5 µl of template DNA preparation. The PCR assays were performed in 0.5 
ml thin-walled dome cap tubes (Thistle Scientific, UK). 
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Table 5.  PCR primers used in this study. 
Primer designation Primer sequence Comments 
Inverse PCR primer 
Forward 5’ to 3’ 
(IPCR F) 
 
GTACCGAGCTCGAATTCATCG 
Amplifies oriP fragment from multiple cloning 
site (MCS) of pAKA16. 
Internal restriction sites in the primer, SacI and 
EcoRI 
Inverse PCR primer 
Reverse 3’ to 5’ 
(IPCR R) 
 
ATCCTCTAGAGTCGACCTGCG 
Amplifies oriP fragment from MCS of pAKA16. 
Internal restriction site in the primer, SalI 
oriP primer 
Forward 5’to 3’ 
(oriP F) 
 
CAGNNNCTGGCGAATGACTTCCTACCG 
Amplifies oriP gene from oriP fragment with an 
additional restriction site, AlwNI 
oriP primer 
Reverse 5’ to 3’ 
(oriP R) 
 
ACATGTAACCGCAGGCGTTTTGAC 
Amplifies oriP gene from oriP fragment with an 
additional restriction site, PciI 
RED primer 
Forward 5’ to 3’ 
(RED F) 
 
CTACATGTCCGCGCCAACCG 
Amplifies sodRED cassette from pMK-RED with 
an additional restriction site, PciI 
RED primer 
Reverse 5’ to 3’ 
(RED R) 
 
GCACATGTTCTACTGGGAG 
Amplifies sodRED cassette from pMK-RED with 
an additional restriction site, PciI 
  Materials & Methods  
48  
2.8.3 Conditions for PCR 
The following thermo-cycling parameters were used unless stated otherwise: 
Initial activation step at 94°C for 2 min, 30 cycles of denaturation at 94°C for 1 
min, annealing between 55°C to 70°C for 1 min, extension at 72°C for 2.5 min 
with a final extension at 72°C for 10 min. The amplified products were analysed 
by electrophoresis in a 0.7% (w/v) agarose gel (section 2.5). 
2.8.4 Inverse PCR (IPCR) 
Ochman et al. (1988) described IPCR as a method for the rapid in vitro 
amplification of DNA sequences that flank a region of known sequence. The 
method manipulates PCR, but it has the primers oriented in the reverse direction 
of the usual orientation. The template for the reverse primers was a restriction 
fragment that had been ligated upon itself to form a circle. 
Plasmid pAKA16 was digested with restriction enzyme PstI and a 1800 bp 
fragment containing the origin of replication was isolated. The fragment was 
then ligated (section 2.10.2.2) and, after deactivation of T4 DNA ligase, the 
mixture was used as a template for PCR (section 2.8.2). The IPCR programme on 
the thermal-cycler was the same as stated in section 2.8.3. 
2.8.5 Colony PCR 
This type of PCR was normally used to screen bacterial clones for positive 
transformants with correctly ligated inserts in plasmid products. In colony PCR, 
the PCR components were the same as in section 2.8.2. However, instead of 
adding prepared DNA, a small amount of colony growth was added to the 
mixture. A slight modification of the PCR conditions, whereby an initial step of 
95°C for 5 min was used to assist in bacterial cell-wall breakage. After that, 
cycles were performed as described in 2.8.3. 
2.8.6 Purification of PCR products 
PCR products were purified using QIAquick PCR purification kit (Qiagen, UK) 
according to manufacturer’s instructions (Appendix 3). This protocol was used to 
purify fragments ranging in size from 100 bp to 10 kb away from primers, 
nucleotides, polymerase and salts.  
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Initially, 5 volumes of buffer PB were added to 1 volume of the PCR sample and 
mixed. The sample was then applied to the QIAquick column to bind DNA, and 
this was centrifuged on a tabletop microcentrifuge (Biofuge, Heraeus, Germany) 
for 1 min at 13 000 x g. The flow-through was discarded and the QIAquick 
column returned to the same tube. Buffer PE (0.75 ml) was then added to the 
column to wash the column by centrifugation at 13 000 x g for 1 min. The flow-
through was again discarded and the column was re-centrifuged at the same 
speed for 1 min. This was done to completely remove residual ethanol from the 
column. The column was then placed in a clean 1.5 ml centrifuge tube and 30-50 
µl of buffer EB was added to the centre of the column membrane. The column 
was left for 1 min and then centrifuged again as in previous steps to finally elute 
DNA. PCR products were used immediately or stored at -20°C. 
2.9 DNA sequencing 
DNA was purified with the relevant cleaning kit (eg: plasmid, PCR product). The 
sample of DNA and appropriate concentrations of primers were sent to The 
Sequencing Unit at the University of Dundee to perform DNA sequencing. A 
MegaBACE1000 (96 capillary) sequencer, which used Big Dye (Applied 
Biosystems) and ET-Dye Terminator (Amersham Bioscience) chemistries, was 
employed based on the dideoxy method developed by Sanger et al. (1977). Each 
dideoxy nucleotide contained a specific fluorescent dye that could be excited by 
a laser. The signals were then collected and analysed by specific software. A 
coloured electropherogram was produced. The data were downloaded and saved 
on to a CD. For data analysis, BioEdit (version 7.0.9.0) software was utilised. 
Preparations of clean template DNA produced a read of around 700 bases, 
including 400-700 bases of accurate sequence. The length of accurate sequence 
was primarily determined by the quality of the template DNA and the efficiency 
of primer annealing. 
2.10 Statistical analysis 
The means, standard deviation and standard error values of results data were 
calculated in Microsoft Excel when needed. Student’s t-test was also applied on 
associated data.   
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2.11 Sequence analysis tools (bioinfomatics) 
Two primary sequence databases; GenBank, which is maintained by the National 
Centre for Biotechnology Information (NCBI) and the Nucleotide Sequence 
Database maintained by the European Molecular Biology Laboratory (EMBL) were 
used to annotate and highlight the important properties of the raw sequence 
data. ENTREZ, a WWW-based data retrieval tool (NCBI), was employed to search 
multiple biological databases and retrieve relevant information including 
nucleotide and whole genomes. Entrez can be accessed via the NCBI web site at 
the following URL: http://www.ncbi.nlm.nih.gov/Entrez/.  
Sequence similarity searches of databases were performed to extract the 
similarities using Basic Local (Linear) Alignment Search Tool (BLAST) and FASTA 
programs. Information about these extracted sequences can be used to predict 
the structure or function of the query sequence. BLAST utilizes statistical theory 
to produce bit score and expert value (E-value) for each alignment pair (query to 
hit). The bit score indicates how good the alignment is; the higher the score, the 
better the alignment. The E-value indicates the statistical significance of a used 
pairwise alignment and reveals the size of the database and the scoring system. 
The lower the E-value, the more significant the hit. A sequence alignment that 
has E-value of 0.05 means that this similarity has a 5 in 100 (1 in 20) chance of 
occurring by chance alone. The p value of a similarity score is the high 
probability of obtaining the score in a chance similarity between two unrelated 
sequences of similar composition. Low p value corresponds to significant 
matches that are likely to have a real biological significance. In general, the 
score is calculated by an equation that considers identical or similar residues 
and any gaps in the aligned sequences using BLOSUM62 to assign a score for 
aligning any possible pair of residues. 
2.12 Cloning 
2.12.1 PCR product cloning 
2.12.1.1 Cloning into pGEM-T EASY™ plasmid 
The pGEM-T EASYTM plasmid is a linearized plasmid DNA with a single 3’–terminal 
thymidine at both ends. The T-overhangs at the insertion site increase the 
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efficiency of ligation of purified PCR products by preventing recircularization of 
the plasmid and providing a compatible overhang for PCR products generated by 
thermostable polymerases. The ligation and transformation procedures were 
performed according to the manufacturer’s instructions (Appendix 3). 
2.12.2 Standard cloning protocol 
2.12.2.1 DNA preparation  
Plasmid and insert DNA were subjected to restriction enzyme digestion to obtain 
complementary cohesive overhangs and the resultant fragments were gel-
purified (section 2.5.5). DNA concentrations were estimated according to section 
2.6 and ratios determined as follows: 
ng of insert = [(ng plasmid x kb size of insert) / kb size of plasmid ]  
x [molar ratio of   Insert/Plasmid] 
Insert: Plasmid ratios of 2:1 and 3:1 were commonly used. 
2.12.2.2 Ligation strategies 
Ligation reactions were performed in a total volume of 10 µl using 3 units of T4 
DNA ligase and 2x ligase buffer (Promega, USA). After incubation at 16°C for 18 
h for a blunt-end ligation, or at room temperature (22°C) for 3 h or 4-8°C 
overnight for a sticky-end ligation, the ligation reaction was terminated by 
heating the reaction mix at 70°C for 10 min, and then the products were stored 
at -20°C until further use. 
2.12.3 Dephosphorylation of linearized DNA 
In order to prevent linearized vectors from self-ligation or recircularization 
during cloning, the 5’-phosphate groups of double-stranded DNA fragments were 
removed by treatment with calf intestinal phosphatase (CIP) (NEB, UK), 
according to the protocol of Sambrook et al. (1989). 
Plasmid DNA (2-4 µg) was digested to completion with the appropriate 
restriction enzyme in a 40 µl volume. Then 2.5 µl (1 U/ µl) of CIP and 4.5 µl 10 X 
CIP buffer (NEB, UK) were added to the digestion mix which was then incubated 
at 37°C for 1-2 h. The CIP was heat inactivated at 75°C for 15 min and the 
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dephosphorylated DNA fragments were purified using QIAGEN MinElute Reaction 
Cleanup kit according to manufacturer’s instructions (Appendix 3). 
2.12.4   “Filling in” or “trimming” reactions for blunt end ligation 
For ease of cloning, incompatible DNA ends were converted into blunt ends. This 
was carried out by “filling in” of 3’ recessed ends (e.g. produced by EcoRI) or 
“trimming” of 3’ protruding ends of DNA (e.g. produced by PstI). 
Plasmid DNA was digested to completion with the appropriate restriction enzyme 
in a 40 µl volume and fragments were separated by agarose gel electrophoresis. 
DNA fragments of interest were purified as in section 2.5.5 and taken up in 30-50 
µl distilled water in a fresh microcentrifuge tube where DNA polymerase buffer 
(Invitrogen, UK) was added. dNTPs mix (a mixture of 25 mM dATP, dCTP, dGTP 
and dTTP, obtained from NEB, UK) was added to the tube at a final 
concentration of 1mM each (filling reaction) or 2 mM (trimming reaction). To this 
was added 1-2 µl of Klenow fragment of E. coli DNA polymerase I (Invitrogen, 
UK). The mixtures were incubated for 15 min at room temperature. DNA 
polymerase enzyme was inactivated by heating the reaction mixture to 75°C for 
10 min before proceeding with the ligation or cloning protocols. 
2.13 DNA transformation 
Electroporation, rendering prokaryotic and eukaryotic cells permeable to nucleic 
acid by exposure to electrical fields is a commonly used technique (Dower et al., 
1988). Both E. coli and P. multocida strains have been transformed to 
reasonable efficiencies with this technique (Dower et al., 1988; Jablonski et al., 
1992). 
2.13.1 Preparation of electro-competent cells 
An overnight culture of E. coli or P. multocida was diluted 1 in 100 in pre-
warmed 500 ml of LB or BHI broth respectively in a 2 L dimpled flask. The flask 
was shaken vigorously at 37°C until an OD540nm of 0.5-0.7 was achieved. The flask 
was then chilled on ice for 20 min and cells harvested at 4 000 x g for 15 min in 
a mid bench 4K15 Centrifuge (Sigma) at 4°C. The pellet was resuspended in 500 
ml of cold sterile distilled water and centrifuged as before. Next, the pellet was 
resuspended in 250 ml of cold sterile distilled water, centrifuged as before and 
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resuspended in 10 ml of cold sterile 10% (v/v) glycerol. Following a final 
centrifugation, the cells were resuspended in 1.5 ml of cold sterile 10% (v/v) 
glycerol and 100 ul aliquots were snap frozen in liquid nitrogen. Cells remained 
cold (on ice) at all times during the procedure and were stored at – 80°C. Cells 
remained electro-competent for up to three months as long as the storage 
temperature was maintained at –80°C. 
2.13.2 Electroporation procedure 
The E. coli and P. multocida strains were transformed by electroporation 
procedures described by Dower et al. (1988) and Jablonski et al. (1992). Prior to 
electroporation, a 2 mm electroporation cuvette (Bio-Rad, UK) and the safety 
chamber were chilled at –20°C. An amount of 1-5 µl of DNA (ligation mixture or 
plasmid preparation) and 50 µl of just thawed competent cells were added to 
the cuvette. The cuvette was tapped gently to ensure that the mixture settled 
at the bottom of the cuvette. A Bio-Rad pulse controller (MicroPulser 
Electroporator, Bio-Rad) was set at 2.0 kV (field strength 10 kV/cm2) for E. coli 
and 2.5 kV (field strength 12.5 kV/cm2) for P. multocida. The cells were pulsed 
once with a time constant of 4-5 ms for E. coli and 5-6 ms for P. multocida 
strains. Immediately following electroporation, 1 ml of pre-warmed SOC medium 
(Appendix 1) for E. coli or BHI broth for P. multocida strains was added and the 
cells were incubated at 37°C with shaking at 180 rpm for 1 h (E. coli) or 3-4 h (P. 
multocida) to allow expression of plasmid-encoded antibiotic resistance. 
Aliquots of 50-100 µl transformed cells were then spread onto selective plates 
containing appropriate antibiotic and the plates were incubated at 37°C to 
obtain transformant colonies. 
2.13.3  Blue and white screening of recombinants 
Following incubation of transformed cells in SOC medium, 100 µl aliquots were 
spread onto pre-warmed LB agar plates containing appropriate antibiotics, 2 
mg/ml of isopropyl-D-thiogalactopyranoside (IPTG, Sigma) and 40 mg/ml of 5-
bromo-4-chloro-3-indolyl-D-galactoside (X-gal, Sigma). The plates were then 
incubated at 37°C overnight. Resultant white colonies (potentially containing 
insert) were sub-cultured and plasmid DNA was purified according to section 2.3. 
The plasmid was then subjected to restriction enzyme analysis (section 2.4) to 
assess the presence of insert. 
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2.14 Conjugation 
The following method was adapted from Bradley et al. (1980). Each strain was 
grown overnight at 37°C, 180 rpm in 5 ml BHI for P. multocida recipient strain or 
LB broth for E. coli donor strain containing appropriate antibiotic. An aliquot 
(0.5 ml) of overnight culture was inoculated into 10 ml pre-warmed BHI or LB 
broth respectively and incubation continued for 2 h with E. coli and 4 h for P. 
multocida or until both cultures reached an optical density (OD540nm ) of 0.5-0.6 
(± 5 x 107 cells/ml). The cells were harvested by centrifugation at 4500 x g for 5 
min and washed with the same respective medium and then resuspended in 200 
µl of medium. Equal volumes (50-100 µl) of the culture of donor and recipient 
strains were mixed gently in a centrifuge tube. Aliquots were then transferred 
onto BHI agar plates containing selective antibiotics and left to dry at room 
temperature before incubating at 37°C, face up, for 48 h. 
2.15 Mammalian cell lines 
The mouse macrophage-like cell line, J774.2 and the bovine lymphoma cell line, 
BL-3, were maintained in RPMI 1640 medium (Sigma, UK) and the embryonic 
bovine lung cell line, EBL, was maintained in MEM 2279 medium (Sigma, UK).  All 
media contained calf serum (10% v/v) and 10 mM glutamine and supplemented 
with antibiotics (1% penicillin and 1% streptomycin). Approximately 105 cells/ml 
were seeded in tissue culture plates or flasks and incubated for 48 to 72 h at 
37°C, 5% CO2 until cell numbers had increased to 5 x 10
5 cells/ml or a confluent 
monolayer had formed in the case of EBL cells. Cell numbers and viability were 
confirmed by trypan blue exclusion counts (section 2.16). Frozen stock was 
prepared by mixing 1 x 105 cells/ml of the mammalian cells in 1 ml of dimethyl 
sulphoxide (DMSO) containing calf serum (90% v/v) in a storage vial and stored in 
a liquid nitrogen tank for future use. 
2.16 Cell viability assessment 
Cell viability was measured using the trypan blue exclusion method. For cell 
counting, a mixture containing 10 µl of trypan blue (0.4% w/v) (Sigma, UK) and 
10 µl of the cell suspension was placed in an improved Neubauer (1/400 mm2 x 
0.1 mm depth) counting chamber. After 10 min, the chamber was viewed by 
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light microscopy and examined under x10 objective lens. For each sample, the 
number of cells in four squares was determined, the average number of cells per 
single square was determined and multiplied by 2 x 104 to give the number of 
cells per ml. Viability of cells was determined by blue stained cells being 
counted as dead cells while clear cells were counted as viable. 
2.17 In vitro assays 
2.17.1 Adherence assay 
P. multocida strains were harvested from 18-h cultures in BHI broth, washed 
twice in Phosphate-buffered saline (PBS) (Appendix 2) and resuspended in MEM 
medium without antibiotics. The density of each strain was adjusted to an 
optical density corresponding to approximately 1 x 107 colony forming units 
(CFU)/ml to allow a final multiplicity of infection (MOI) of 100 bacteria/ 
mammalian cell. One microlitre of bacterial suspension was added to each well 
of 24-well tissue culture plates containing J774.2 suspension, BL-3 suspension or 
EBL monolayer. The plates was centrifuged at 1200 x g for 5 min in a Heraeus 3 
S-R centrifuge and then incubated in a CO2 incubator at 37°C for 2 h. The EBL 
monolayer was washed once with PBS and trypsinized by addition of 1 ml of 0.5% 
trypsin-EDTA (pH 7.0) (Sigma, UK) per well and incubated for 5 min at 37°C with 
5% CO2. All mammalian cells were harvested in PBS into universal tubes and the 
plates washed again with PBS to recover remaining cells. Pooled suspensions 
were centrifuged at 1200 x g for 5 min at room temperature, pellets 
resuspended with PBS and then re-centrifuged (to remove remaining bacteria 
and, for EBL cells, any traces of trypsin-EDTA). Cells were then resuspended in 
mammalian cells assay medium (Appendix 4) and an aliquot was removed for 
trypan blue staining (section 2.16) to assess cell viability. The remaining cells 
were lysed by addition of digitonin (100 ug/ml) and incubation for 30 min at 
37°C with 5% CO2. The adherent bacteria were estimated by serial dilution of 
the suspension, plating aliquots onto BHI and LB agar and incubating at 37°C 
overnight before counting. 
2.17.2 Invasion assay 
The invasion assay was performed according to the adherence assay with an 
additional step. After incubation of the bacteria/mammalian cell mixture in the 
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24-well plate for 2 h, the wells were washed gently with PBS to remove the 
unattached bacteria, for EBL cells. For J774.2 cells, the cells were centrifuged 
at 1200 x g for 5 min in a Heraeus 3 S-R centrifuge and the pellet was 
resuspended with J774.2 assay medium (Appendix 4). The washing step was 
repeated twice. A millilitre of assay medium with antibiotics [polymyxin (50 
ug/ml) and gentamicin (50 ug/ml)] was added to each well to kill any remaining 
extracellular bacteria. The plate was then incubated for 1 h at 37°C with 5% 
CO2. The methods for assessment of mammalian cell viability and quantification 
of intracellular bacteria were done as above. 
2.17.3 Intracellular survival assay 
The intracellular survival assay was done according to the invasion assay with an 
additional incubation step. After the antibiotic treatment for 1 h in the second 
incubation period of the invasion assay, the experimental wells were washed 
twice with PBS. A millilitre of EBL assay medium (Appendix 4) with various 
concentrations of antibiotics [polymyxin (0-50 ug/ml) and gentamicin (0-50 
ug/ml)] was added to the designated wells. The plates were further incubated 
up to 4 h at 37°C with 5% CO2. The methods for assessment of EBL cell viability 
and quantification of intracellular bacteria were done as above. 
2.17.4 Invasion inhibition assay 
Bacterial strains were prepared as in the adherence assay. The EBL cell 
monolayers in the wells of the tissue culture plates were treated with 1 ug/well 
of cytochalasin D for 1 h. The wells were then washed twice with PBS, and MEM 
medium without antibiotics was added prior to addition of the bacteria. The 
invasion assay was then performed as described above. 
2.17.5 Transfection assay 
Briefly, for one well of a 6 well plate, 100 µl Opti-MEM (Invitrogen, UK) was 
mixed with 4 µl Lipofectamine 2000 (Invitrogen, UK) in a sterile centrifuge tube 
prior to incubation at room temperature for 5 min. In a separate sterile 
centrifuge tube, a total of 1 µg DNA was added to 100 µl Opti-MEM and mixed by 
gentle tapping. Following incubation, the entirety of the Lipofectamine 
2000/Opti-MEM mixture was added to the centrifuge tube containing DNA. The 
contents were mixed by gentle tapping and incubated at room temperature for 
Materials & Methods 
 
57 
20 min. Cell culture medium on cells was discarded and replaced with 2 ml/well 
of antibiotic-free, supplemented growth medium. 200 µl of transfection mixture 
was added per well and cells incubated overnight at 37°C, 5% (v/v) CO2. At 24 h 
post-transfection, growth medium was discarded and replaced with 1.5 ml of 
fresh growth medium. Transfected cells were maintained for 24 h at 37°C, 5% 
(v/v) CO2 before viewed under an inverted microscope (Zeiss Axiovert 40 CFL). 
Phase contrast light images were captured at x20 and x40 magnification using a 
Zeiss AxioCam MRcS camera attached to a Zeiss Axiovert 40 CFL Microscope and 
images were processed with Zeiss Axiovision software. 
2.18 Fluorimetry assessment 
The patterns of GFP expression in bacterial strains expressing fluorescent 
protein were monitored using a fluorimeter (FLUOstar OPTIMA, BMG Labtech, 
UK). A sterile flask containing 100 ml of fresh broth supplemented with 
antibiotics at a final concentration of 50 µg/ml was inoculated with 1 ml of an 
overnight culture of P. multocida B:2 or E. coli XL-1 BLUE. It was then left 
shaking at 180 rpm, 37°C. 1 ml of growth culture was taken at every hour 
interval and its optical density at 600 nm (OD600nm) were measured using a cell 
density meter (WPA CO8000, Biochrom Ltd., UK) in a polystyrene cuvette 
(FisherBrand, UK). The suspension were then transferred into a centrifuge tube 
and centrifuged at 13 000 x g for 1 min. The pellet was resuspended in 1 ml of 
PBS and the OD600nm was measured again and a 200 µl aliquot placed in a well of 
a 96 well flat-bottom dish (Corning, USA) in triplicate before assessing the 
fluorescence intensity (FI) via the fluorimeter set with a fluorescent light filter: 
Excitation 485-12 nm, Emission 590 nm. All samples were compared with 
bacteria only to eliminate background. Samples were taken at hourly intervals 
until OD600nm reached stationary phase (~2.0). 
2.19 Transmission electron microscopy (TEM) 
All bacterial strains and EBL cells were prepared as described in the adherence 
assay. The bacteria/EBL cells mixture was incubated for 4 h at 37°C with 5% 
CO2. After trypsinization, cell viability was assessed and the remainder of the 
cells were centrifuged at 1200 x g for 5 min. The pellet was fixed with 2% (v/v) 
glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.2) at 4-8°C overnight, 
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washed three times with 0.1 M cacodylate buffer and embedded in 2% agar gel. 
One millimeter cubes were dehydrated in graded alcohol 70-100%, post-fixed in 
1% osmium tetroxide and embedded in epoxy resin. Ultra-thin sections were 
obtained by a MT-2B ultramicrotome and stained with lead citrate and 0.5% 
(w/v) uranyl acetate. Sections were examined with a LEO 912AB transmission 
electron microscope operating at 80 kV at 1000x magnification. 
2.20 Fluorescence imaging 
2.20.1 Cell fixation 
2.20.1.1 EBL cells 
EBL cells were treated according to the invasion assay above (section 2.14.2). 
The only difference for fluorescence microscopy (FM) slide preparation was that 
the EBL cells were seeded in a chamber-slide (NUNC, UK) rather than a 6-well 
plate. This is because cells can be fixed directly to the slide after removing the 
removable well off the chamber slide. This method proved to be more efficient 
than the conventional method by increasing the quantity of cells to be analyzed 
after fixation. 
As mentioned in the above method (section 2.14.2), after antibiotic treatment 
to eliminate extracellular and adherent bacteria, the monolayer was washed 
twice with PBS. CellMask plasma membrane stain (GE Healthcare, UK) (5 µg/ml) 
(diluted according to manufacturer’s instructions) was added at 200 µl per well. 
The chamber-slide was then incubated for 7 min at 37ºC supplemented with 5% 
CO2. The staining solution was removed from the well and the cells washed two 
to three times with PBS. About 200 µl of pre-warmed paraformaldehyde (PFA) 
(4% v/v) was added to each well and incubated for 30 min at 37ºC supplemented 
with 5% CO2. PFA was then removed from the well by washing three times with 
PBS. The removable wells were then removed from the chamber-slide and the 
slide was left to dry. 
Fluorescence mounting medium (DAKO, UK) was used to cover the fixation area 
on the chamber-slide. A cover slip was then gently applied on top of the medium 
to avoid air bubble formation. Any gap between the cover slip and the chamber-
slide was then sealed-off using a nail polish to prevent air pockets from forming. 
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The slide was left for 10 min to properly fix the mounting media. It was then 
cleaned and labelled before arranging in a slide box and stored in the dark. 
2.20.1.2 Fluorescence measurement and staining of bacterial strains 
An overnight culture of P. multocida B:2 strains with respective plasmid was 
diluted (1:100) in 100 ml of pre-warmed BHI broth in a 500 ml dimpled flask. The 
flask was shaken vigorously at 37°C until an OD540nm of 0.3-0.5 was obtained. One 
millilitre of the bacterial suspension was taken and centrifuged at 13 000 x g for 
1 minute. The pellet was then resuspended in 1 ml of PBS and its OD540nm was 
again measured. An aliquot of 200 µl was transferred from the PBS suspension 
into a flat-bottom 96-well plate. All samples were done in triplicate. 
Fluorescence intensity (FI) was then measured using a fluorimeter (Fluostar, UK) 
according to a customized set-up (section 2.18). 
A vial of CyeDye (Amersham, UK) was mixed with 100 µl of PBS according to the 
manufacturer’s instructions and was ready for use. The dye was then mixed with 
bacterial suspension at a ratio of 1:20 (25 µl of dye to 500 µl of bacterial 
suspension). The mixture was then incubated in the dark at room temperature 
for an hour to allow staining of bacterial free-peptide groups on the outer 
membrane. After incubation, the suspension was pelleted at 13 000 x g for 1 min 
and washed with 1 ml of PBS before being re-centrifuged. The washing step was 
repeated until the suspension was no longer coloured.  
For fixation, an aliquot of the suspension was mixed with 4% (v/v) of 
paraformaldehyde (PFA) (1:1). About 20 µl of the fixation mixture was spotted 
onto a clean spot-slide which was then left at room temperature to dry. 
Fluorescence mounting medium (DAKO) was used to cover the fixation area on 
the spot-slide. A cover slip was then gently applied on top of the medium to 
avoid air bubble formation. Any gap between the cover slip and the slide was 
then sealed-off using nail polish. The slide was left for 10 min to properly fix the 
mounting media. It was then cleaned and labelled before arranging in a slide box 
and stored in the dark. 
2.20.2 Fluorescence microscopy (FM) 
Fluorescence imaging was carried out using the Zeiss AxioImager M1 upright 
fluorescence microscope (Carl Zeiss, UK) connected to a Hamamatsu Orca 03 and 
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QIClick digital charge-coupled device (CCD) camera. The system allows 
visualization of fluorescence at high spatial resolution (1200 x 1300 pixels) and 
high bit depth (12-bit gray scale). Acquisition, visualization, measurement and 
restoration of the images were then processed with Volocity software (Perkin 
Elmer, UK). 
2.21 Immunosuppression by P. multocida B:2 
2.21.1 Preparation of bacterial cell-free extract (CFE) 
CFE of different bacterial strains were prepared from 18 h broth cultures. Cells 
were collected by centrifugation at 3 000 x g for 30 min at 4ºC (RC-5B, Sorvall, 
UK) and washed three times with PBS. A thick suspension of bacteria in 5 ml PBS 
was lysed by sonication using a Vibra Cell ultrasonic processor (Jencons-PLS, 
Leighton Buzzard, UK) for three 60-s bursts with intermittent cooling on ice. The 
broken-cell suspension was centrifuged at 3 000 x g for 30 min at 4ºC, and the 
supernatant was filtered through a 0.2 µm-pore size membrane (Sartorius, UK). 
The protein concentration was determined by Bradford assay (section 2.21.2) 
and adjusted to a desired concentration by adding sterile PBS. 
2.21.2 Protein quantification 
The Bradford assay was used to measure the protein content of all CFE 
preparations in this study. The Bradford reagent (Bio-Rad, UK) was used to 
provide a quantitative measurement of protein concentration of samples 
containing soluble proteins. When Coomassie dye binds protein in an acidic 
environment, an immediate absorbance shift occurs from 465 nm to 595 nm with 
a simultaneous colour change of the reagent from green/blue to blue. The 
Bradford’s reagent was diluted 1 in 5 with sterile distilled water and filtered 
through a 0.45 µm-pore size membrane filter (Sartorius, UK) before use. The 
method required a standard curve that was established with different 
concentrations of bovine serum albumin (BSA) (NEB, UK) in PBS. A solution of 2 
mg/ml of BSA was prepared in PBS and 2-fold dilutions of this in PBS were 
prepared in a 96-well flat bottom plate. PBS alone was used as a blank or 
negative control. To a new 96-well flat bottom plate, 25 µl of each dilution of 
BSA and sample were mixed with 200 µl of diluted Bradford’s reagent. After 
incubation for 10 min at room temperature, the absorbance values were read at 
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OD620nm in a plate reader (FluoStar, UK). The sample-adjusted value was 
obtained after subtraction of the background value of the medium and the 
protein concentrations of the sample was then determined from the BSA 
standard curve. 
2.21.3 Isolation and preparation of peripheral blood mononuclear cells 
(PBMC) 
PBMC was isolated by the procedure of Vanden Bush with some modifications 
(Vanden Bush & Rosenbusch, 2002). Blood samples were provided by Dr Mara 
Rocchi from the Moredun Research Institute (MRI), Edinburgh. Samples were 
collected from the jugular vein of calves in heparinised Vacutainers (Becton 
Dickinson, Meylan, France) containing 170 I.U. heparin and kept on ice until 
being centrifuged at 1730 x g for 20 min at 20ºC (Heraeus, multifuge 3 S-R). The 
buffy coat was transferred into a universal tube containing Hank’s balanced salt 
solution (HBSS, Invitrogen, UK) without Ca2+ and Mg2+, at room temperature. 
Then the mixture was layered carefully on top of an equal volume of NycoPrepTM 
1.077 A (Fresenius Kabi Norge, Norway) and centrifuged at 600 x g for 20 min at 
20ºC. The interface opaque band was transferred to HBSS and washed once by 
centrifugation at 200 x g at 4ºC for 10 min. To lyse the contaminating 
erythrocytes, the pellet was suspended in red blood cell lysis buffer (Appendix 4) 
and kept for 10 min on ice and then washed with HBSS by centrifugation at 200 x 
g at 4ºC for 10 min. The pellet was then suspended in complete RPMI medium 
(Sigma, UK) supplemented with 10% heat-inactivated fetal bovine serum (Sigma, 
UK), 2 mM L-glutamine (Gibco, UK), 100 U of penicillin per ml, 100 µg/ml of 
streptomycin, 0.5% (w/v) nystatin, 1% (w/v) gentamycin, and 30 mM HEPES 
(Sigma, UK), to reach a final concentration of 1.0 x 106 viable cells/ml, as 
estimated by trypan blue staining and haemocytometer cell count, (Life 
Technologies, UK) (Appendix 4).  
2.21.4 Lymphocyte proliferation inhibition assay 
To investigate inhibitory effects of P. multocida B:2 on the proliferative 
response of PBMC to concanavalin A (ConA), 50 µl of the required concentration 
of a CFE was added to the designated wells and 100 µl of PBMC was added 
subsequently. The cells were pre-incubated with CFE for 1 h in the CO2 
incubator. After incubation, 50 µl of RPMI containing the required concentration 
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of ConA was added to the wells. Plates were incubated at 37ºC in a humidified 
atmosphere of 5% (v/v) CO2 and 95% air (Wolf Laboratories, Galaxy R). On the 
third day of incubation, each well was pulsed with 37 KBq [methyl-3H] thymidine 
(Amersham, UK) in 20 µl RPMI and incubated for another 18 h. The cultures were 
then harvested onto printed filtermat (glass fibre filter size 90-120 mm) (Wallac, 
Finland) by a semi-automated 96-well plate harvester (Tomtec M111) and 
allowed to dry at 37ºC. Dried filtermats then were bagged (Sample bag, Perkin 
Elmer, UK) with 4 ml of liquid scintillation cocktail (Betaplate Scint, 
PerkinElmer, UK) and sealed. The amount of incorporated [methyl-3H] thymidine 
was determined by a scintillation counter (Microbeta TriLux, PerkinElmer) and 
expressed as counts per minute (cpm). The stimulation index (SI) was expressed 
as: cpm of treated cultures/cpm of control cultures without treatment. 
  
 
3. RESULTS 
3.1 Rate of bacterial killing by antibiotics 
In order to establish whether P. multocida was able to enter and survive within 
mammalian cells, it would be necessary to ensure that all extracellular bacteria 
were killed before cells were lysed and intracellular bacteria released. As a 
preliminary to this, the optimum concentration of antibiotics to kill >99.9% of 
bacteria in 1 h was established. A sterile flask containing 20 ml of fresh BHI 
broth was inoculated with 1 ml of an overnight culture of P. multocida B:2 
JRMT12 in BHI broth. It was then incubated for 4 h (log-phase) at 37°C in an 
orbital incubator at 150 rpm. The bacterial cells were then collected by 
centrifuging at 3 000 x g for 30 min and the resulting pellet was resuspended in 1 
ml of PBS and diluted down to 105 CFU/ml. It was then added into a sterile BHI 
broth supplemented with the antibiotics gentamicin and polymyxin B sulphate, 
either separately or together, at concentrations ranging from 50 µg/ml to 350 
µg/ml. At 30, 60 and 120 min, samples were taken and plated onto BHI agar. The 
numbers of bacterial colonies were recorded after overnight incubation at 37°C. 
The antibiotics gentamicin and polymyxin B sulphate have been reported to have 
little effect on mammalian cells in 1 h (Rudin et al., 1970; Feingold et al., 
1974).  
According to the data in Table 6, the viability of the strain decreased rapidly 
upon treatment with either gentamicin or polymyxin B or when both antibiotics 
were used together. However, when the two antibiotics were used together, no 
viable bacteria was detected, even after 30 min with the lowest concentration 
of antibiotics. Hence, it can be concluded that P. multocida B:2 JRMT12 were 
eliminated completely (>99.99% killing) after 30 min of incubation with both 
antibiotics at 50 µg/ml.  The study was then followed by testing the antibiotics, 
gentamicin or polymyxin B either single or together, at a final concentration of 
50 µg/ml towards the parent strain (85020) of JRMT12 and other strains of 
Pasteurellaceae (P. multocida A3 and M. haemolytica A1) to observe the 
bacterial rate of killing. All three strains showed similar results to those for P. 
multocida B:2 JRMT12 (data not shown). This information gave confidence that 
the combination antibiotics at 50 µg/ml for 1 h would ensure killing of 
extracellular bacteria in subsequent invasion assays. 
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Table 6. Effect of antibiotics on viability of P. multocida B:2 JRMT12. 
 
Antibiotics (µg/ml) 
Polymyxin B (Pm) Gentamicin (G) Pm & G 
Time 
(min) 
50 100 250  350 50 100 250  350 50 100 250  350 
30 2 3 N N 3 N N N N N N N 
60 N N N N 2 N N N N N N N 
120 N N N N N N N N N N N N 
Bacteria were diluted to 105 CFU/ml in BHI broth containing a final concentration of 50-350 µg/ml each of gentamicin or polymyxin, alone or in 
combination. Cells were incubated at 37°C for 30, 6 0 and 120 min. Viable P. multocida B:2 were enumerated by plating 100 µl samples onto BHI agar in 
triplicate and incubated at 37°C, overnight. Contro l without antibiotic was executed in parallel. Values are average number of colonies detected on BHI 
agar.  
N    : no colony detected 
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3.2 Interaction between mammalian cells and Pasteurella 
species 
3.2.1 Effect of P. multocida B:2 on viability of J774.2 cells 
To obtain meaningful data on the adherence and invasive capacities of 
Pasteurella strains, it was necessary to show that bacteria were not killing a 
large percentage of mammalian cells during the 2 h incubation period used for 
the adherence and invasion assays. To determine the effect of P. multocida B:2 
on viability of mouse macrophage-like cells, J774.2, the cells were collected by 
centrifugation at 1500 x g at 3 h post-infection with bacteria at MOI 100:1, 
resuspended in assay medium and stained with trypan blue (0.4% w/v) (Sigma, 
UK) (section 2.16). Macrophage viability in the presence of bacteria was 
compared to the control J774.2 cells where no bacteria were present throughout 
the experiment. From graph A in Figure 10, it was demonstrated that none of 
the strains caused any toxicity affecting macrophage viability during the invasion 
assay. When compared to the control cells (J774.2 only), all the experimental 
cells (J774.2 + bacteria) gave a similar percentage of total cell viability at 80% - 
85% after 3 h of incubation.  There was also no significance difference in cell 
viability observed from J774.2 cells mixed with either the wild-type or mutant P. 
multocida B:2. 
3.2.2 Effect of P. multocida B:2 on viability of EBL cells 
To determine the effect of P. multocida B:2 on the viability of embryonic bovine 
lung (EBL) cells, the cells were trypsinized at 3 h post-infection with bacteria at 
MOI 100:1 and resuspended in EBL assay medium and stained with trypan blue 
(0.4% w/v) (Sigma, UK). EBL viability in the presence of bacteria was compared 
to that of the control cells where no bacteria were present throughout the 
experiment. According to graph B in Figure 10, none of the Pasteurella strains 
showed a toxic effect towards EBL viability during the time period of the 
standard invasion assay. All control and experimental cells were found to be at 
least 80 % to 90 % viable after incubation for 3 h.  
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Figure 10. Viability assessments of J774.2 and EBL cells by trypan blue 
staining. 
  Approximately 105 cells were infected with log-phase Pasteurella 
and E. coli strains at MOI of 100:1 (bacteria:mammalian cell) 
according to the standard invasion assay procedure (section 
2.14.2). After incubation for 3 h, cells were stained with trypan 
blue and counted in a haemocytometer under 10 x objective lens 
(section 2.16). Viability of cells was determined by blue stained 
cells being counted as non-viable while clear cells were counted as 
viable. Data represent the means (+ SEM) of three independent 
assays with duplicate samples.  
  A:  
Percentage of viable and non-viable J774.2 cells in; 
Uninfected controls [J774.2 (J7) only],  
J774.2 cells infected with P. multocida B:2 JRMT12 [J7 + JRMT12],  
J774.2 cells infected with P. multocida B:2 85020 [J7 + 85020],  
J774.2 cells infected with P. multocida A3 [J7 + A3],  
J774.2 cells infected with E. coli XL-1 BLUE [J7 + XL]. 
  B: 
  Percentage of viable and non-viable EBL cells in; 
Uninfected controls [EBL (E) only],  
EBL cells infected with P. multocida B:2 JRMT12 [E + JRMT12],  
EBL cells infected with P. multocida A3 [E + A3],  
EBL cells infected with M. haemolytica A1 [E + A1]. 
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3.2.3 Invasion of J774.2 cells by P. multocida and E. coli 
Detection within cultured mouse macrophage-like cells (J774.2) of the parent 
strain (85020) an attenuated derivative strain (JRMT12) of P. multocida B:2 and 
P. multocida A3 was determined by infecting the cells at ratios of 500:1 and 
100:1 bacteria per J774.2 cell (section 2.17.2). In order to enhance cell-to-cell 
contact, the mixture was centrifuged at 1500 x g for 3 min, followed by 
incubation for 2 h. Macrophages were then washed to remove the majority of 
extracellular bacteria and the residual extracellular bacteria were killed with a 
combination of gentamicin and polymyxin B sulphate each at a final 
concentration of 50 µg/ml for 1 h. After the incubation period, suspensions were 
washed 3 times with PBS to remove antibiotics before exposing the cells to 
digitonin (100 µg/ml) in assay medium for 30 min to lyse the mammalian cells 
and release any intracellular bacteria. Serial 10-fold dilutions were prepared 
from each sample in PBS and 100 µl portions were spread on BHI agar and 
incubated at 37°C for 48 h. E. coli XL-1 Blue was also included in the 
experiments as a presumed negative control for invasion and intracellular 
survival. 
Table 7 shows numbers of viable intracellular bacteria in J774.2 cells after 
incubation for 3 h and at two different multiplicities of infection. Uptake of the 
putative control strain, E. coli XL-1 Blue, was noted at 0.061 viable bacteria/ 
J774.2 cell. Because of the nature of macrophages, all strains do get 
phagocytosed and taken up. The uptake of P. multocida A3 was similar to that of 
E. coli XL-1 Blue. However, for the mutant strain, JRMT12, and parent strain, 
uptake was approximately 10-fold higher than that for the E. coli XL-1 Blue and 
P. multocida A3 strains. At MOI 500:1, JRMT12 uptake rate is 0.559 viable 
bacteria/J774.2 cell and at MOI 100:1 it reduced slightly to 0.483 viable 
bacteria/J774.2 cell. Similar results were obtained with the wild type strain, 
85020. At MOI 500:1, 85020 uptake rates was 0.459 viable bacteria/ J774.2 cell 
and it reduced slightly to 0.346 viable bacteria/ J774.2 cells when mixed at MOI 
100:1. There was no significant difference in the rate of uptake even when the 
MOI was reduced to 100:1. This results strongly indicated that the B:2 strains 
were invading or inducing their uptake over and above the baseline phagocytic 
capacities of the J774.2 cells. This ability could be one of the virulence 
properties possessed by the B:2 strain. 
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3.2.4 BL-3 cells  
The capacity of P. multocida strains to invade or be taken up by a bovine 
lymphoma (BL-3) cell line was also investigated. BL-3 cells were chosen as they 
were derived from one of the hosts of this pathogen. 
BL-3 cells were maintained and cultivated as described in section 2.15 and the 
invasion assay was carried out as detailed in sections 2.17.2 and 3.2.1. The 
experiment was done once comparing the wild-type B:2 85020 and its mutant 
derivative JRMT12 (Table 8). The invasion rate was not significantly different 
between the two strains, and gave similar values to those observed with the 
J774.2 cells. Since BL-3 cells are not phagocytic, the detection of the bacteria in 
the intracellular compartment of these cells confirmed that the B:2 strains had 
the capacity to promote their uptake into BL-3 cells. This invasive capacity was 
further examined using a bovine embryonic lung cells which represented more 
closely a cell barrier likely to be encountered by P. multocida B:2 during natural 
infection. 
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Table 7. Invasion of P. multocida and E. coli strains with J774.2 mouse 
macrophage-like cells at different multiplicities of infection 
(MOI).  
 
Bacterial invasion 
(No. of viable intracellular bacteria/ 
J774.2 cell) 
 
Strains 
MOI  
(500:1) 
MOI  
(100:1) 
P. multocida B:2 AroA- 
(JRMT12) 
0.56 + 0.13 
 
0.48 + 0.20 
P. multocida B:2 wt 
(85020) 
0.46 + 0.23 0.35 + 0.12 
P. multocida A3 0.05 + 0.02 0.06 + 0.04 
E.coli XL-1 Blue 0.06 + 0.03 0.09 + 0.03 
Invasion is expressed as no. of viable bacteria/J774.2 cell that resist exposure to polymyxin 
B and gentamicin each at a final concentration of 50 µg/ml for 1 h after an infection period 
of 2 h. Data represent the means (+ SEM) of three independent assays with duplicate 
samples. 
wt: wild-type 
 
 
Table 8. Uptake of Pasteurella multocida strains into bovine lymphoma 
(BL-3) cells at MOI 500:1. 
 
Strains Bacterial invasion 
(No. of viable intracellular 
bacteria/BL-3 cell) 
P. multocida B:2 AroA- (JRMT12) 0.72 
P. multocida B:2 wild-type (85020) 0.39 
Invasion is expressed as no. of viable bacteria/BL-3 cell that resist exposure to 
polymyxin B and gentamicin at a final concentration of 50 µg/ml for 1 h after an 
infection period of 2 h. 
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3.2.5 EBL cells 
The embryonic bovine lung cell line, EBL (DSMZ ACC192 BgVV, Jena, Germany) 
was maintained and cultivated as mentioned in section 2.15. A feature of P. 
multocida B:2 during HS disease is the rapid spread of infecting bacteria from 
the respiratory tract to the blood and lymph to cause a fatal septicaemia in less 
than 48 h. This may, in part, be caused by invasion of the respiratory epithelium 
by the P. multocida B:2 cells. Thus, using a mammalian cell line in vitro that is 
derived from the bovine respiratory system should parallel stages of the actual 
of infection in vivo.   
3.2.5.1 Establishment of an appropriate MOI between Pasteurella strains 
and EBL cells 
The extent of P. multocida B:2 invasion of EBL cells at different MOI ratios was 
the first experiment applied to this cell line. The invasion assay using JRMT12 
and parent strain was performed according to section 2.17.2 at 4 different MOIs: 
25:1, 50:1, 100:1 and 200:1 bacteria per cell. Table 9 shows that uptake of P. 
multocida B:2 JRMT12 at MOI 25:1 and 50:1 was poor compared to the uptake 
seen at MOIs of 100:1 and 200:1. From these observations, the minimum MOI 
necessary to achieve a significant invasion efficiency of JRMT12 into EBL cells 
was 100:1. 
3.2.5.2 Comparison of the extent of adherence and invasion between P. 
multocida B:2 strains and EBL cells 
As detailed in section 2.17.1, adherence of Pasteurellaceae strains towards EBL 
cells was determined by infecting the mammalian cells with bacteria in a 24- 
well tissue culture plate at an MOI of 100:1 bacteria per cell. The plate was 
briefly centrifuged to encourage close contact between EBL and bacterial 
strains. After exposure of the bacteria to EBL for 2 h, the cells were washed to 
remove any unattached bacteria. The cells were then exposed to digitonin for 30 
min at a final concentration of 100 µg/ml to lyse the mammalian cells and 
release attached bacteria and any possible intracellular bacteria. Serial 10-fold 
dilutions were prepared for each sample in PBS and aliquots (100 µl) were spread 
onto a BHI agar and incubated at 37°C for 24 h to 48 h. Bacterial counts would 
represent adherent plus intracellular bacteria. An adherence experiment was 
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normally done in parallel with an invasion experiment as the invasion assay has 
an additional step added where a parallel batch of cells was incubated with 
polymyxin B and gentamicin at a final concentration of 50 µg/ml for 1 h after 
the initial incubation for 2 h.  
Table 10 shows a comparison of adherence and invasion between the wild-type 
and mutant strains of P. multocida B:2 and EBL cells. Although this represents 
only a single assay, it appeared that JRMT12 bacteria adhered to EBL cells at 
higher rate than wild type 85020 cells and this was reflected in a slightly higher 
invasive capacity. This higher invasion capacity is in keeping with previous data 
(Tables 7 & 8) where JRMT12 also showed a slightly higher invasive capacity than 
85020 for J774.2 and BL-3 cells.  
3.2.5.3 Comparison of adherence and invasion between bovine 
Pasteurellaceae strains with EBL cells 
In order to confirm the ability of the mutant strain to adhere and to invade EBL 
cells, both the adherence and invasion assay were repeated and two other 
bovine Pasteurellaceae strains, P. multocida A3 and M. haemolytica A1 were 
used for comparison. Data in Table 11 shows that all bovine Pasteurellaceae 
strains were able to adhere to EBL cells at roughly the same rate of between 6 
and 8 bacteria per EBL cell after incubation for 2 h. However, in an invasion 
assay done in parallel with the adherence assay (Table 11 A), only the B:2 strain 
was detected intracellularly, at 0.76 bacteria per EBL cell, a value similar to 
those previously recorded (Tables 9 & 10). These data were then further 
confirmed when invasion assays were repeated with the bovine Pasteurellaceae 
strains. P. multocida B:2 JRMT12 was shown to be viable intracellularly in EBL 
cells at 0.67 bacteria per EBL cell (Table 11 B) and intracellular bacteria were 
again undetectable (for P. multocida A3) or present at a very low level (for M. 
haemolytica). These findings showed that all bovine Pasteurellaceae strain 
tested in this studies were able to adhere to EBL cells but only the B:2 strains 
were detected intracellularly. This strongly suggested that the B:2 strain may 
possess invasive properties which allow intracellular access to mammalian cells. 
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Table 9.     Invasion of EBL cells by P. multocida B:2 JRMT12 at different 
MOIs. 
        
 
 
 
 
 
Invasion is expressed as no. of bacteria/EBL that resisted exposure to polymyxin B 
and gentamicin at a final concentration of 50 µg/ml for 1 h after an infection period of 2 
h. Data represent the means (+ SEM) of three independent assays with duplicate 
samples. 
 
 
Table 10. Comparison of adherence and invasion rates between strains of 
P. multocida B:2. 
 
Strains aBacterial adhesion 
(No. of bacteria/EBL) 
bBacterial invasion 
(No. of viable 
intracellular 
bacteria/EBL) 
P. multocida B:2 
aroA- (JRMT12) 
23.2 1.58 
P. multocida B:2 
wild-type (85020) 
13 1.12 
 a Adhesion is expressed as no. of bacteria/EBL after exposure of EBL to bacteria for 2 h 
at MOI 100:1. 
b Invasion is expressed as no. of viable intracellular bacteria/EBL that resist exposure to 
polymyxin B and gentamicin each at a final concentration of 50 µg/ml for 1 h after an 
infection period of 2 h at MOI 100:1. 
 
0.25 + 0.08 200:1 
0.84 + 0.06 100:1 
0.07 + 0.01 50:1 
0.04 + 0.01 25:1 
Bacterial invasion  
(No. of viable intracellular 
bacteria/EBL) 
MOI 
(bacteria/EBL) 
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 3.2.5.4 Intracellular survival of P. multocida B:2 JRMT12 in EBL cells 
It was of interest to determine the length of time bacteria remain viable 
intracelullarly. In this section, an intracellular survival assay with the mutant 
strain JRMT12 was done, with a prolonged incubation time (total of 7 h) after 
the antibiotic treatment step in the invasion assay (section 2.17.3) before viable 
intracellular bacteria numbers were determined. 
Besides assessing intracellular survival, the observation were extended in an 
attempt to record any intracellular growth and replication of internalised P. 
multocida B:2 which might have occurred within the EBL cells. Three conditions 
were used to measure intracellular bacteria. After the standard invasion assay, 
some cells were further incubated without antibiotics for up to 4 h and some 
cells were further incubated for the same length of time in the presence of 
polymyxin B and gentamicin (P&G) at a final concentration of each of 10 µg/ml 
or 50 µg/ml. These latter two conditions were employed as a precaution. If, 
without the presence of antibiotic, any extracellular bacteria left after the 
initial antibiotic treatment had survived, they would replicate and invalidate the 
assessment of intracellular bacteria. Thus, P&G at 50 µg/ml was added during 
the prolonged incubation to eliminate any extracellular bacteria that might be 
left or might be released by dying mammalian cells. However, there was also the 
possibility that external antibiotic may enter mammalian cells during prolonged 
incubation (Eltahawy, 1983) and thus kill the intracellular bacteria. Thus, a 
batch of the cells was incubated with medium supplemented with P&G at only 
10 µg/ml of each in order to slow down or eliminate replication of any 
extracellular bacteria but also to minimise the possibility of uptake of antibiotic 
into mammalian cells and eradicating internalised bacteria. However, the data 
obtained (Table 12) showed that, after 5 or 7 hours of incubation, all three 
conditions showed a similar rate of decrease with time of the number of viable 
intracellular bacteria per cell when compared to the initial time (3 h) of the 
standard invasion assay, although there was some variation in the total number 
of intracellular bacteria recorded in the different batches of cells. This 
suggested that internalised bacteria might not be able to replicate 
intracellularly but were gradually eradicated by the EBL cells.  
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Table 11. Comparison of adherence and invasion rates between strains of 
Pasteurellaceae. 
Bacterial invasion 
(No. of viable intracellular 
bacteria/EBL) 
Strains Bacterial 
adhesion 
(No. of 
bacteria/EBL) A B 
P. multocida B:2 
AroA-  (JRMT12) 
 
6.94 + 6.08 0.76 + 0.07 0.67 + 0.46 
P. multocida A3 7.52 + 5.79 < 0.0001 
 
< 0.0001 
 
M. haemolytica A:1 6.59 + 5.13 < 0.0001 
 
0.002 + 0.002 
Adhesion is expressed as no. of bacteria/EBL cell after 2 h exposure of the EBL cells to 
bacteria at MOI of 100:1. 
Invasion is expressed as no. of bacteria/EBL cell that resist exposure to polymyxin B 
and gentamicin each at a final concentration of 50 µg/ml for 1 h after an infection period 
of 2 h at MOI 100:1. A: Invasion assays executed in parallel with adherence assays. B: 
Individual invasion assays without assessing adherence rate. Data represent the means 
(+ SEM) of three independent assays with duplicate samples. 
 
 
Table 12. Period of intracellular survival of P. multocida B:2 JRMT12 in 
EBL cells at MOI 100:1. 
No. of viable intracellular bacteria/EBL Invasion 
time (h) 
 Standard 
invasion 
assay 
No antibiotic 
added after 
washing 
P&G 10 µg/ml 
added after 
washing 
P&G 50 µg/ml 
added after 
washing 
3 1.49 + 0.55    
5  0.33 + 0.07 1.47 + 0.93 0.56 + 0.25 
7  0.22 + 0.05 0.59 + 0.27 0.24 + 0.24 
Internalized viable bacteria were evaluated as no. of bacteria/EBL after incubation of EBL 
with bacteria for 2 h followed by exposure to polymyxin B and gentamicin (P&G) each at 
a final concentration of 50 µg/ml for 1 h prior to further incubation for 2 h and 4 h in the 
presence of either 0, 10 or 50 µg/ml each of polymyxin B and gentamicin in the medium. 
Data represent the means (+ SEM) of three independent assays with duplicate samples. 
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These findings have important implications for the delivery of the inbound 
plasmid during bactofection (section 1.6.2.7), where the bacteria presumably 
need to die and undergo lysis for the release of the plasmid into the mammalian 
cells. Hence, gradual death of the bacteria intracellularly, as indicated by the 
data should help in gradual release of plasmid into the cytoplasm of the 
mammalian cells. Moreover, for the three antibiotic conditions used, the data 
suggested that the rate of decline of viable intracellular bacteria per EBL during 
prolonged incubation (total 7 h) was not influenced by the absence or presence 
of the antibiotics.   
3.2.5.5 Invasion inhibition assay of EBL cells with cytochalasin D 
In order to further examine the findings that P. multocida B:2 JRMT12 was 
invasive, an experiment to inhibit the actin-dependent phagocytosis of the 
mammalian cell might confirm not only the active uptake of bacteria but also a 
possible mechanism of entry into the host cell for this particular species.  
Cytochalasin D (CD) is a cell permeable mycotoxin, which causes both the 
association and dissociation of actin subunits. Pre-incubation of EBL cells with 
this mycotoxin would disrupt actin polymerization and actin filament formation 
necessary for phagocytosis. The invasion inhibition assay (section 2.17.4) was 
slightly modified from the standard invasion assay. The EBL cells were pre-
incubated with the mycotoxin before addition of bacteria. In one assay, CD was 
left with the cells throughout the experiment but, in another, CD was 
completely removed by washing before addition of bacteria. Table 13a shows 
the effect of cytochalasin D at different concentrations on invasion of EBL cells 
by the mutant JRMT12 strain. The data showed that CD was active at 1 µg/ml in 
preventing invasion. In Table 13b, EBL cell were pre-incubated with 1 µg/ml of 
CD. CD was then removed by washing the cells 3 times with PBS before adding 
the bacteria at MOI 100:1 (bacteria/EBL). Incubation was then followed as for 
the standard invasion assay but also prolonged as for the intracellular survival 
assay (total 7 h). It was observed that there was a steady decline in intracellular 
bacteria over the 7 h period in EBL not treated with CD. It was also clear that 
the effect of CD was not reversible, at least during the 2 h period when washed 
EBL cells were incubated with bacteria prior to antibiotic treatment. Thus, these 
confirmed the decline in viable intracellular bacteria with time and the CD 
treatment confirmed the active nature of bacterial uptake by EBL cells.  
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Table 13a. Effect of cytochalasin D at different concentrations on invasion 
of EBL by P. multocida B:2 JRMT12. 
Cytochalasin D 
(µg/ml) 
 
Bacterial invasion 
(No. of viable intracellular 
bacteria/EBL) 
0 1.95 
1 0.03 
2 0.07 
4 0.02 
8 0.01 
Invasion is expressed as no. of viable intracellular bacteria/EBL that resist exposure to 
polymyxin B and gentamicin each at a final concentration of 50 µg/ml for 1 h after an 
infection period of 2 h. EBL were pre-exposed to cytochalasin D for 1 h before adding 
the bacteria. Cytochalasin D was present throughout the experiment. 
 
 
Table 13b. Effect of cytochalasin D on invasion of EBL by P. multocida B:2 
JRMT12.   
Bacterial invasion 
(No. of viable intracellular bacteria/EBL) 
Cytochalasin D 
(µg/ml) 
 
3 h 5 h 7 h 
0 0.22 + 0.07 0.11 + 0.04 0.01 + 0.01 
1 < 0.0001 < 0.0001 < 0.0001 
After cytochalasin D treatment, monolayers were washed 3 times with PBS then treated 
with bacteria for the standard invasion procedure. Incubation was continued for 5 h and 
7 h. Data represent the means (+ SEM) of three independent assays with duplicate 
samples. 
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3.2.6 The transmission electron microscopy (TEM) of the interaction of 
bacteria with EBL cells 
To corroborate the invasive capacity of P. multocida B:2 towards mammalian 
cells and also to investigate intracellular location and possible fate of the 
bacteria once internalized, samples were taken for TEM after bacterial invasion 
of the EBL cells, at 2 and 3 h (section 2.19). 
EBL cells were treated with either P. multocida B:2 (JRMT12), P. multocida A3 
or M. haemolytica A:1 in a 24-well tissue culture plate at MOI 100:1. Samples 
were taken for fixation with glutaraldehyde and osmium tetroxide after 
incubation periods of 2 h and 3 h. After dehydration via graded alcohol steps, 
samples were embedded in epon araldite resin and serial ultra thin sections 
were stained with uranyl acetate and lead citrate before examination with the 
LEO 912AB transmission electron microscope.  
Micrograph images A and B (Figure 11) show examples of normal EBL cells not 
infected with bacteria. As early as 2 h after infection, some of the JRMT12 cells 
were found to adhere closely to EBL membrane. Micrograph C (Figure 11) shows 
a P. multocida B:2 JRMT12 bacterium in the process of being taken up by an EBL 
cell. Intracellular localization of P. multocida B:2 JRMT12 in EBL cells was 
observed after 3 h of incubation. For example, in micrograph image D (Figure 
11), bacteria were shown to be present in the vacuoles of the mammalian cells 
and many of the internalized bacteria appeared to be ruptured and in the 
process of degradation. At 2 h after infection, P. multocida A3 and M. 
haemolytica A1 were found around the EBL cells either near the surface or not 
associated with it (Figure 11: E & F). However, a search for intracellular bacteria 
of these 2 strains proved unsuccessful, in keeping with the apparent lack of 
uptake of these strains in the previous invasion assays (section 3.2.5.3). 
Table 14a shows morphological assessment of 90 EBL cells for each bacterial 
strain after incubation for 3 h. Out of 90 EBL cells infected with the JRMT12 
strain, 11% of the mammalian cells were shown to possess bacteria internally in 
vacuoles and 29% of the mammalian cells showed closely adherent bacteria 
around their cell surface. For the other two Pasteurella strains, although 
previous data from the adherence assay showed a similar capacity to adhere to 
EBL cells as the P. multocida B:2 (section 3.2.5.3), from the TEM observations, 
Results 
 
79 
only 3% of the EBL cells had adherent P. multocida A3 and only 4% of EBL cells 
had adherent M. haemolytica. The reason for this diference is not clear. As 
noted above, no internalised P. multocida A3 or M. haemolytica A1 bacteria 
were detected. In keeping with the results presented in section 3.2.2, 95.96% of 
EBL cells were viable by trypan blue staining at the time that the samples were 
taken for TEM.  
EBL cells infected with strain JRMT12, as reported in Table 14a, were scrutinized 
closely in the electron microscope to determine the approximate number of 
bacteria per individual EBL cell (Table 14b). Out of 90 EBL cells containing 
bacteria only 3% possessed between 12 and 16 visible bacteria and 8% between 2 
and 8 visible bacteria. Thus, 89% of the mammalian cells appeared to have no 
intracellular bacteria in these thin sections. This agrees with the data in Tables 
7, 8 and 9 from the invasion assays which showed an average of between 0.8 and 
1.5 bacteria per EBL cell. The TEM data showed that <10% of EBL cells actually 
internalised bacteria but, when they did, several bacteria were present.  
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Figure 11. TEM micrographs of EBL cells infected with bacteria. 
EBL cells were infected with P. multocida B:2 JRMT12, P. multocida A3 and M. 
haemolytica A1 at MOI 100:1 (bacteria per cell). Cells were centrifuged at 1200 x 
g for 3 min and incubated for 2 h. This was followed by washing of the cells to 
remove most of the extracellular bacteria and prepared for TEM at 2 h (A, C, E & 
F). In some experiments, after washing, cells were further incubated for 1 h 
with media supplemented with P&G at a final concentration of 50 µg/ml. Cells 
were then washed and prepared for TEM at 3 h (B & D). The main features to 
note are the localization of intracellular bacteria and non-internalized bacteria. 
A: EBL cells after 2 h of incubation. Normal appearance of the cell with 
existing vacuoles. 
B: EBL cells after 3 h of incubation.  
C: An EBL cell infected with P. multocida B:2 JRMT12 at MOI 100:1 after 2 h 
of incubation. The bacterium is adhering to the EBL cell surface and EBL 
cell shows extended membrane projections in the process of engulfing it 
(arrowed). 
D: An EBL cell infected with P. multocida B:2 JRMT12 at MOI 100:1 after 3 h 
of incubation. Bacteria localized in the vacuoles of an EBL cell (arrowed). 
E: An EBL cell infected with P. multocida A3 at MOI 100:1 after 2 h of 
incubation. Arrows show extracellular bacteria around the EBL cell. 
F: An EBL cell infected with M. haemolytica A1 at MOI 100:1 after 2 h of 
incubation. Arrows show extracellular bacteria around the EBL cell. 
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Table 14a. Assessment of the morphological features seen by TEM micrographs after infection of EBL cells with different 
Pasteurellaceae strains at MOI 100:1. 
Cells were centrifuged briefly after mixing and incubated for 2 h. After removal of most of the extracellular bacteria by washing, EBL assay medium with P&G at final 
concentrations of 50 µg/ml was added to the cells and incubation continued for 1 h. Samples for TEM were taken after 3 h of incubation. For each strain, 90 individual 
EBL cells were examined. Cells were assessed to be non-viable if the cell membrane was discontinuous or ruptured. Data represent the means (+ SEM) of three 
independent assays with duplicate samples.  
---- Not found 
Treatments Intracellular 
localisation 
of bacteria 
Percentage of EBL cells 
with intracellular 
bacteria in the vacuoles 
Percentage of non-viable EBL Percentage of EBL with bacteria 
attached on the outer surface 
P. multocida B:2  
JRMT12 + EBL 
 
Observed 11 + 2 5 + 1 29 + 14 
P. multocida A:3 
+ EBL 
 
---- ---- 5 + 1 3 + 1 
M. haemolytica 
A:1 + EBL 
 
---- ---- 4 + 0 4 + 4 
EBL only ---- ---- 4 + 0 ---- 
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Table 14b.  Percentage distribution of total intracellular P. multocida B:2 JRMT12 within 90 individual EBL at 3 h after challenge. 
 
No.of P. multocida B:2 JRMT12 within individual EBL 
 
Percentage of total number of EBL 
0 
1 
89 
0 
2 
3 
3 
1 
8 
9 
10 
11 
12 
13 
14 
15 
4 
0 
0 
0 
1 
0 
0 
1 
16 1 
 Cells were briefly centrifuged after mixing and incubated for 2 h. After removal of most of the extracellular bacteria by washing, EBL 
assay media with P&G at final concentration of 50 µg/ml were supplemented to the cells and incubated for 1 h. Samples for TEM 
were taken for fixation at this point. 90 individual EBL cells were examined. 
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To conclude the first part of the study, it was confirmed that both P. multocida 
B:2 strains were capable of adhering to and invading J774.2, BL-3 and EBL cells. 
It was also noted that, although all Pasteurella strains tested were able to 
adhere to EBL cells, only the B:2 strains were taken up intracellularly. P. 
multocida B:2 JRMT12 was able to survive intracellularly for at least 7 h 
although a steady decline of the number of viable intracellular bacteria was 
noted with time. The use of the actin microfilament formation inhibitor 
cytochalasin D indicated that the entry into mammalian cells might be by actin-
dependant process even in the non-phagocytic EBL cell line. From the cell 
viability assessment, mammalian cells were shown to be free from toxicity due 
to the pathogens added. TEM micrographs for strain JRMT12 showed bacteria 
both closely-associated with the cell surface and also located intracellularly, 
with most bacteria found in the vacuoles of the mammalian cells after 3 h of 
incubation. The other 2 strains of Pasteurella used were not detected 
intracellularly but were found loosely adhering at the cell surface of EBL cells 
after 2 h of incubation. Further, morphological assessment by TEM showed 
JRMT12 apparatus co-localising in a low percentage of mammalian cells rather 
than being invasive individually towards the majority of mammalian cells. These 
observations on the fate of P. multocida B:2 JRMT12 upon interaction with EBL 
cells were important preliminary observations that established that the B:2 
strain should act as a suitable carrier vehicle to deliver plasmids to mammalian 
cells. 
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3.3 Construction of a Pasteurella eukaryotic expression 
plasmid 
In order to develop a bactofection system for P. multocida B:2 JRMT12, one 
needs to understand the fate of the plasmid carried by the bacterium after it 
enters into mammalian cells. This understanding would be enhanced by actual 
visualization of fluorescence proteins from reporter genes. To achieve this, a 
eukaryotic expression plasmid that can stably replicate in P. multocida B:2 
JRMT12 is needed for fluorescent protein expression in mammalian cells. 
Eukaryotic expression plasmids have long been developed to study intracellular 
trafficking in mammalian cells and also for intracellular protein expression. A 
range of commercial plasmids has been designed to assist in achieving these 
purposes. They are mostly derivatives that carry a eukaryotic promoter for 
protein expression within the mammalian cell coupled to a ColE1 origin of 
replication that allows manipulation and propagation in E. coli. However 
plasmids originated with either ColE1 or pUC-based replication functions have 
not been reported to replicate in Pasteurellaceae family. 
This section explains the strategy for developing a eukaryotic expression plasmid 
that can replicate and be maintained in Pasteurella. As illustrated in Figure 12, 
two plasmids were manipulated in this strategy to develop a Pasteurella 
eukaryotic expression plasmid, pSJR. Plasmid pAKA16 (Azad et al., 1994) is a 
shuttle cloning plasmid developed in this laboratory for gene transfer to M. 
haemolytica and P. multocida. This plasmid was derived from a bovine isolate of 
M. haemolytica serotype A1 and was proven for its stability and ready 
amplification in E. coli and high mobilization frequency to M. haemolytica 
(Azad, 1992). Plasmid pCMV-sCRIPT (Stratagene, UK) is derived from a high-copy 
number pUC-based plasmid and is designed to allow replication in E. coli and 
replication and protein expression in mammalian systems. 
3.3.1 Inability of plasmid pCMV-sCRIPT to replicate in P. multocida B:2 
JRMT12 
Plasmid pCMV-sCRIPT was electroporated into P. multocida B:2 JRMT12 (section 
2.13.2). No colonies were detected on the antibiotic selection agar after 
incubation for 24 h after electroporation. The experiment was repeated several 
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times and each experiment included a control Pasteurella plasmid, pAKA16, 
electroporated into the same electro-competent host used. The control plasmid 
was successfully recovered from P. multocida after each experiment. This was 
taken as confirmation that plasmid pCMV-sCRIPT, which is a pUC-based plasmid, 
failed to replicate and to be maintained stably in P. multocida B:2 JRMT12. 
3.3.2 Development of plasmid pSJR  
3.3.2.1 Isolation of Pasteurella origin of replication (oriP) from pAKA16 
From the strategy (Figure 12), the origin of replication for the Pasteurella 
plasmid, oriP needed to be isolated from plasmid pAKA16 and ligated into 
plasmid pCMV-sCRIPT. Based on the pAKA16 map that Azad (1992) developed, 
several restriction enzymes were selected in order to isolate the oriP region. 
Restriction enzymes ApaLI, NdeI and AvaI were used to isolate the oriP region. 
However, after determination of plasmid size by gel electrophoresis after 
digestion, inaccuracies in location or existence of the restriction enzyme sites 
were detected and only undigested plasmids were recovered. 
As shown in Figure 12, PstI sites (fuchsia lines) are located at one side of the 
mob gene and another one is in the multiple cloning site (MCS) of pAKA16. After 
digestion and agarose gel electrophoresis analysis, a PstI fragment containing 
the oriP gene (1800 bp) was visible (Figure 13). The fragment was purified for 
further manipulation.  
3.3.2.2 Characterisation of oriP locus 
In order to sequence the oriP locus, primers were designed based on the only 
known sequence on the oriP fragment, the multiple cloning site (MCS). The MCS 
that was cloned in by Azad (1992) in developing plasmid pAKA16 was originally 
from plasmid pIC2OH and the full sequence of the MCS was published by Marsh 
et al. (1984). The location of the MCS is at one end of the oriP fragment. By 
using inverse PCR, possibilities to sequence the whole fragment and introduce 
required restriction enzyme sites were higher. The oriP PstI fragment from 
pAKA16 was ligated as described in section 2.12.2.2 and used as a template for 
inverse PCR (section 2.8.4) with inverse PCR primers (Table 5). PCR products 
were purified and cloned into plasmid pGEM-T-EASY™ (section 2.12.1.1).
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Figure 12. Cloning strategy: Development of plasmid pSJR. 
 
 
 
 
 
 
 
 
 
 
 
Fragment was self-ligated and served as 
inverse PCR template. PCR product was 
sequenced and primers designed with 
AlwNI and PciI restriction enzymes sites. 
oriP gene was isolated from pGEM-oriP 
after digestion with AlwNI and PciI.   
 
pSJR 
5.2 kb pCMV-sCRIPT 
3.5 kb 
Digestion with PstI Digestion with 
AlwNI and PciI 
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Figure 13. Agarose gel showing plasmid pAKA16 digested with PstI. 
 
 
 
 
 
 
 
 
 
 
              1                2 M 
1: Digested pAKA16 with PstI 
  
2: Undigested pAKA16 
  
M: 1 kb DNA ladder  
4000 bp 
3000 bp 
2000 bp 
1500 bp 
oriP fragment 
(1800 bp) 
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After transformation into E. coli DH5α, positive transformants were selected 
from the antibiotic selection plate. Plasmid purification and restriction enzyme 
analysis were executed to confirm the existence of the oriP fragment in the 
resulting plasmid, pGEM-oriP (Figure 14).  
The oriP gene was sequenced with inverse PCR primers and sequencing results 
were then analyzed with BioEdit (ver. 7.9.0) and sequences were compared in 
NCBI databases using BLAST (Figure 15). Six colour indicators were used to 
describe the sequence. The sequence in the yellow box was recognized as part 
of the MCS and lacZ gene from pIC2OH and the sequence upstream of this part of 
the fragment was used to design the inverse PCR primers (A and A). The blue 
boxes highlighted open reading frames (ORF) found in this fragment. The first 
ORF was found just before the sequence in grey box and the second ORF was 
located just before the sequence in the purple box. The sequences in these 
boxes are designated as the putative oriP gene. This assumption is supported 
with further evidence of an homologous region from the sequence in the red box 
towards similar sequences in the origin of replication from other Pasteurella 
plasmids. This was confirmed when the sequence of the whole fragment was 
compared with origin of replication from plasmid pJR1 (AY232670) from P. 
multocida, plasmid pD70 (DQ125466) from M. haemolytica, plasmid pIG1 
(U57647) from P. multocida and plasmid pAB2 (Z21724) from M. haemolytica. 
Numbers in bracket indicate PubMed accession numbers. All plasmids showed a 
99% match towards the sequence in the red box. A direct repeat was also 
recognized in the middle of the homologous sequence (green box).  
Direct repeats and inverted repeats (not found in this sequence) are some of the 
distinctive traits characteristic of the origin of replication in Pasteurella 
plasmids. After nucleotide BLAST analysis, the sequence in the purple box was 
highly matched with part of the mobilization gene, mbeAy from plasmid pIG1 
(U57647). The top un-highlighted sequence of the fragment was equivalent to 
the sequence in the ROB ß-lactamase region in plasmid pAB2 (Z21724). This 
possible designation was supported by the strategy used in developing plasmid 
pAKA16 (Appendix 6) which showed that the MCS of pIC2OH was cloned in near 
to the ß-lactamase region of the original plasmid.  
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3.3.2.3 Isolation of the oriP gene from oriP fragment 
The strategy outlined in Figure 12 shows that the oriP fragment from the inverse 
PCR product was cloned into plasmid pGEM-T-EASY™ (section 2.12.1.1). A new 
set of primers were designed based on the oriP fragment sequence (Figure 15). 
The primers sequences are underlined as indicated in the figure legend. In order 
to facilitate ligation of the oriP insert into plasmid pCMV-sCRIPT, restriction 
enzyme sites were incorporated into the oriP primers. An AlwNI site was 
included into the forward oriP primer and a PciI site was included into the 
reverse oriP primer. PCR was performed as in section 2.8 and PCR products were 
purified and cloned into plasmid pGEM-T-EASY™ (2.12.1.1). Positive 
transformants (pGEM-P) were digested with both restriction enzymes, AlwNI and 
PciI. After analysis with agarose gel electrophoresis, a ~400 bp band was 
identified and purified. This band represented the digested oriP gene ready for 
ligation into pCMV-sCRIPT (Figure 16a). 
3.3.2.4 Removal of pUC origin of replication (oriE) from pCMV-sCRIPT 
As shown in Figure 12, the oriE locus was removed from pCMV-sCRIPT using 
restriction enzyme digestion. Enzyme AlwNI cuts twice at the oriE locus at 3409 
bp and 3817 bp and the enzyme PciI cuts at 4909 bp. Double digestion with both 
of these enzymes removed the whole oriE gene from the plasmid. Digested 
pCMV-sCRIPT was then dephosphorylated with calf intestinal alkaline 
phosphatase (CIAP) and purified, before ligation with the oriP locus cut from 
pGEM-P (Figure 16b). 
The oriP gene prepared as above was ligated with prepared pCMV-sCRIPT. 
Numerous attempts at ligation were done but after transformation or 
electroporation, either in E. coli or P. multocida, positive transformants were 
never recovered. Thus, either the ligation failed to work or the putative oriP 
locus was unable to function as a replication origin. The latter possibility is more 
likely, as gel analysis of the ligation mixture showed an obvious higher molecular 
weight band at 3900 bp as well as the 400 bp fragment of oriP and the 3500 bp 
fragment of pCMV-sCRIPT (data not shown).  
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Figure 14. Agarose gel showing pGEM-oriP digested with EcoRI. 
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Figure 15. Sequence of oriP fragment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
CAAGCTTG CATGCCTGCA GGTCGACTCT AGAGGATCCC CGGGTACCGA GCTCGAATTC   
ATCGATATC TAGATCTCGA GCTCGCGAA CTTGGCACTG GCCGTCGTTT TACAACGTCG 
TGACTGGGAA AACCCTGGCG TTACCCAACT TAATCGCCTT GCAGCACATC CCCCTTTCGC 
CAGCTGGCGT AATAGCGAAG AGGCCCGCAC CGATCGCCCT TCCCAACAGT TGCGCAGCCT 
GAATGGCGAA TGACTTCCTA CCGACATCTT ACAATAAGCC GAGTGTTTGA GAAATACCAT 
TTATTAAACT GTCTTTTTCC ATAAGTGTTG CCATAATTCT CCCCCTTGTT TTATCTGCTC 
ATACCCCTGC TTTGTCTTTT GCGTTGAGAT ATTACCGTTT CAAGCTGTTT ATTAAACTCT 
GTAATGTCGT TAATTGCTCG CTGATTTCGT TGTACTGTTG AATGATCAAG GCGTTTTCGG 
CTCGCAAGCT CTCTAATTCT TTCGATAATT TCACTCGCTC TGTTTCTTGC TGTTCTAGCA 
AGGTTTTCAA GGTTTTCTCG TAAAGTAGTT CTAGTTCGGT CGCCATTTAT TTTTTCCCCT 
GTTTCTTGGT TTCTTGGATT TCGATTACTT TCAGGTTCTC GCCCCACGTT GAGTTGATAA 
AATCCTTGTC CACTGCTACA CAAGGCTTTA TCCCTTTCTC CGTTTTGCAA GTTGATAGCT 
TGATCCCCCC ACTCTGCTCT TTGGCTATCT CGGCTGAATT TTGTCGGTCT CTCTTGAAGG 
CGTTCTTCGC CTGCCACGTC AAAACGCCTG CGGTTATGGC TATCAAGGCT AATATCGTCA 
AGGCGATTAG GGTCGGCAAG CGATACATTC TCACGGTATT TTTTATCAAT TTCGCCTGCT 
CGATTTGGAT ATTTTCGGCT AAATTGTTCC CTGCGTGCTG TAACTGCTGT ATCAAGTTTT 
GCTCGTGCCG TTTGATAGCG TTCTGCACTA TCTCGCTTGT ACTCTCTAGC TCTTTCTGTG 
ATGTCTGCTG AAAGGTCTGT GCTAAATCTA AAATCTTGCT CATAGAAAGC CCCTTTTAAT 
CTTAAATTCT GTCCGTCAGT CTTGATTGAT AGGTTTTTTG GCGTAATGCG TGCAATTTCA 
AAACCTGCAC GTTCTAGGGC ATTTATAACG TCCTGTCGGT CGTTTATCTG CCCTGCGTTC 
GCTAAAGCTG TTAAACCGTC CGTAATCGCC TGTAAAGCCT GTTTTTTATC GGTTGGTAGG 
TCTTTGCGGT CAATCAGGTT TTTTTGCTTT ATAGGGTTGT TTGGGTCGCT TAGGCTGTAT 
TCGTGGTTGA TTACCTGCTT GAAGTTTTCA GCAAGTGGGC GGTCTGCCCT GTCGTAGTAG 
GGTTGTAGGC GTTTTCCGCT TGTCATCTCT ACGTTTGGGG ATAACGAAAT TCAGCTCAAG 
CCTGCCTTTG TCGGTGTGTT GTACCCACGC AATGTTATAT TGTTCAGGCT CAAGCCCTGC 
AAACATTGCC TTTTCAAAGC GTGCCATAAT CTCACGCTTT TGTATTTCGG GTAGGTCGCT 
TTCTTCAAAA GACAAGCAAC CTGCGGTGTA AGTGTTATTA AAATCAAGAC TATCAGCAAT 
ACTTTGTGAT AGTCGGGGAT CGCCCGAGAC CCCCCCAAAA AAAAAAAAAA A 
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Figure 16a. Agarose gel electrophoresis of oriP gene removed from pGEM-
P with AlwNI and PciI. 
 
 
 
 
 
 
 
 
 
 
Figure 16b. Agarose gel electrophoresis of pCMV-sCRIPT after digestion 
with AlwNI and PciI. 
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3.3.3 Analysis of pUC base eukaryotic expression plasmid, pEGFP-N1™ 
After numerous attempts to develop a Pasteurella eukaryotic expression plasmid 
from pCMV-sCRIPT had been unsuccessful, it was decided to change to another 
eukaryotic expression plasmid. The plasmid pEGFP-N1™ (Clontech, US) (Appendix 
4) was available in the laboratory. The plasmid has a similar backbone to pCMV-
sCRIPT but, in addition to that, it incorporated a reporter gene, EGFP, 
downstream of the viral immediate early promoter of cytomegalovirus (CMV). 
The EGFP gene encodes a red-shifted variant of wild type green fluorescent 
protein (GFP) which has been optimized for brighter fluorescence and higher 
expression in mammalian cells (excitation wavelength (Exc.) = 488 nm and 
emission wavelength (Ems.) = 507 nm). A MCS is located upstream of EGFP gene 
and a gene cloned here will be expressed as a fusion to the N-terminus of EGFP. 
However EGFP can still be expressed from the eukaryotic promoter individually 
without any protein coding gene fused at its N-terminal end. 
3.3.3.1 Electroporation into P. multocida B:2 JRMT12 and E. coli XL-1 Blue 
Although previous work had indicated that pCMV-sCRIPT was unable to replicate 
in Pasteurella, it was decided to conduct a more thorough examination with 
pEGFP-N1 in the hope that a few break-through clones would be detected that 
managed to overcome the replication barrier in Pasteurella. In order to detect 
the ability of plasmid pEGFP-N1™ to replicate and survive stably in P. multocida 
B:2 JRMT12, the plasmid was electroporated into this strain (2.13.2). 
Electroporation was also done, in parallel, with plasmid pAKA16 as a control and 
positive transformant were readily selected. With pEGFP-N1™, however, no 
colonies were detected on the antibiotic selective agar after 18 h of incubation 
at 37°C. However, when the plate was further incubated up to 36 h, small 
colonies were detected from the antibiotic (Km 50 µg/ml) selection plate. A 
dozen colonies were selected and transferred onto a duplicate plate and 
incubated for another 36 h. They were then transferred into BHI broth (Km 50 
µg/ml) and incubated overnight at 37°C with shaking at 180 rpm. Plasmid DNA 
was purified from individual cultures and analyzed with restriction enzyme 
digestion. All the 12 colonies originally selected proved to harbour plasmid 
pEGFP-N1™.  
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Electroporation was then repeated using several types of plasmid, pEGFP-N1™ 
purified from P. multocida B:2 JRMT12, pEGFP-N1™ purified from E. coli XL-1 
Blue, pGEM-oriP (section 3.3.2.2), pCMV-sCRIPT and pAKA16 (as a positive 
control). The experiment was repeated, first, to confirm the repetition of 
previous electroporation, and second, to assess whether pEGFP-N1™ purified 
from P. multocida B:2 JRMT12 was able to replicate more easily in Pasteurella 
than the original plasmid and produce faster-growing colonies. This would 
determine if any modification had been made towards the plasmid after 
replication in the mutant strain. In addition, this repeat experiment would verify 
whether or not pGEM-oriP and pCMV-sCRIPT would manage to replicate in 
JRMT12. In parallel, all the above plasmids were also electroporated into E. coli 
XL-1 Blue. 
After electroporation, positive transformants were selected from BHI agar (P. 
multocida B:2 JRMT12) or LB agar (E. coli XL-1 Blue) supplemented with either 
ampicillin (50 µg/ml) for plasmid pAKA16 and pGEM-oriP or kanamycin (50 
µg/ml) for plasmid pEGFP-N1™ and pCMV-sCRIPT. Observation after 18 h of 
incubation showed that all plasmids were successfully electroporated into E. coli 
XL-1 Blue without any significant difference in the number of colonies on 
individual selective plates.  For P. multocida B:2 JRMT12, colonies were 
detected only with pAKA16 after incubation for 18 h. When incubation was 
extended to 36 h, small colonies started to be visible on all other plates 
including those with plasmid pCMV-sCRIPT, and at a similar number (data not 
shown).  
Plasmid pEGFP-N1™ either purified from P. multocida B:2 JRMT12 or from E. coli 
XL-1 Blue, and electroporated into the mutant strain, showed no significant 
difference in either the number of colonies formed or the rate of colony 
formation on the selective agar plates after 36 h. After plasmid purification and 
restriction enzyme digestion analysis, it was proven that all plasmids were 
successfully electroporated into P. multocida B:2 JRMT12 and E. coli XL-1 Blue.  
3.3.3.2 Plasmid stability in P. multocida B:2 JRMT12 
Plasmid pEGFP-N1™ has the advantage of harbouring a fluorescence reporter 
gene, gfp (EGFP) downstream of its immediate early viral expression promoter 
(PCMVIE). Hence, among the plasmids tested above in section 3.3.3.1, this 
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plasmid is a more suitable candidate for following the fate of the plasmid after 
bacterial invasion into the intracellular compartment of mammalian cells. 
Therefore, P. multocida B:2 JRMT12 pEGFP-N1™+
 
was tested for its stability to 
harbour pEGFP-N1™. 
P. multocida B:2 JRMT12 pEGFP-N1™+ was plated onto a BHI agar with and 
without kanamycin (50 µg/ml). After incubation for 24 h, selected colonies were 
picked from both plates and were streaked onto fresh plates. After a further 24 
h, a dozen colonies were picked from both plates and inoculated into BHI broth 
with or without kanamycin (50 µg/ml) respectively. Plasmids were purified and 
analyzed by restriction enzyme digestion for confirmation of identity. Strains 
were subcultured everyday for 14 days and plasmids were purified and analyzed 
every alternate day. After 14 days, all 12 colonies of P. multocida B:2 JRMT12 
pEGFP-N1™+ taken from BHI agar without antibiotic were found to be still 
harbouring the plasmid, pEGFP-N1™. This demonstrate that pEGFP-N1™ was 
stable in P. multocida B:2 JRMT12 even in the absence of an antibiotic selection. 
 3.3.3.3 Growth curve of P. multocida B:2 JRMT12 pEGFP-N1™+
 
The growth curve of P. multocida B:2 JRMT12 pEGFP-N1™+ was compared to the  
E. coli XL-1 BLUE pEGFP-N1™+
 
strain. Figure 17, graph A shows the growth curves 
of P. multocida B:2 JRMT12 pEGFP-N1™+ cultured in BHI broth supplemented 
with kanamycin (50 µg/ml) and E. coli XL-1 BLUE pEGFP-N1™+
 
cultured in LB 
broth supplemented with kanamycin (50 µg/ml). Both strains showed a similar 
pattern in their growth curve. Next, P. multocida B:2 JRMT12 and P. multocida 
B:2 JRMT12 pEGFP-N1™+ were compared. In parallel, the mutant strain 
harbouring the plasmid was cultured in BHI broth with and without kanamycin 
(50 µg/ml) and the mutant strain without plasmid was cultured in BHI broth 
without antibiotic.  
Graph B shows that as expected, the mutant strain without plasmid entered 
exponential phase more quickly than the mutant strain harbouring pEGFP-N1™. 
However, comparison of P. multocida B:2 JRMT12 pEGFP-N1™+growth in BHI 
broth with and without antibiotic supplementation showed that the strain 
cultured in media without antibiotic entered exponential phase slightly quicker 
than the strain cultured in media supplemented with antibiotic, though the 
difference in the exponential phase was insignificant. The presence of plasmid in 
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P. multocida B:2 JRMT12 pEGFP-N1™+ was determined at the end of this 
experiment from both conditions. In fact, cells harvested at the same OD600nm 
showed the presence of pEGFP-N1™ DNA at similar concentrations (data not 
shown). These findings demonstrated that P. multocida B:2 JRMT12 was able to 
stably maintain pEGFP-N1™, even without the presence of kanamycin, for at 
least 14 days. 
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Figure 17. Growth curves of P. multocida B:2 JRMT12 pEGFP-N1™+. 
Overnight cultures were diluted to OD600nm ~0.08 with sterile media (BHI broth 
for P. multocida and LB broth for E. coli). 1 ml of culture was removed at 
regular intervals and OD600nm measured, the remaining culture was incubated at 
37°C. Readings were taken until the growth cultures entered stationary phase. 
All experiments were done in parallel. 
Graph A shows a comparison of P. multocida B:2 JRMT12 pEGFP-N1™+ with  E. 
coli XL-1 BLUE pEGFP-N1™+. Strains were cultured with BHI broth supplemented 
with kanamycin (50 µg/ml) or LB broth supplemented with kanamycin (50 
µg/ml), respectively.  
Graph B shows a comparison of P. multocida B:2 JRMT12 and P. multocida B:2 
JRMT12 pEGFP-N1™+. The mutant strain harbouring pEGFP-N1™ was cultured in 
BHI broth with and without kanamycin (50 µg/ml) and the mutant strain without 
plasmid was cultured in BHI broth without antibiotic.  
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3.4 Development of the P. multocida B:2 bactofection 
model system 
3.4.1 Characterisation of plasmid pEGFP-N1™ in mammalian cells 
3.4.1.1 Transfection of plasmid pEGFP-N1™ into embryonic bovine lung 
(EBL) cells. 
Eukaryotic expression vector, pEGFP-N1™ (CLONTECH) is a pUC-based plasmid, 
but was shown to adapt to replication in P. multocida (section 3.3.3). In order to 
examine the ability of EBL cells to express GFP from the gene controlled by a 
viral promoter (PCMVIE) on pEGFP-N1™, the plasmid (1 µg/well) was transfected 
into EBL cells assisted by lipofectamine 2000 (Invitrogen, UK) (section 2.17.5). 
Cells were plated and allowed to adhere overnight at 37°C, in 5% (v/v) CO2. The 
following day, plasmid DNA was introduced to cells using the lipofectamine 2000 
transfection reagents.  
Figure 18 shows two different sets of transfected EBL cells at different 
magnifications. Both were taken at 48 hours after transfection with plasmid 
pEGFP-N1. At each magnification, images were taken of the same field under 
differential interference contrast (DIC) light (white) and filtered fluorescent 
light (Exc. = 488 nm, Ems. = 507 nm). Both images were then brought together 
to produce an overlay image. Images at each magnification were taken from a 
different experiment.  
When the monolayer was observed under x20 optical objective, some EBL cells 
were shown to express GFP when viewed under the filtered fluorescent light. In 
the overlay it was difficult to tell exactly which cells were expressing the GFP. 
In another experiment, images of the EBL cell monolayer were taken at x40 
magnification. At this magnification, cells were more clearly focused and overlay 
of the images showed individual EBL cells that were expressing GFP. These 
images demonstrated that approximately 5% of the transfected EBL cells were 
able to express gfp from plasmid pEGFP-N1. 
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Figure 18. Transfection of plasmid pEGFP-N1 into EBL cells. 
DIC (white light) Filtered fluorescent light (FFL)                               
(Exc. = 488 nm Ems. = 507 nm) 
Overlay (DIC/FFL at 50% opacity) 
   
   
Plasmid pEGFP-N1 was transfected into EBL cells (section 2.17.5). After 48 h of incubation, cells were viewed under x20 and x40 
magnification with using a Zeiss AxioCam MRcS camera attached to a Zeiss Axiovert 40 CFL Microscope and images were 
processed with Zeiss Axiovision software under DIC (white light) and filtered light [Excitation (Exc.) = 488 nm, Emission (Ems.) = 507 
nm] to view EBL cells expressing GFP (section 2.17.5). Each magnification represents cells from two different experiments. 
x20 
x40 
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3.4.1.2 Invasion of EBL cells with P. multocida B:2 JRMT12 pEGFP-N1™+ 
Plasmid pEGFP-N1™ was electroporated into P. multocida B:2 JRMT12 (section 
3.3.3.1). EBL cells were then infected with this strain in a standard invasion 
assay (section 2.14.2). However, in this assay, instead of cell lysis by digitonin at 
the final step, monolayers were supplemented with fresh EBL assay medium 
followed by further incubation for 24 h at 37°C, under 5% (v/v) CO2. Cells were 
then viewed under DIC light (white) and filtered fluorescent light (Exc. = 488 
nm, Ems. = 507 nm) at x20 magnification. 
Figure 19 shows images of EBL cells taken at 24 h post-invasion with P. 
multocida B:2 JRMT12 pEGFP-N1™+. Images were taken at x20 magnification of 
the same field under DIC light (white) (A) and filtered fluorescent light (Exc. = 
488 nm, Ems. = 507 nm) (B). The overlay image (C) showed less than 5% of the 
EBL cells expressing gfp. In this images <1% seem to be expressing GFP compared 
with 5% in previous figure. Even though plasmid delivery via bactofection was 
not as efficient as transfecting the plasmid directly into EBL cells, these data 
showed that this P. multocida strain was capable of releasing the plasmid into 
the cell cytosol of EBL cells to allow GFP expression from the viral promoter by 
the EBL cells at 24 h post-invasion. 
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Figure 19.       Invasion of EBL by P. multocida B:2 JRMT12 pEGFP-N1™+. 
 
Images of a EBL cell monolayer in an experimental well 
on a 6-well tissue culture plate taken 24 h after invasion 
of EBL cells by P. multocida B:2 JRMT12 carrying 
pEGFP-N1™. Images were taken under A: DIC light 
(white) and B: filtered fluorescent light (Exc. = 488 nm, 
Ems. = 507 nm) at x20 magnification. Both images 
were then overlaid (C) to display the cells expressing 
GFP. 
 
B 
A 
C 
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3.4.2 Development of P. multocida B:2 JRMT12 expressing fluorescent 
proteins 
In order to develop a model system to more clearly understand the process of 
bactofection with P. multocida, it was decided to create a pEGFP-N1™ derivative 
that expressed another fluorescent protein under the control of a constitutive 
prokaryotic promoter. This would represent a marker for the bacterium 
containing the plasmid and would allow the fate of the bacteria, once inside the 
EBL cells, to be followed more closely. Two broad-host-range plasmids (Appendix 
5) were obtained as a courtesy from Prof. Paul R. Langford, Imperial College 
London. Plasmid pMK-Express and pMC-Express (Bossé et al., 2009) contained 
versatile restriction sites, expressed kanamycin (pMK-Express) or 
chloramphenicol (pMC-Express) resistance for the selection of plasmid-containing 
strains, and a A. pleuropneumoniae sodC promoter active in other 
Pasteurellaceae bacteria which controlled a gfpmut3 gene coding for Aequorea 
victoria green fluorescent protein (GFP: Exc. = 501 nm, Ems. = 511 nm).  
Both plasmids were electroporated (section 2.13.2) separately into P. multocida 
B:2 JRMT12. Plasmid pMK-Express appeared to replicate more stably in P. 
multocida B:2 JRMT12 than plasmid pMC-Express. Plasmid DNA purified from P. 
multocida B:2 JRMT12 pMK-Express+ was more defined and concentrated when 
compared to the latter (results not shown). Thus, the mutant strain harbouring 
plasmid pMK-Express was utilized further in this study. 
 3.4.2.1 P. multocida B:2 JRMT12 pMK-Express+  
Several positive transformants were picked after the electroporation procedure 
and plasmid pMK-Express was purified from them. All strains harbouring this 
plasmid underwent GFP expression assessment (section 2.18). One strain was 
chosen which showed significant GFP expression. Figure 20 shows a bar graph of 
fluorescence intensity (FI) of this strain over time, accompanied by a line graph 
which shows the bacterial growth curve (OD600nm) over the same time period. 
Bacteria were sampled at intervals to determine OD600nm and FI. During lag phase 
(0-120 min), bacteria were observed to express low levels of GFP. GFP 
expression increased gradually as the growth curve entered the exponential 
phase, after 180 min of culture, and continued to increase until 300 min of 
culture which produced the highest peak of FI at 8571 RFU when OD600nm had 
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reached 0.68. After that, the GFP expression gradually declined, especially when 
the growth curve entered stationary phase. After 420 min of culture, FI had 
dropped to more than 50% of the peak value. It continued to drop further in the 
stationary phase. These data indicated that the bacteria expressed GFP 
optimally during early to mid exponential phase, between OD600nm 0.14 to 0.68. 
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Figure 20. Assessment of GFP expression by P. multocida B:2 JRMT12 
pMK-Express+  during growth. 
 GFP expression during the growth curve of P. multocida B:2 JRMT12 
pMK-Express+ was monitored using a fluorimeter. The fluorescence 
intensity (FI) in relative fluorescence units (RFU) of the bacteria 
(bar graph) and the bacterial density (OD600nm) (line graph) were 
measured at intervals. For each FI reading, the background 
fluorescence from P. multocida B:2 JRMT12 has been subtracted. 
Experiments were performed in triplicate and the error bars 
indicate standard deviations of the means.    
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The next step was to visualize P. multocida B:2 JRMT12 pMK-Express+ using 
fluorescence microscopy (FM). The strain was prepared as mentioned above. 
However, this time, sampling of the bacteria was only undertaken between OD600 
0.14 to 0.68 in order to capture the bacteria during maximum GFP expression. 
After obtaining maximum GFP expression by measuring FI by fluorimetry, 
bacteria were counterstained with Cy5 Dye (Amersham, UK) according to 
manufacturer’s instructions. The Cy5 Dye is a monofunctional NHS-Ester for the 
labelling of free amino groups on the bacterial surface. It can be detected under 
fluorescence filter light between Exc. 649 nm and Ems. 670 nm. Bacteria were 
then mixed with 4% of paraformaldehyde (PFA) before fixing onto a poly-L-lysine 
coated microscope slide. The slide was left to air dry and mounted with DAKO 
fluorescence mounting medium (DAKO, USA) in preparation for FM. A cover slip 
was then applied on top of the slide and stored in the dark until viewing (section 
2.20.1.2). 
It can be seen from Figure 21, that two sets of images were viewed under the 
100 x objective lens of a Zeiss AxioImager M1 fluorescence microscope (Carl 
Zeiss) using a Hamamatsu Orca 03 and a QIClick digital charge-coupled device 
(CCD) camera. Images were then captured and processed with Volocity software 
(Perkin Elmer, UK). Left and right images were taken of the same field but under 
different light paths, A are images taken under DIC light (white) and B are 
images taken under filtered fluorescent light  (Exc. = 649 nm, Ems. = 670 nm) 
(blue) to visualize the counterstain, Cy5 Dye (Amersham, UK) and filtered 
fluorescent light (Exc. = 488 nm, Ems. = 507 nm) (green) to visualized bacteria 
expressing GFP. This helped to determine whether GFP expression was within 
the bacteria cell. 
The top pair of images were of P. multocida B:2 JRMT12 pMK-Express+ bacteria 
from a culture grown to OD600nm 0.2. The strain was sampled at this OD600nm and 
processed as above before fixing onto a spot slide and mounted for fluorescence 
microscopy viewing. The left image shows a cluster of coccobacilli under the DIC 
light. The right image is a 3D image under filtered fluorescence light of GFP 
expression (green) within the bacterial cell membranes (counterstained blue 
with Cy5 dye stain). If observed closely, it can be seen that not all bacteria were 
expressing gfp at this OD600nm. However, this corroborates with the previous 
fluorimeter data which indicated only low level of gfp expression during the 
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early stages of exponential phase, e.g. at OD600nm 0.2. The bottom images were 
of P. multocida B:2 JRMT12 pMK-Express+ sampled at OD600nm and processed as 
above. The left image shows a cluster of coccobacilli under the DIC light. The 
right image is a 3D image under filtered fluorescence light of GFP expression 
(green) within the bacterial cell membranes (counterstained blue with Cy5 dye 
stain). At OD600nm 0.6, the strain showed heavier clustering and greater GFP 
expression by P. multocida B:2 JRMT12 pMK-Express+ at this stage, where more 
bacteria were observed to be expressing GFP at the same time. This finding was 
promising for the next stage of the investigation, to allow visualization of the 
JRMT12 strain during the various stages of invasion. All 3D images (B) were 
developed from multiple 2D images captured from the prepared slide. The 
vertical elongated shape of the bacteria is presumably an artefact of iterative 
restoration during image manipulation using Volocity software (Perkin Elmer, 
UK).  
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Figure 21. Visualization of P. multocida B:2 JRMT12 pMK-Express+ via 
fluorescence microscopy (FM). 
 
Images of P. multocida B:2 JRMT12 pMK-Express+ fixed with 4% PFA on a poly-L-lysine 
microscope slide, mounted with DAKO mounting medium and viewed under 100x objective lens 
with a Zeiss AxioImager M1 fluorescence microscope (Carl Zeiss). Images were captured using 
Hamamatsu Orca 03 and QIClick digital charge-coupled device (CCD) cameras and processed 
with Volocity software (Perkin Elmer, UK). Left and right images were taken of the same field under 
different light paths. Top images were P. multocida B:2 JRMT12 pMK-Express+ at OD600nm 0.2 and 
bottom images were P. multocida B:2 JRMT12 pMK-Express+ at OD600nm 0.6. A: Image taken 
under DIC light (white) B: Image taken under filtered fluorescent light  (Exc. = 649 nm, Ems. = 670 
nm) (blue) to visualize the counterstain, Cy5 Dye (Amersham, UK) and filtered fluorescent light 
(Exc. = 488 nm, Ems. = 507 nm) (green) to visualize bacteria expressing GFP. 
A B 
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3.4.2.2 P. multocida B:2 JRMT12 pMK-RED+ 
In a previous section (3.3.3), plasmid pEGFP-N1™ was confirmed as a suitable 
eukaryotic expression plasmid for P. multocida B:2 JRMT12. This plasmid carries 
the EGFP gene with a modified Shine-Dalgarno sequence to make it suitable for 
expression in mammalian cells. This is accomplished using the cytomegalovirus 
promoter (PCMVIE). P. multocida B:2 JRMT12 harbouring this plasmid carried it 
into EBL cells during invasion and released the plasmid intracellularly followed 
by GFP expression in the mammalian cells (section 3.4.1.2). In order to visualize 
bacteria intracellularly and to follow their fate after uptake, strain JRMT12 
expressing a different type of fluorescent protein to the one expressed by the 
mammalian cell was required. Hence, it was decided as a first step to replace 
the gfpmut3 gene on pMK-Express with DsRed-Monomer gene which coded for 
red fluorescent protein (RFP) from plasmid pDsRed-Monomer (ClonTech, UK). 
This would then put the rfp gene under the control of prokaryotic sodC 
promoter. 
Plasmid pDsRed-Monomer (Appendix 5) is a prokaryotic expression vector that 
encodes DsRed-Monomer (DsRed.M1), a monomeric protein derived from the 
tetrameric Discosoma sp. red fluorescent protein DsRed. This modified protein 
contains 45 amino acid substitutions, increasing its stability. The excitation 
wavelength (Exc.) maximum is 557 nm and emission wavelength (Ems.) maximum 
is 585 nm. In this plasmid, DsRed-Monomer coding sequence is flanked at the 5’ 
and 3’ ends by separate and distinct multiple cloning sites (MCS) which facilitate 
the isolation of the gene. This protein can be expressed by E. coli from the lac 
promoter, but this promoter would not function well in P. multocida. 
The strategy employed (Figure 22) was to remove the gfpmut3 gene from 
plasmid pMK-Express and replace it with the DsRed-Monomer gene from plasmid 
pDsRed-Monomer. The GFP gene, gfpmut3, and the DsRed.M1 gene were 
removed from their respective plasmids by digestion (section 2.4) with BamHI 
and NotI sites. The digested pMK-Express (6583 bp) and DsRed.M1 gene (700 bp) 
were then ligated (section 2.12.2.2) giving a 7283 bp plasmid called pMK-RED. 
This plasmid was then electroporated into P. multocida B:2 JRMT12 (section 
2.13.2). 
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Figure 22. Cloning strategy: Development of plasmid pMK-RED. 
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Several positive transformants were picked after the electroporation procedure 
and plasmid pMK-RED was purified from them. After confirmation of plasmid 
identity, a strain harbouring this plasmid was chosen to undergo assessment of 
RFP expression. P. multocida B:2 JRMT12 pMK-RED+ was assessed for its ability to 
express RFP using a fluorimeter (FLUOstar OPTIMA, BMG Labtech). The 
procedure is similar to the one noted in section 3.4.2.1. The only difference is 
the set programme of the FLUOstar OPTIMA. For RFP detection, the fluorescent 
light filter was set at excitation maximum at 544 nm and emission maximum at 
590 nm. All samples were compared with P. multocida B:2 JRMT12 to eliminate 
background. Samples were taken at hourly intervals until the OD600nm showed 
that the culture had reached stationary phase (~2.0).  
Figure 23 shows a bar graph of fluorescence intensity (FI) of this strain over time 
(min) accompanied by a line graph showing the bacterial growth curve (OD600nm). 
During the lag phase (0-120 min), bacteria were observed to express some RFP. 
This markedly increased as the growth curve entered the exponential phase, 
after 180 min of culture, at OD600nm 0.12, where the FI was at 21483 RFU, and 
continued to increase slightly until 300 min which gave the highest peak of FI at 
22809 RFU when OD600nm had reached 0.69. After that, RFP expression declined, 
especially when the growth curve entered the stationary phase. These data 
indicated that the bacteria expressed RFP best during exponential phase in a 
similar manner to expression of GFP from the same plasmid backbone (section 
3.4.2). 
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Figure 23. Assessment of RFP expression by P. multocida B:2 JRMT12 
pMK-RED+ during growth. 
 RFP expression during the growth curve of P. multocida B:2 JRMT12 
pMK-RED+ was monitored using a fluorimeter. The fluorescence 
intensity (FI) of the bacteria (bar graph) and the bacterial density 
(OD600nm) (line graph) were measured at intervals. For each FI 
reading, the background fluorescence from P. multocida B:2 
JRMT12 has been subtracted. Experiments were performed in 
triplicate and the error bars indicate standard deviations of the 
means.    
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The next step was to visualize P. multocida B:2 JRMT12 pMK-RED+ using 
fluorescence microscopy (FM). The strain was prepared as mentioned above, and 
sampling of the bacteria culture was undertaken between OD600 0.12 to 0.69 
during the maximum expression of RFP. After measuring RFP using the 
fluorimeter, bacteria were counterstained with Cy5 Dye (Amersham, UK) 
according to manufacturer’s instruction. This was done to ease visualization of 
the bacteria expressing the RFP. Bacteria were then mixed with 4% 
paraformaldehyde (PFA) before fixing onto a spot slide. The slide was left to air 
dry and mounted with DAKO fluorescence mounting medium (DAKO, USA) in 
preparation for viewing by fluorescence microscopy. A cover slip was then 
applied on top of the slide and stored in the dark until viewing. As a control, E. 
coli XL-1 Blue containing pDSRed-Monomer was grown under similar conditions, 
but in LB medium. 
In Figure 24, images in row I were taken from a spot slide of P. multocida B:2 
JRMT12 pMK-RED+ when the OD600nm of the culture had reached 0.6. Images were 
taken of the same field on the slide under 3 different light paths to ease 
visualization. In A, the image taken under DIC (white) light showed a heavy 
cluster of bacteria. This was expected because of the high density of growth at 
OD600nm 0.6. When the same field of the slide was captured in B under filtered 
fluorescent light (Exc. = 649 nm, Ems. = 670 nm) (blue) to visualize the 
counterstain, Cy5 Dye, on the bacterial cell surface a more distinguishable shape 
of the bacteria was recognized. This image was taken at 0.6 µm splicing through 
the field, in order to view a single layer of the bacteria, using the optical 
sectioning function of the Volocity software (Perkin Elmer, UK). The image was 
set to section optically at 0.3 µm intervals from top to bottom; an image was 
captured at every 0.3 µm of depth, with a total section stacking of 3.0 µm. The 
Volocity software was then further utilized to deconvolve the captured images 
by focusing the light emitted to the exact spot where it was originally from. This 
was to eliminate background light diffraction. In C, the image was taken under 
filtered fluorescent light (Exc. = 557 nm, Ems. = 585 nm) (red), to visualize 
bacteria expressing RFP from plasmid pMK-RED, and under filtered fluorescent 
light (Exc. = 649 nm, Ems. = 670 nm) (blue) to show the counterstain and to 
localize the RFP expression within the bacteria. This image was also taken at 0.6 
µm splicing and then deconvolved using the Volocity software. Image C showed 
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purplish pink coccobacilli of P. multocida B:2 JRMT12 pMK-RED+ mostly 
expressing RFP at OD600nm 0.6. 
The images in row II show E. coli XL-1 Blue pDsRed-Monomer+. This was used as a 
control for visualization of RFP expression from the DsRed-Monomer gene in 
another Gram-negative bacterium. The images of the same field were taken 
under three different light paths, as above. Image A was taken under DIC (white) 
light and showed a heavy cluster of bacteria similar to that of P. multocida, 
although the cells appeared larger and less concentrated. The same field of the 
slide, captured in image B, was taken under filtered fluorescent light (Exc. = 649 
nm, Ems. = 670 nm) (blue) to visualize the counterstain, Cy5 Dye. The bacterial 
shape was again more clearly recognized. This image was again taken at 0.6 µm 
splicing through the slide in order to view a single layer of the bacteria with 
background light diffraction eliminated as above. Image C was taken under 
filtered fluorescent light (Exc. = 557 nm, Ems. = 585 nm) (red) to visualize E. 
coli expressing RFP from plasmid pDsRed-Monomer and under filtered 
fluorescent light (Exc. = 649 nm, Ems. = 670 nm) (blue) to show the counterstain 
and to localize the RFP expression in the bacteria. The image was also taken at 
0.6 µm splicing and then deconvolved using the Volocity software. Image C 
showed purplish-pink rod-shaped E. coli XL-1 Blue pDsRed-Monomer+ expressing 
RFP when the culture was sampled at OD600nm 0.6. 
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Figure 24. Visualization of P. multocida B:2 JRMT12 pMK-RED+ via FM. 
Images of P. multocida B:2 JRMT12 pMK-RED+ (I) and E. coli XL-1Blue pDsRed-
Monomer+ (II) counterstained with Cy5 Dye (Amersham, UK) and fixed with 4% 
(w/v) PFA on a spot-slide, then mounted with DAKO mounting medium and 
viewed under a 100x objective lens with a Zeiss AxioImager M1 fluorescence 
microscope (Carl Zeiss). Images were captured using Hamamatsu Orca 03 and 
QIClick digital charge-coupled device (CCD) cameras and processed with Volocity 
software (Perkin Elmer, UK). Images were taken of the same field under three 
different light paths; 
A: Image taken under DIC (white) light. 
B: Image taken under filtered fluorescent light (Exc. = 649 nm, Ems. = 670 nm) 
(blue) 
C: Image taken under filtered fluorescent light (Exc. = 557 nm, Ems. = 585 nm) 
(red) and filtered fluorescent light (Exc. = 649 nm, Ems. = 670 nm) (blue). 
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The images in Figure 24 confirmed the ability of DsRed-Monomer gene to be 
expressed by P. multocida. Plasmid pMK-RED was derived by removing the 
DsRed-Monomer gene from pDsRed-Monomer and placing it upstream of the 
PsodC promoter in plasmid pMK-Express to replace the deleted gfpmut3 gene. 
After electroporation of the plasmid into P. multocida B:2 JRMT12, fluorimeter 
assessment of RFP expression showed highest fluorescence production during the 
exponential phase at OD600nm 0.6. Images captured with the fluorescence 
microscopy (FM) showed individual bacteria expressing RFP and counterstained 
with Cy5 dye.  
3.4.3 Assessment of intracellular viability of P. multocida B:2 JRMT12 
expressing fluorescent protein 
In the previous section, plasmid pMK-RED was constructed and assessed for the 
ability of P. multocida B:2 JRMT12 to express RFP from this plasmid. RFP 
fluorescence was visualized in the mutant strain using FM. In the next step, the 
ability of the plasmid to express RFP in JRMT12 in the intracellular environment 
of mammalian cells was assessed using the invasion assay. 
3.4.3.1 Imaging of P. multocida B:2 JRMT12 pMK-RED+ in EBL cells 
In order to visualize P. multocida B:2 JRMT12 pMK-RED+ after invasion of EBL 
cells at high definition, an invasion assay at MOI 100:1 (bacteria/cell) was 
prepared as in section 2.17.2 and 2.20.1.1. Prepared slides were then viewed 
under the x100 objective lens of a Zeiss AxioImager M1 (Carl Zeiss). Images were 
captured using Hamamatsu Orca 03 and QIClick digital charge-coupled device 
(CCD) cameras and processed with Volocity software (Perkin Elmer, UK). 
A single EBL cell is shown in Figure 25 as representative of the cells examined. 
All images of the cell were taken under the x100 objective lens of the same field 
but under different light paths. Images were then deconvolved using Volocity 
software.  In A, the EBL cell was visualized under DIC (white) light. In B, the EBL 
cell was observed under filtered fluorescent light (Exc. = 649 nm, Ems. = 670 
nm) (blue) to visualize the counterstain, CellMask™ (GE Healthcare, UK), which 
stained the plasma membrane of live cells. This stain is composed of a 
amphipathic molecule providing a lipophilic moiety to improve membrane 
loading and a negatively-charged hydrophilic dye for stable fixation in the 
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plasma membrane. In this image, the nucleus of the cell, the cytoplasm and the 
cell outline are distinguishable. In C the EBL cell was observed under filtered 
fluorescent light (Exc. = 557 nm, Ems. = 585 nm) (red) to visualize internalized 
RFP-expressing bacteria in the EBL cell cytoplasm. The red coccobacilli shaped 
spots show the presence of P. multocida B:2 JRMT12 pMK-RED+ expressing RFP 
from the DsRed-Monomer gene. In order to corroborate the presence of the 
bacterium internally within the mammalian cell, image D was captured under 
filtered fluorescent light (Exc. = 649 nm, Ems. = 670 nm) (blue) and filtered 
fluorescent light (Exc. = 557 nm, Ems. = 585 nm) (red) at selected depths by 
Volocity optical sectioning. The cell was sectioned optically at 0.3 µm intervals 
from top to bottom; the images shown were captured at every 0.3 µm depth as 
shown in the table (bottom, right). First (0 µm) and last (3.0 µm) images 
indicate the top and bottom of the EBL cell. The 2nd (0.3 µm) until the 10th (2.7 
µm) images show the optical sectioning of the cell. There are a number of 
bacteria present intracellularly in this cell. For example, the yellow circles point 
out an area where the fluorescence intensity (FI) of the RFP is greatly enhanced 
as the depth of the section increases. This was at the highest FI within 0.9 µm to 
1.5 µm depth of the optical section. The intensity gradually decreased as the 
optical sectioning progressed deeper than that. This confirmed the RFP 
expression in this area by P. multocida B:2 JRMT12 pMK-RED+. Another example 
is outlined by the green circles. In this area, the RFP became visible just after 
the optical sectioning reached 2.1 µm and 2.4 µm. However, as the image 
progressed to a higher depth, some of the RFP fluorescence disappeared but, for 
other spots, their intensity was greatly enhanced. Both examples serve to 
illustrate that the bacterium persisted intracellularly within the EBL cell at 3 h 
of the standard invasion assay. It should be noted that some spots were present 
at 0 µm and appeared to persist in most of the sections. It is not clear what 
these spots may represent as a surface-located bacterium, visible at 0 µm, 
would not be expected to show fluorescence in later sections. For this 
experiment, out of 60 EBL cells examined, 37% of the EBL cells showed the 
presence of P. multocida B:2 JRMT12 pMK-RED+ intracellularly. 
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Figure 25. Imaging of P. multocida B:2 JRMT12 pMK-RED+ in EBL cells. 
Slides for visualization of P. multocida B:2 JRMT12 pMK-RED+ after invasion of 
EBL cells were prepared as in section 2.16.1.1. Prepared slides were then 
viewed under the x100 objective lens of a Zeiss AxioImager M1 FM (Carl Zeiss). 
Images were captured using Hamamatsu Orca 03 and QIClick digital charge-
coupled device (CCD) cameras and processed with Volocity software (Perkin 
Elmer, UK). The image of a representative single EBL cell taken under different 
light paths is shown. 
A: EBL cell taken under the DIC (white) light.  
B: EBL cell taken under filtered fluorescent light (Exc. = 649 nm, Ems. = 670 nm) 
(blue) to visualize the counterstain, CellMask™ plasma membrane stain (GE 
Healthcare). 
C: EBL cell taken under filtered fluorescent light (Exc. = 557 nm, Ems. = 585 nm) 
(red) to visualize internalized bacteria expressing RFP in the cytoplasm of the 
EBL cell.  
D: EBL cell taken under filtered fluorescent light (Exc. = 649 nm, Ems. = 670 nm) 
(blue) and filtered fluorescent light (Exc. = 557 nm, Ems. = 585 nm) (red) at 
selected depths by manipulation of optical sectioning. The slide was set to be 
sectioned optically at 0.3 µm from top to bottom; the images shown were 
captured at every 0.3 µm depth to a total section stacking of 3.0 µm. The 
table (bottom, right) shows the section depth (µm) of each image. 
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3.4.4 Development of the ‘traffic light’ plasmid 
Work detailed in the previous section showed that the JRMT12 strain expressing 
RFP from plasmid pMK-RED could be visualized intracellularly in EBL cells using 
FM. In section 3.4.1.2, it was shown that the bacterium could carry plasmid 
pEGFP-N1™ into EBL cells, followed by visualization of EBL cells expressing GFP 
from the plasmid when observed with FM. In order to develop an understanding 
of how bacteria behave after entry into mammalian cells, it was thought useful 
to develop a plasmid with both a prokaryotic and a eukaryotic expression system 
with each expression system having a different reporter gene to differentiate 
their activation.  
In this section, both systems were to be distinguished by different types of 
fluorescent protein expressed. To this end, it was decided to use a prokaryotic 
expression system and the DsRed-monomer gene which coded for RFP and a 
eukaryotic expression system with the EGFP gene which coded for GFP. The 
plasmid carrying both systems was termed ‘traffic light’ plasmid because, when 
it is present in viable bacteria, the prokaryote expression system would be 
active from a constitutive promoter and the bacteria would be seen as red by FM 
after expressing RFP. This would include a situation where mammalian cells 
internalized the bacteria, for as long as the bacteria remained viable and intact. 
After the plasmid was released in the mammalian cells via bacterial lysis, the 
eukaryotic expression system would be activated and the mammalian cells would 
express GFP and be visualized as green cells.  If the bacteria were destroyed, 
the RFP expression would no longer be possible. The JRMT12 strain carrying this 
plasmid into EBL cells provides a method to monitor bacterial invasion and 
intracellular survival via RFP expression and the GFP reporter, of eukaryotic 
expression to show the potential for delivery of a DNA vaccine by bactofection.  
3.4.4.1 Cloning of Psod-C/DsRed-Monomer (sodRED) fragment into plasmid 
pEGFP-N1™ 
The cloning strategy is illustrated in Figure 26. Plasmid pMK-RED was used as a 
template for PCR with RED primers (Table 5) following the method in section 
2.8.3 to amplify the sodRED fragment. Both forward and reverse primers have a 
restriction enzyme site at each end of the sequence, either AseI or PciI. The PCR 
products (Figure 27) were purified (section 2.8.6) and then cloned into the PCR 
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cloning plasmid pGEM®-T-Easy (section 2.12.1.1) to increase the concentration of 
purified DNA in order to generate a good quantity of completely-digested 
fragment after either PciI or AseI restriction enzyme digestion. All the criteria 
above were crucial in acquiring a successful ligation (Figure 26).  
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Figure 26. Cloning strategy: Development of ‘traffic light’ plasmid, pSRG. 
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The ligation mixture containing linearised pGEM-T-Easy and the PCR product, 
derived using RED-P or RED-A primers (Figure 27), was transformed into E. coli 
XL-1 Blue. After plating on LB agar supplemented with ampicillin (50 µg/ml), 
some colonies were selected for further analysis. However, successful 
transformants were only found to harbour pGEM®-sodRED that was digested 
through PciI sites rather than AseI sites. Plasmid DNA was then purified from 
selected transformants and digested (section 2.4) with KpnI, a single site on 
sodRED MCS which will linearize pGEM®-sodRED at 4016 bp (Figure 28). After 
confirmation, plasmids harbouring the sodRED fragment (1016 bp) were digested 
with PciI. The restriction digest map is shown in Figure 29. The restriction 
enzyme, PciI, cuts the plasmid once at 517 bp and cuts twice at each end of the 
insert, thus giving 3 fragments after digestion. From the agarose gel image, the 
sodRED fragment was circled in red; gel extraction was performed to isolate the 
digested fragment (section 2.5.5).  
In parallel, plasmid pEGFP-N1™ was also digested with the same restriction 
enzyme PciI (section 2.4) and dephosphorylated with enzyme CIAP (section 
2.12.3). The plasmid was then isolated by gel extraction (section 2.5.5) and 
purified for ligation. The agarose gel image in Figure 30 shows the undigested 
plasmid pEGFP-N1™ as a control and the digested and dephosphorylated pEGFP-
N1™. DNA concentrations were then estimated (section 2.6) for the digested 
insert fragment, sodRED, and the digested plasmid pEGFP-N1™ to aid the ligation 
strategy (section 2.12.2.2). Ligation mixtures (1:1, 1:2, 1:4, 1:8 vector:fragment 
concentration) were then transformed into E. coli XL-1 Blue. In Figure 26, the 
cloning strategy shows two diagrams of plasmid pSRG after the ligation step 
showing two possible orientations of the sodRED fragment in plasmid pSRG 
(diagrams I and II). After transformation, plasmid DNA was purified from positive 
transformants (colonies derived from the antibiotic selection plate) and 
subjected to restriction enzyme analysis with EcoRI to assess the presence of 
sodRED fragment and to determine its orientation. The enzyme EcoRI, cuts the 
plasmid twice, once at the MCS after the eukaryotic promoter PCMVIE and the 
other at the MCS in the middle of the sodRED cassette (Figure 26). This would 
give two distinct sizes of fragment that would determine the orientation of the 
insert in plasmid pSRG (5700 bp).  After agarose gel analysis, all positive clones 
were showed to be in the second orientation (diagram II, Figure 26). Figure 31 
shows the plasmid restriction map with the EcoRI sites and fragment sizes after 
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digestion. The agarose gel image demonstrates two of the positive clones after 
digestion with EcoRI showing the fragment sizes that classified them as in the 
second orientation in pSRG. For further confirmation, the sodRED fragment was 
isolated from plasmid pSRG by digestion with PciI and sequenced (section 2.9). 
The complete sequence of the sodRED fragment is shown in Figure 32. The 
plasmid was electroporated into electro-competent P. multocida B:2 JRMT12 
(section 2.13.2) for further manipulation. 
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Figure 27. Agarose gel showing sodRED fragment PCR from plasmid pMK-
RED using RED-A and RED-P primer pairs. 
 
 
 
 
 
 
 
 
 
Figure 28. Agarose gel showing plasmid pGEM®-T-Easy-sodRED from E. 
coli XL-1 Blue after digestion with KpnI. 
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Figure 29. Agarose gel showing pGEM®-T-Easy-sodRED after digestion 
with PciI. 
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Figure 30. Agarose gel showing pEGFP-N1™ after digestion with PciI and 
dephosphorylation with CIAP. 
 
 
 
 
 
 
 
 
 
Figure 31. Agarose gel showing pSRG after digestion with EcoRI. 
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Figure 32. Complete sequence of sodRED fragment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CAGTCTCTCG AGCCGCGCCA ACCGATAAAA CCTACATTTT GCATTTTATG CTCCTAATTA 
---------- ---------- ---------- ---------- -----TTATG CTCCTAATTA 
  
AATTTACTAA GTTGTGTTTG AATTTATTTT GAGAAATAGA ATCTGATAAA TACAGGATTT 
AATTTAGTAA GTTGTGTTTG AATTTATTTT GAGAAATAGA ATCTGATAAA TACAGGATTT 
  
TCTACTAAAA TGCAATTAGT TTTAGACTAT TTAAATAATA TTATTTAAAT TCTTTACTAT 
TCTACTAAAA TGCAATTAGT TTTAGACTAT TTAAATAATA TTATTTAAAT TCTTTACTAT 
 
AGTGTACAAT ACACACAGTC CATTAACCAA AATAAAAGGA GGAATTCTGC AGTCGACGGT 
AGTGTACAAT ACACACAGTC CATTAACCAA AATAAAAGGA GGAATTCTGC AGTCGACGGT 
 
ACCGCGGGCC CGGGATCCGA TCCCCGGGTA CCGGTCGCCA CCATGGACAA CACCGAGGAC 
ACCGCGGGCC CGGGATCCGA TCCCCGGGTA CCGGTCGCCA CCATGGACAA CACCGAGGAC  
 
GTCATCAAGG AGTTCATGCA GTTCAAGGTG CGCATGGAGG GCTCCGTGAA CGGCCACTAC 
GTCATCAAGG AGTTCATGCA GTTCAAGGTG CGCATGGAGG GCTCCGTGAA CGGCCACTAC 
 
TTCGAGATCG AGGGCGAGGG CGAGGGCAAG CCCTACGAGG GCACCCAGAC CGCCAAGCTG 
TTCGGGATCG AGGGCGAGGG CGAGGGCAAG CCCTACGAGG GCACCCAGAC CGCCAAGCTG 
 
CAGGTGACCA AGGGCGGCCC CCTGCCCTTC GCCTGGGACA TCCTGTCCCC CCAGTTCCAG 
CAGGTGACCA AGGGCGGCCC CCTGCCCTTC GCCTGGGACA TCCTGTCCCC CCAGTTCCAG 
 
TACGGCTCCA AGGCCTACGT GAAGCACCCC GCCGACATCC CCGACTACAT GAAGCTGTCC 
TACGGCTCCA AGGCCTACGT GAAGCACCCC GCCGACATCC CCGACTACAT GAAGCTGTCC 
 
TTCCCCGAGG GCTTCACCTG GGAGCGCTCC ATGAACTTCG AGGACGGCGG CGTGGTGGAG 
TCCCCCGAGG GCTTCACCTG GGAGCGCTCC ATGAACTTCG AGGACGGCGG CGTGGTGGAG 
 
GTGCAGCAGG ACTCCTCCCT GCAGGACGGC ACCTTCATCT ACAAGGTGAA GTTCAAGGGC 
GTGCAACAGG ACTCCTCCCT GCAGGACGGC ACCTTCATCT ACAAGGTGAA GTTAAAGGGC 
 
GTGAACTTCC CCGCCGACGG CCCCGTAATG CAGAAGAAGA CTGCCGGCTG GGAGCCCTCC 
GTGAACATCC CCGACGACGG CCCCGTAATG CAAAAAAAAA CTGCCGGCTG GGAGCCCTCC 
 
ACCGAGAAGC TGTACCCCCA GGACGGCGTG CTGAAGGGCG AGATCTCCCA CGCCCTGAAG 
ACCGAGAAGC TGTACCCCCA GGACGGCGTG CTGAAGGGCG AGATCTCCCA CGCCCTGAAG 
 
CTGAAGGACG GCGGCCACTA CACCTGCGAC TTCAAGACCG TGTACAAGGC CAAGAAGCCC 
CTGAAGGACG GCGGTCACTA CACCTGCGAC TTCAAGACCG TGTACAAGGC CAAGAAGCCC 
 
GTGCAGCTGC CCGGCAACCA CTACGTGGAC TCCAAGCTGG ACATCACCAA CCACAACGAG 
GTGCAGCTGC CCGGGAACCA CTACATGGAC TCCAAGCTGG ACATCACCAA CCACAACGAG 
 
GACTACACCG TGGTGGAGCA GTACGAGCAC GCCGAGGCCC GCCACTCCGG CTCCCAGTAG 
GAACACACCG TGGAGGACCA GTACGAGCAC ACCAAGGCCC GCCACTCCGG CTCCCAGTAG 
 
AGCGGCCGCC  
AACATGTGCC  
 
Psod promoter region 
DsRED region 
sodRED primers 
 PciI site 
A Original sequence 
A sodRED sequence from pRG  
Results 
 133 
3.4.4.2 Stability and expression of plasmid pSRG in P. multocida B:2 
JRMT12 
After electroporation of plasmid pSRG into P. multocida B:2 JRMT12, positive 
transformants were selected from BHI agar supplemented with kanamycin (50 
µg/ml). Once the strains were confirmed to harbour pSRG, they were assessed 
for plasmid stability after routine subculture and also assessed for their 
capability to express RFP from the plasmid. For plasmid stability, P. multocida 
B:2 JRMT12 pSRG+ was plated on BHI agar with and without kanamycin (50 
µg/ml). After incubation for 24 h, selected colonies from both plates were 
streaked to a fresh plate. After a further 24 h, a dozen colonies were picked 
from both plates and inoculated into BHI broth with or without kanamycin (50 
µg/ml) respectively. After 24 h, plasmids were purified and analyzed by 
restriction digestion with EcoRI for confirmation. Strains were subcultured into 
fresh broth medium everyday for 14 days and plasmids from each culture were 
purified and analyzed every alternate day. After 14 days, P. multocida B:2 
JRMT12 pSRG+ cultured without antibiotic was found to be still harbouring the 
plasmid, pSRG, in each of the 12 colonies originally subcultured. This 
demonstrated that pSRG is stable in P. multocida B:2 JRMT12 even after the 
bacterium has undergone very many cell division. 
RFP expression was then assessed in a stable isolate of P. multocida B:2 JRMT12 
pSRG+ according to the procedure given in section 3.4.2.1. Figure 33 shows FI 
(RFU) of P. multocida B:2 JRMT12 pSRG+ plotted against bacterial density 
(OD600nm). At OD600nm 0.04, the strain was clearly expressing RFP. As expected, 
this increased with increasing bacterial density showing 1657 RFU when the 
OD600nm had reached 0.14. After that, the RFP expression was seen to decline 
markedly, even at OD600nm of 0.35. This graph indicated that the RFP expression 
from this strain peaked in the early exponential phase of the growth. This was a 
similar result to that obtained with JRMT12 pMK-RED (Figure 23).  
 
 
 
 
Results 
 134 
Figure 33. Assessment of RFP expression by P. multocida B:2 JRMT12 
pSRG+  during growth. 
 An overnight culture was diluted to OD600nm ~ 0.08 with sterile BHI 
and incubated at 37°C. 1 ml of culture was removed at regular 
intervals and OD600nm measured. The 1 ml sample was then 
centrifuged at 13 000 x g for 1 min. After resuspending the 
bacterial pellet in 1 ml PBS, 200 µl aliquots were analyzed in 
triplicate for fluorescence in a fluorimeter plate reader (RFP: Exc.= 
557 nm, Ems.= 585 nm) P. multocida B:2 JRMT12 acted as a control 
for background fluorescence; fluorescence was plotted against 
OD600nm using Microsoft Excel software and data were corrected for 
background fluorescence. Experiments were performed in triplicate 
and the error bars indicate standard deviations of the means. 
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The next step was to visualize RFP expression in P. multocida B:2 JRMT12 pSRG+ 
using fluorescence microscopy (FM). The strain was prepared as in section 
3.4.2.1, and sampling of the bacteria was done between OD600nm 0.04 to 0.30 in 
order to capture the bacteria during maximum RFP expression. After obtaining 
maximum RFP expression at OD600nm 0.3 by measuring FI using the fluorimeter, 
bacteria were counterstained with Cy5 Dye (Amersham, UK) according to the 
manufacturer’s instructions. Bacteria were then mixed with 4% (w/v) of 
paraformaldehyde (PFA) before fixing onto a poly-L-lysine coated microscope 
slide. The slide was left to air dry and mounted with DAKO fluorescence 
mounting medium (DAKO, USA) in preparation for FM. A cover slip was applied 
on top of the slide which was stored in the dark until viewing. 
In Figure 34, a set of images were captured from the spot slide prepared with P. 
multocida B:2 JRMT12 pSRG+ taken at OD600nm 0.3. Images were taken of the 
same field using the 100x objective lens under three different light paths to ease 
visualization. Image A, taken under DIC (white) light, showed a heavy cluster of 
bacteria. When the same field of the slide was captured in B, where the image 
was taken under filtered fluorescent light (Exc. = 649 nm, Ems. = 670 nm) (blue) 
to visualize the counterstained, Cy5 Dye, the shape of the bacteria was more 
defined. This image was taken at 0.6 µm splicing through the slide in order to 
view a single layer of the bacteria. As before, the slide was set to be sectioned 
optically at 0.3 µm intervals from top to bottom; an image was captured at 
every 0.3 µm depth at a total section stacking of 3.0 µm. The Volocity software 
was then utilized to deconvolve images captured by reversing the optical 
distortion to produce a sharper and clearer image. This technique also 
eliminates background light diffraction. Image C was taken under filtered 
fluorescent light (Exc. = 557 nm, Ems. = 585 nm) (red) to visualize bacteria 
expressing RFP from plasmid pSRG and under filtered fluorescent light (Exc. = 
649 nm, Ems. = 670 nm) (blue) to show the counterstain in order to localize the 
RFP expression in the bacteria. The image showed purplish pink coccobacilli of 
P. multocida B:2 JRMT12 pSRG+ expressing RFP. Image D shows a 3D image of 
image C to generate a 3D modelling of the RFP-expressing bacteria. The vertical 
elongated shape of the bacteria is presumably an artefact of iterative 
restoration after image manipulation using Volocity software (Perkin Elmer, UK). 
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Figure 34. Visualization of P. multocida B:2 JRMT12 pSRG+ via FM. 
Images of P. multocida B:2 JRMT12 pSRG+ counterstained with Cy5 Dye 
(Amersham, UK) and fixed with 4% (w/v) PFA on a poly-L-lysine coated 
microscope slide, then mounted with DAKO mounting media and viewed under a 
100x objective lens with a Zeiss AxioImager M1 fluorescence microscope (Carl 
Zeiss). Images were captured using Hamamatsu Orca 03 and QIClick digital 
charge-coupled device (CCD) cameras and processed with Volocity software 
(Perkin Elmer, UK). Images were taken of the same field under three different 
light paths; 
A: DIC light (white),  
B:  filtered fluorescent light (Exc. = 649 nm, Ems. = 670 nm) (blue) to 
visualize the counterstain, Cy5 Dye (Amersham, UK),  
C:  two filtered lights; filtered fluorescent light (Exc. = 557 nm, Ems. = 585 
nm) (red) to visualize bacteria expressing RFP from plasmid pSRG and 
filtered fluorescent light (Exc. = 649 nm, Ems. = 670 nm) (blue) to 
visualize the counterstain, Cy5 Dye. This helps to show that RFP 
expression was within the bacteria cell membrane, 
D: 3D imaging of the 2D image from C using Volocity software (Perkin Elmer, 
UK). 
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3.4.4.3 Transfection of plasmid pSRG into EBL cells 
EBL cells were prepared as in section 3.4.1.1 for transfection of plasmid pSRG. 
Figure 35 shows two different sets of transfected EBL cells. All images were 
captured from the prepared chamber-well slide (section 2.20.1.1). Slides were 
viewed under the x100 objective lens of a Zeiss AxioImager M1 FM (Carl Zeiss). 
Images were then captured using Hamamatsu Orca 03 and QIClick digital charge-
coupled device (CCD) cameras, deconvolved and processed with Volocity 
software (Perkin Elmer, UK). 
In Figure 35, images in set I (top row) were taken at 24 h post-transfection and 
those in set II were taken at 48 h post-transfection with pSRG. All images in a set 
were taken of the same field but under different light paths. In set I, cells of the 
monolayer were captured under DIC (white) light in image A. The cells were 
outlined in blue with the plasma membrane stain in image B. Overlay of the 
filtered light generated image C which showed localization of GFP in each EBL 
cell. Parts of the three cells expressing GFP were visible in this image. After 
optical sectioning, the images in D showed fluorescent intensity throughout 
these cells at every 0.4 µm of splicing. GFP expression was visible throughout 
the images but decreased in later sections (stack 17-20) as the splicing went 
nearer to the surface indicating GFP expression was indeed intracellular in the 
EBL cells. Image E shows 3D imaging of the 2D image from C. At 48 h post-
transfection, slides were again prepared as in section 2.20.1.1. Set II shows 
images of EBL cells on part of the monolayer captured at the same field under 
different light paths. One prominent EBL cell in image A was outlined in blue 
with the plasma membrane stain in image B and the overlay of the filtered light 
in image C showed localization of GFP within the EBL cell. Fluorescence 
intensity captured at each 0.4 µm optical splicing throughout the cell. Image D 
showed the intensity of GFP fluorescence throughout the cell although it again 
decreased as the splicing went nearer to the cell surface (stack 18-20). This 
again indicated internal expression of GFP by the EBL cells. Image E shows 3D 
imaging of the 2D image from C. 
Detailed observation of both slides found that out of 60 EBL cells examined, 67% 
of EBL cells were found to express GFP as early as 24 h after transfection. 
Another 60 EBL cells were assessed from slides prepared at 48 h post-
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transfection and 82% were found to express GFP. The duration of GFP expression 
by the cells was not determined. 
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Figure 35. Transfection of plasmid pSRG into EBL cells. 
Slides for visualization of pSRG during transfection of EBL cells at high definition 
were prepared as in section 3.4.1.1. Prepared slides were then viewed under the 
x100 objective lens of a Zeiss AxioImager M1 FM (Carl Zeiss). Images were then 
captured using Hamamatsu Orca 03 and QIClick digital charge-coupled device 
(CCD) cameras and processed with Volocity software (Perkin Elmer, UK). Images 
show two sets of EBL cells: 
I: EBL cells transfected with plasmid pSRG at 24 h post-transfection. 
II: EBL cells transfected with plasmid pSRG at 48 h post-transfection. 
For both sets of images, the same field was taken under different light paths; 
A: EBL cell taken under DIC (white) light.  
B: EBL cell taken under filtered fluorescent light (Exc. = 649 nm, Ems. = 670 nm) 
(blue) to visualize the counterstained plasma membrane stain. 
C: EBL cell taken under filtered fluorescent light (Exc. = 488 nm, Ems. = 507 nm) 
(green) to visualize expression of gfp in the cytoplasm of EBL cell and filtered 
fluorescent light (Exc. = 649 nm, Ems. = 670 nm) (blue) to visualize the 
counterstained plasma membrane stain.  
D: EBL cell taken under filtered fluorescent light (Exc. = 649 nm, Ems. = 670 nm) 
(blue) and filtered fluorescent light (Exc. = 488 nm, Ems. = 507 nm) (green) at 
selected depths by manipulation of optical sectioning. The slide was set to be 
sectioned optically at 0.4 µm intervals from top to bottom; the images shown 
were captured at every 0.4 µm of depth at a total section stacking of 8.0 µm. 
The table below shows the optical section number for every stack in the 
image, with stack 1 at 0.4 µm and stack 20 at 8.0 µm. 
E: 3D image of C. 1 2 3 4 
5 6 7 8 
9 10 11 12 
13 14 15 16 
17 18 19 20 
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3D image of the 2D image of C. Image was generated using the 
Volocity software (Perkin Elmer, UK). 
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3.4.4.4 Localization of prokaryotic and eukaryotic fluorescent protein 
expression 
By this stage, it had been shown that plasmid pSRG was able to express 
fluorescent proteins using either prokaryotic or eukaryotic promoter systems. P. 
multocida B:2 JRMT12 was able to express RFP from the plasmid’s sodRED 
cassette using the constitutive sodC promoter and EBL cells were able to express 
GFP from the plasmid’s eukaryote promoter (PCMVIE) and gfpmut3 gene. In the 
next step, it was hoped to monitor the activity of the traffic light plasmid, 
pSRG, during invasion of EBL cells by P. multocida B:2 JRMT12 pSRG+. 
Cells and bacteria were prepared as in section 3.4.3.1 with the modification that 
the bacterium, P. multocida B:2 JRMT12 pSRG+, was grown to OD600nm 0.3 (at 
maximum RFP expression) before the invasion assay. Slides were prepared as in 
section 2.20.1 for FM and viewed under the x100 objective lens of the Zeiss 
AxioImager M1 microscope (Carl Zeiss).  
Four sets of images are displayed in Figure 36. Sets I and II were captured from 
slides prepared after 3 h of the standard invasion time, while sets III and IV were 
captured from slides prepared at 5 h post-invasion. All images in a set were 
captured in the same field of the slides but under different light paths. In set I, 
image A shows a single EBL cell taken under white light. When the light path was 
changed to blue-filtered fluorescent light in image B, the plasma membrane was 
stained blue. In image C, an overlay of blue- and red-filtered fluorescent light 
showed the cell membrane as blue and the internalized P. multocida B:2 JRMT12 
pSRG+ as red. In order to confirm the internal location of RFP expression in the 
EBL cell, the slides underwent optical sectioning. Image D shows optical sections 
of the slide of 20 slices at every 0.4 µm of depth. Referring to the table below 
the figure description, at stack 7 (2.8 µm), RFP started to become visible, 
indicating internalized bacteria. The intensity of the red fluorescence increased 
as the optical sections went deeper into the cell. The maximum appearance of 
red fluorescence was observed between stack 10 (3.6 µm) and stack 15 (5.6 µm). 
Image E shows a 3D image of image C using Volocity software (Perkin Elmer, 
UK). However, when the fluorescent light path was changed to green to visualize 
GFP, no green fluorescence was found to be expressed by this EBL cell. Hence, 
at 3 h post-invasion, internalized bacteria were found in this EBL cell but no 
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expression of GFP was detected. This could be interpreted as indicating that the 
bacteria were still intact and had not released plasmid into the intracellular 
environment of the EBL cell. 
As in set I, images in set II were also captured at 3 h post-invasion. In image A, a 
single EBL cell is clearly defined under the white light. In image B, filtered 
fluorescent blue light demonstrated the cell membrane in blue when stained by 
the plasma membrane stain. Image C was taken under red and blue filtered 
fluorescent light to visualized RFP expression (red) which appeared to be 
localised to the membrane boundaries that were stained blue. By switching the 
filtered fluorescent light path into green and blue, in image D, the EBL cell was 
seen to express GFP within the cell cytoplasm. Image E shows the stack of 
images when the slide underwent optical sectioning of 20 slices at every 0.4 µm. 
The existence of a few P. multocida B:2 JRMT12 pSRG+ internally were 
demonstrated in stack 5 (1.6 µm) until stack 17 (6.4 µm) (the table below the 
figure legend shows the numbered stack images in E and F). The intensity of red 
fluorescent was still however confined mainly to the periphery of the cell. The 
same optical sectioning was applied when the filtered fluorescent light path was 
switched to green and blue. In image F, the intensity of green fluorescence was 
clearly displayed in stack 7 (2.4 µm) progressing through until stack 15 (5.6 µm) 
before it declined. Observation of fluorescence intensity between the sections 
of this stack suggested that the localization of GFP occurred in the cytoplasm of 
the EBL cell and not in the nucleus. Image G and image H show 3D images of C 
and D, respectively. The data could be interpreted to indicate that, in this EBL 
cell, free plasmid was available for expression of GFP in the cytoplasm of the 
cell. The presence of only a few RFP-expressing bacteria within this cell might 
mean that others had been lysed so that they were no longer able to express 
RFP, but had released plasmid into the cytoplasm. The clear presence of 
bacteria at the periphery of the EBL cell, expressing rfp, might indicate that 
these bacteria had not yet been taken up the cell.  
Seventy EBL cells were assessed from slides prepared at 3 h post-invasion. 56% of 
these cells were found not to be expressing GFP and no RFP-expressing bacteria 
were found intracellularly. 44% of the EBL cells were found to harbour a number 
of RFP-expressing P. multocida B:2 JRMT12 pSRG+ intracellularly and, of this 
44%, 12 EBL cells were already expressing GFP. No EBL cells expressing GFP 
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without harbouring any RFP-expressing P. multocida B:2 JRMT12 pSRG+ 
intracellularly were found at this stage.  
In set III, images were captured at 5 h post-invasion. Under DIC (white) light in 
image A, a single EBL cell on a monolayer was captured. When viewed under 
filtered fluorescent light blue, the labelled membrane boundaries were visible as 
a blue fluorescence (Image B). When viewed with two different filtered 
fluorescent light paths, red and blue, the image in C showed internalized 
bacteria (red) within membrane boundaries (blue) at 2.8 µm splicing after 
optical sectioning. In D, the EBL cell was viewed green and blue under filtered 
fluorescent light. Extended focus of the image showed green fluorescence in the 
EBL cell cytoplasm within membrane boundaries. In image E, putting the stack 
together (extended focus) and viewing the cell under all three filtered 
fluorescent light paths, red, green and blue, the image showed internalized 
bacteria as red fluorescence and gfp expression as green fluorescence within 
membrane boundaries outlined in blue fluorescence. Image F and image G show 
3D images of image C and D respectively. In these images, localization of RFP 
and GFP expression is clearly displayed within the labelled (blue) membrane 
boundaries. 
As above, set IV displayed images captured at 5 h post-invasion. Image A showed 
a single EBL cell taken under DIC (white) light. In image B, the same cell was 
viewed under filtered fluorescent light blue to visualize the labelled cell 
membrane. When switching to both green and blue filtered fluorescent light, the 
image in C showed expression of GFP by the EBL cell displayed as green 
fluorescence within the cell membrane (blue). D shows images of optical 
sectioning of the slide. As demonstrated in the image stack, the localization of 
green fluorescence was gradually enhanced between stack 9 (3.2 µm) and stack 
16 (6.0 µm). Images between this stack showed clear discrimination of the cell 
cytoplasm and its nucleus, indicating that GFP was expressed only in the EBL cell 
cytoplasm. Image E shows a 3D image of image C using Volocity software (Perkin 
Elmer, UK). When cell were viewed under two filtered fluorescent light paths, 
red and blue, the image showed only the EBL cell with membrane boundaries 
outlined in blue fluorescence (image not shown). These data showed that, at 
this stage, internalized RFP-expressing bacteria had been lysed so that they 
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were no longer able to express RFP but had released the plasmid into the EBL 
cytoplasm for eukaryotic GFP expression.  
Sixty EBL cells were assessed from slides prepared at 5 h post-invasion. 47% of 
the EBL cells were found not to be expressing GFP and no RFP-expressing 
bacteria were found intracellularly. 53% of the EBL cells were found to be 
expressing GFP.  Out of that 53%, 12 cells were found to be still harbouring some 
RFP-expressing P. multocida B:2 JRMT12 pSRG+ intracellularly. Unfortunately, 
time constraints and technical difficulties with the stock of EBL cells meant that 
these experiments could not be repeated in another invasion assay. 
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Figure 36. Localization of prokaryotic and eukaryotic protein expression. 
The images show EBL cells after invasion with P. multocida B:2 JRMT12 pSRG+. 
Slides for visualization of EBL cells at high definition were prepared as in section 
2.16.1.1. Prepared slides were then viewed under the x100 objective lens of a 
Zeiss AxioImager M1 microscope (Carl Zeiss). Images were captured using a 
Hamamatsu Orca 03 and QIClick digital charge-coupled device (CCD) cameras 
and processed with Volocity software (Perkin Elmer, UK). Images were captured 
at 3 h (I and II) and 5 h (III and IV) post-invasion. 
(I)  EBL cell captured at 3 h post-invasion. Images were taken of the same field 
but under different light paths. 
A: EBL cell taken under the DIC (white) light.  
B:  EBL cell taken under filtered fluorescent light (Exc. = 649 nm, Ems. = 670 
nm) (blue) to visualize the counterstain, CellMask™ plasma membrane 
stain (GE Healthcare). 
C:  EBL cell taken under filtered fluorescent light (Exc. = 557 nm, Ems. = 585 
nm) (red) to visualize internalized RFP-expressing bacteria and filtered 
fluorescent light (Exc. = 649 nm, Ems. = 670 nm) (blue) to visualize the 
counterstained plasma membrane. 
 D:  EBL cell taken under filtered fluorescent light (Exc. = 649 nm, Ems. = 670 
nm) (blue) and filtered fluorescent light (Exc. = 557 nm, Ems. = 585 nm) 
(red) at selected depths by manipulation of optical sectioning. The slide 
was set to be sectioned optically at 0.4 µm intervals from top to bottom; 
images shown were captured at every 0.4 µm of depth at a total section 
stacking of 8.0 µm. The box below shows optical section number for every 
stack in the images. 
E: 3D image of C. 
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(II) EBL cell captured at 3 h post-invasion. Images were taken of the same field 
but under different light paths. 
A: EBL cell taken under the DIC (white) light.  
B:  EBL cell taken under filtered fluorescent light (Exc. = 649 nm, Ems. = 670 
nm) (blue) to visualize the counterstain, CellMask™ plasma membrane 
stain (GE Healthcare). 
C:  EBL cell taken under filtered fluorescent light (Exc. = 557 nm, Ems. = 585 
nm) (red) to visualize internalized bacteria expressing RFP and filtered 
fluorescent light (Exc. = 649 nm, Ems. = 670 nm) (blue) to visualize the 
counterstained plasma membrane. 
D: EBL cell taken under filtered fluorescent light (Exc. = 488 nm, Ems. = 507 
nm) (green) to visualize expression of GFP and filtered fluorescent light 
(Exc. = 649 nm, Ems. = 670 nm) (blue) to visualize the counterstained 
plasma membrane. 
E: EBL cell taken under filtered fluorescent light (Exc. = 649 nm, Ems. = 670 
nm) (blue) and filtered fluorescent light (Exc. = 557 nm, Ems. = 585 nm) 
(red) at selected depths by manipulation of optical sectioning. The slide 
was set to be sectioned optically at 0.4 µm intervals from top to bottom; 
images shown were captured at every 0.4 µm of depth at a total section 
stacking of 8.0 µm. The box below shows optical section number for every 
stack in the images. 
 F:  EBL cell taken under filtered fluorescent light (Exc. = 649 nm, Ems. = 670 
nm) (blue) and filtered fluorescent light (Exc. = 488 nm, Ems. = 507 nm) 
(green) at selected depths by manipulation of optical sectioning. The slide 
was set to be sectioned as in E. The box below shows optical section 
number for every stack in the images. 
G: 3D image of C. 
H: 3D image of D. 
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 G: 3D image of C generated using Volocity software. 
 
 
 
 
 
 
 
 
 
 H: 3D image of D generated using Volocity software. 
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 (III) EBL cell captured 5 h post-invasion. Images were taken of the same field 
but under different light paths.  
A: EBL cell taken under the DIC (white) light.  
B:  EBL cell taken under filtered fluorescent light (Exc. = 649 nm, Ems. = 670 
nm) (blue) to visualize the counterstain, CellMask™ plasma membrane 
stain (GE Healthcare). 
C:  EBL cell taken under filtered fluorescent light (Exc. = 557 nm, Ems. = 585 
nm) (red) to visualize RFP-expressing bacteria at 2.8 µm depth by 
manipulating optical sectioning and filtered fluorescent light (Exc. = 649 
nm, Ems. = 670 nm) (blue) to visualize the counterstained plasma 
membrane. 
D: EBL cell taken under filtered fluorescent light (Exc. = 488 nm, Ems. = 507 
nm) (green) to visualize expression of GFP and filtered fluorescent light 
(Exc. = 649 nm, Ems. = 670 nm) (blue) to visualize the counterstained 
plasma membrane. 
E: EBL cell taken under filtered fluorescent light (Exc. = 649 nm, Ems. = 670 
nm) (blue) to visualize the counterstained plasma membrane, filtered 
fluorescent light (Exc. = 557 nm, Ems. = 585 nm) (red) to visualize RFP-
expressing bacteria and filtered fluorescent light (Exc. = 488 nm, Ems. = 
507 nm) (green) to visualize expression of GFP. 
F: 3D image of C. 
G: 3D image of D. 
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(IV) EBL cell captured at 5 h post-invasion. Images were taken of the same field 
but under different light paths. 
A: EBL cell taken under the DIC (white) light.  
B:  EBL cell taken under filtered fluorescent light (Exc. = 649 nm, Ems. = 670 
nm) (blue) to visualize the counterstain, CellMask™ plasma membrane 
stain (GE Healthcare). 
C:  EBL cell taken under filtered fluorescent light (Exc. = 488 nm, Ems. = 507 
nm) (green) to visualize expression of GFP in the cytoplasm of EBL cell 
and filtered fluorescent light (Exc. = 649 nm, Ems. = 670 nm) (blue) to 
visualize the counterstained plasma membrane. 
D: EBL cell was taken under filtered fluorescent light (Exc. = 649 nm, Ems. = 
670 nm) (blue) and filtered fluorescent light (Exc. = 488 nm, Ems. = 507 
nm) (green) at selected depths by manipulation of optical sectioning. The 
slide was set to be sectioned optically at 0.4 µm intervals from top to 
bottom; images shown were captured at every 0.4 µm of depth at a total 
section stacking of 8.0 µm. The table below shows optical section number 
for every stack in the images. 
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Images I and III showed the capability of P. multocida B:2 JRMT12 pSRG+ to 
express RFP from plasmid pSRG within EBL cells. Images II, III and IV showed the 
apparent capacity of JRMT12 to release plasmid pSRG into EBL cytoplasm and 
the capacity of EBL cells to express GFP from pSRG released from internalized P. 
multocida B:2 JRMT12 pSRG+. The images also illustrated that P. multocida B:2 
JRMT12 pSRG+ was able to express RFP even at 5 h post-invasion (image III). It 
also demonstrated that pSRG were delivered into the EBL cytoplasm during the 
initial invasion period, allowing the mammalian cells to express GFP as early as 3 
h (images I and II) post-invasion. 
From observation of the slides, at 3 h post-invasion, three categories of EBL cells 
were found. Some EBL cells were found without any bacteria internally (no RFP 
expression), some EBL cells were found with internalized bacteria but the 
mammalian cells were not expressing GFP and some EBL cells, at the lowest 
percentage, were found to harbour internalized P. multocida B:2 JRMT12 pSRG+ 
and at the same time expressed GFP. At 5 h post-invasion, three categories of 
EBL cells were also found, some without any bacteria internally, some EBL cells 
were found to harbour internalized viable P. multocida B:2 JRMT12 pSRG+ 
expressing RFP and at the same time they expressed GFP and some EBL cells 
were found without any RFP expression but they expressed GFP. The last 
category could not be found at 3 h post-invasion and the second category of EBL 
cells found at 3 h post-invasion could not be found at 5 h post-invasion. Taken 
together, these data present good evidence that JRMT12 can carry plasmid pSRG 
into EBL cells and, while the bacteria remain viable, they will express RFP. Loss 
of RFP expression at 5 h post-invasion plus expression of GFP would indicate 
release of pSRG into the cytoplasm from the non-viable bacteria, where it was 
able to express GFP from the PCMVIE promoter. 
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3.5 Possible immunosuppressive effect of P. multocida 
B:2 infection 
Previous work by Ataei (2007) showed an apparent immunosuppressive effect of 
P. multocida B:2 on the proliferative response to concanavalin A (ConA) of 
peripheral blood mononuclear cells (PBMC) taken from infected animals or from 
normal animals when treated in vitro with P. multocida cells and cell-free 
extracts (CFE). In order to confirm these findings PBMC obtained from normal 
calves were cultured in vitro and treated with CFE of P. multocida B:2 strains. 
3.5.1 In vitro responses of PBMC 
An in vitro system to assess possible suppression of lymphocyte proliferation in 
response to ConA was developed as described in section 2.21. The first assay was 
done with CFE prepared from P. multocida B:2 JRMT12 (this study) and also with 
a batch of CFE from the wild-type strain (85020) that had been used previously 
by Ataei (2007). Aliquots of this preparation had been stored at –80°C. PBMC 
were obtained from normal calves at the Moredun Research Institute (MRI), 
Edinburgh. Figure 37 shows the PBMC response towards different concentrations 
of ConA after pre-treatment for 1 h with different concentrations of CFE. In the 
absence of CFE, PBMC showed a similar high proliferation to all three 
concentrations of ConA up to ~170 000 cpm as shown by the uptake of 3H-
thymidine, whereas little proliferation was observed without ConA. From graph 
A, exposure of the PBMC to different concentration of CFE from strain JRMT12 
(this study) gave a dose-dependent suppression of PMBC proliferation. Pre-
incubation of PBMC for 1 h with CFE at 5 µg/ml followed by addition of ConA at 
any concentration showed a slight suppression of PBMC proliferation but this was 
more marked at 10 µg/ml and 20 µg/ml of CFE. 
Graph B shows the effect of pre-treatment of the PBMC with CFE prepared 
previously from the wild-type strain, 85020. Without ConA, minimal proliferation 
of PBMC was observed even with increasing concentrations of CFE. When PBMC 
were incubated with different concentrations of ConA alone, proliferative 
responses up to ~170 000 cpm were observed but after pre-treatment with the 
CFE, there was no clear dose-dependent inhibition of proliferation. CFE at 5 
µg/ml slightly reduced PBMC proliferation and it appeared to have a greater 
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suppressive effect at 10 µg/ml. However, at 20 µg/ml, PBMC proliferation had 
increased. This contrast with Ataei’s finding (2007) whereby CFE from 85020 at 2 
µg/ml greatly suppressed PBMC proliferation in response to presence of ConA.  
Taking account of the results of the first assay with a freshly-prepared CFE, it 
was concluded that the putative active components responsible for proliferation 
inhibition in CFE prepared by Ataei (2007) might be labile, as the CFE had been 
prepared two years previously even though it had been stored at -80°C. 
However, fresh CFE, from JRMT12 generated some dose response in terms of 
suppression of PBMC proliferation.  
This assay was repeated twice, with PBMC obtained from normal calves at MRI, 
and treated in vitro with a freshly-prepared CFE from the wild-type strain, 
85020 and with the CFE prepared from the mutant strain, JRMT12. However, in 
these assays, no clear suppression of the PBMC proliferation was observed and 
results from the initial assay were not reproduced.  
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Figure 37. Effect of CFE from P. multocida B:2 on the proliferative 
response of PBMC to ConA. 
The data represent proliferative responses of normal calf PBMC after incubation 
for 1 h with CFE at different concentration (0, 5, 10 and 20 µg/ml) before 
addition of 0, 5, 10 or 20 µg/ml of concanavalin A (ConA). Proliferation was 
detected by measurement of tritiated thymidine incorporation and expressed as 
counts per minute (cpm). All tests were done in triplicate and results are mean 
values (+ SEM). 
 
A PBMC treated with CFE from P. multocida B:2 JRMT12 (this study) 
B PBMC treated with CFE from P. multocida B:2 85020 (Ataei, 2007) 
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The assay was repeated again using fresh batches of CFE prepared from the 
same mutant (JRMT12) and wild type (85020) strains. PBMC were obtained from 
calves at the School of Veterinary Medicine, University of Glasgow. Figure 38 A 
shows the PBMC response after pre-treatment with CFE from the mutant strain 
(JRMT12). Without ConA, proliferation was not significant. When CFE was not 
present in the assay, ConA at 5 µg/ml or 20 µg/ml greatly enhanced PBMC 
proliferation.  Pre-incubation of PBMC with CFE at 1 µg/ml for 1 h before 
addition of ConA did not show any significant suppression of PBMC proliferation. 
However, with higher CFE concentrations, a reduction of PBMC proliferation was 
observed, especially with ConA at 20 µg/ml. Thus, this experiment showed a 
similar result to the first assay (Figure 37 A) where PBMC proliferation was 
suppressed by CFE from strain JRMT12 in a dose-dependent manner. 
Figure 38 B shows the PBMC response after treatment with CFE prepared from 
the wild type, 85020. However, the results are similar to those observed in the 
first assay (Figure 37 B). PBMC proliferation was not significantly suppressed 
when pre-incubated with CFE from strain 85020, followed by addition of ConA. 
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Figure 38. Effect of new preparations of CFE P. multocida B:2 on 
proliferative response of PBMC to ConA. 
The data represent proliferative responses of normal calf PBMC after incubation 
for 1 h with CFE at different concentration (0, 1, 5, 10 and 20 µg/ml) before 
addition of 0, 5, or 20 µg/ml of concanavalin A (ConA). Proliferation was 
detected by measurement of tritiated thymidine incorporation and expressed as 
stimulation index (SI). Which shows the ratio of incorporation in treated (CFE 
was added) compared to untreated cells. PBMC were cultured in triplicate and 
results are mean values (+ SEM).  
A PBMC treated with CFE from P. multocida B:2 JRMT12 
B PBMC treated with CFE from P. multocida B:2 85020 
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The assay was again repeated, with the same prepared CFE from the previous 
experiment and PBMC obtained from calves at the School of Veterinary Medicine, 
University of Glasgow. Results showed no clear suppression of the PBMC 
proliferation and data from the initial assay were not reproduced. Despite 
irreproducibility and inconsistencies in the data obtained, a trend towards 
suppression on PBMC proliferation had been observed with CFE prepared from 
strain JRMT12. 
  
4.0 DISCUSSION 
4.1 Interaction between mammalian cells and Pasteurella 
P. multocida B:2 causes haemorrhagic septicaemia (HS) in cattle and buffaloes. 
The successful transmission of disease by the intranasal and oral routes, 
producing a syndrome with clinical signs and lesions resembling natural disease 
indicates that these may be the natural routes of infection (De Alwis, 1992). 
However, a feature of the HS disease is the rapid spread of infecting bacteria 
from the respiratory tract to the blood and lymph to cause a fatal septicaemia in 
less than 48 h. To pass into the bloodstream, the bacteria must migrate through 
the epithelial layer into the pulmonary interstitium. The potential of Pasteurella 
for attachment to and invasion of mammalian cells may constitute a mechanism 
that enables the bacteria to invade the blood stream. In this study, two strains 
of P. multocida B:2 were assessed for their interactions with several types of 
mammalian cells. Beside the parent strain, P. multocida B:2 85020 (HS-
associated strain obtained from Sri Lanka), a marker-free aroA deletion 
derivative of this strain, JRMT12, were observed for their ability to adhere to 
and invade mouse macrophage-like, J774.2 cells, bovine lymphoma, BL-3 cells 
and embryonic bovine lung, EBL cells. For comparison, bovine P. multocida A:3, 
bovine M. haemolytica A:1 and E. coli XL-1 Blue were included.  
As attachment is a primary prerequisite for bacterial infection, many studies 
have examined potential receptors and ligands during host-pathogen 
interactions. P. multocida serotype A:3 was found to adhere to the mucosal 
epithelium of the nasopharynges of rabbits (Glorioso et al., 1982). The study 
showed that bacteria specifically attached to squamous epithelial cells of the 
pharyngeal mucosa both in vivo and in vitro and to some tissue culture cell lines 
such as HeLa cells. The attachment to pharyngeal and HeLa cells was inhibited 
by N-acetyl-D-glucosamine. These findings suggested that this amino sugar may 
be a component of the receptor on both cell surfaces and that fimbriae may 
have mediated adhesion (Glorioso et al., 1982). However, they also found that 
the hyaluronic acid capsule of the A:3 strain reduced adhesion, possibly because 
of its high-charge density which increased repulsion between the animal cell and 
the bacteria (Jones, 1977). It was suggested in another study that the hyaluronic 
acid capsule was not involved in the adherence process during pathogenesis but 
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played a role in increasing resistance to cellular defence mechanisms during 
Pasteurella infections (Maheswaran & Thies, 1979).  
Adherence of a P. multocida serotype A strains to HeLa cells was also shown by 
Esslinger et al. (1994). The strain adhered strongly to HeLa cells and alveolar 
macrophages from rabbits, mice, cattle and horses. They also showed that by 
pre-treating the Pasteurella with hyaluronidase or pre-incubating the HeLa cells 
with hyaluronic acids, bacteria adherence was dramatically reduced. They thus 
suggested that hyaluronic acid in the capsule of the type A strain played a role 
in adhesion and subsequent colonization of the bacteria (Esslinger et al., 1994). 
These data contradict the earlier study of Glorioso et al. (1982), but were 
confirmed in another study when acapsulated strain of P. multocida A:3 was 
found to adhere to turkey air sac macrophages in culture but were not 
internalized, while non-capsulated variants of the A:3 strain showed little or no 
adherence and also were not internalized (Pruimboom et al., 1996). 
Depolymerization of the bacterial capsule with hyaluronidase increased 
phagocytosis by macrophage cultures, and addition of hyaluronic acid to the 
macrophages inhibited bacterial adherence. The study suggested that capsular 
hyaluronic acid facilitates adherence to, but not internalization of, macrophages 
cultures. It also suggested that a host-specific glycoprotein receptor is involved 
for recognition of this bacterial polysaccharide. 
In vitro adherence of P. multocida A:3 and a type D:1 strain, isolated from a 
rabbit with septicaemia, towards explants of tracheal mucosa, lung and aorta 
from freshly killed rabbits were assessed by Al-Haddawi et al. (2000). Under a 
scanning electron microscope, the type D strain was found to adhere more to 
trachea and aorta when compared to the type A strain. However, the type A 
strain adhered to the lung explants more efficiently. The results were obtained 
after 45 min of incubation, but prolonged incubation to 2 h found that both 
strains adhered at a similar rate to the lung explants. It was noted that the 
capsular material of type A strain and the toxin of the type D strain may have 
influenced the adherence to lung tissue in the rabbit. This study also suggested, 
from the ability of the type D strain to adhere to aorta, that the expression of 
receptors on the endothelium could possibly explain the ability of certain strains 
to cause septicaemia (Al-Haddawi et al., 2000). 
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P. multocida types A, D and B:2 strains are known to possess type 4 fimbriae 
[designated PtfA] (Ruffolo et al., 1997; Dabo et al., 2007; Siju et al., 2007). 
Under microaerophilic conditions, P. multocida showed an increased expression 
of the fimbriae, which were observed to form bundles. Purification of fimbriae 
with high performance reverse phase liquid chromatography isolated a single 18-
kDA subunit and the first 21 amino acids shared a very high similarity with the N-
terminal amino acid sequence of type 4 fimbrial subunits from other bacteria. 
The gene ptfA which coded for type 4 fimbrial protein from P. multocida B:2 was 
later studied and characterized (Siju et al., 2007). This study revealed that type 
4 fimbriae are probably one of the most important surface components that 
mediate colonization of host surfaces and which correlate to bacterial virulence. 
It has also been shown known that many pathogens, including members of the 
family Pasteurellaceae, exploit host extracellular matrix (ECM) molecules for 
virulence through adherence and colonization. ECM is a mixture of many 
glycoproteins including fibronectin, fibrinogen, collagen, elastin, laminin and 
glycosaminoglycans present in the cell membrane of eukaryotic cells (Kreis & 
Vale, 1993). The broad host range characteristics of P. multocida A:3 suggest 
recognition of host cell surface components (ECM molecules) common to 
multiple animal species and tissue types. Recent studies have investigated the 
binding of P. multocida A to ECM molecules including fibronectin (Fn) (Dabo et 
al., 2005). Bacteria bound both soluble and immobilized Fn and preferentially 
bound the N-terminal heparin-binding fragment (Hep-1) of Fn, similar to that 
described for other bacterial pathogens (Dabo et al., 2005). OmpA, TonB-
dependent receptor HgbA (a hemoglobin-binding protein A) and transferrin-
binding protein A (TbpA) were among the P. multocida and M. haemolytica 
proteins identified as putative Fn-binding proteins. The OmpA protein was found 
to bind Madin-Darby bovine kidney (MDBK) cells via heparin and/or Fn bridging 
(Dabo, 2003) and ELISA study using bovine fibronectin as the substrate 
demonstrate antibody to the 45 kDa OmpA of M. haemolytica A1 bound 
specifically to the fibronectin but not to fibrinogen (Lo & Sorensen, 2007). This 
study was further elaborated by Kisiela & Czuprynski (2009) who demonstrated 
that OmpA and lipoprotein 1 (Lpp1) were involved in adherence of bovine M. 
haemolytica A1 towards bovine bronchial epithelial cells.  
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M. haemolytica has been reported to adhere to epithelial cells of the bovine 
respiratory tract (Clarke et al., 2001) and Mardin-Darby bovine kidney (MDBK) 
cells (Galdiero et al., 2002). M. haemolytica field isolates from ovine mastitis 
were also found to adhere to a primary culture of ovine mammary epithelium 
(Vilela et al., 2004). In another study, confluent bovine aortic endothelial cells 
(BAEC) were infected with P. multocida serotype B and M. haemolytica serotype 
A:1 at MOI 10, 50, 100 or 1000 bacteria/cell. An association assay was carried 
out at 30 or 60 min post-infection. The infected cells were fixed with methanol 
and Giemsa staining was utilized to illustrate cell-association of bacteria. 
Assessment of adherence showed no significance differences between the two 
species at the different bacteria:cell ratios (Galdiero et al., 2001). Although the 
above studies did not indicate potential adherence substances, they did 
demonstrate adherence of P. multocida to different cell types, tissues or organs 
and often reflected a serogroup-specific host preference and pathogenicity. 
In this study, in the absence of killing of extracellular bacteria (by omitting 
gentamicin and polymyxin B) the number of intracellular plus adherent bacteria 
of different strains of P. multocida B:2, P. multocida A:3 and M. haemolytica A:1 
with EBL cells could be determined. By comparison with the number of 
intracellular bacteria (after using gentamicin and polymyxin B) to kill 
extracellular bacteria, the number of adherent bacteria could then be assessed. 
After incubation for 1 or 3 h with EBL cells, all strains tested showed a similar 
rate of adherence, although the attenuated derivative P. multocida B:2 JRMT12 
adhered to EBL cells slightly better than its parent strain, 85020 (Table 10). This 
might be due to modification in the surface properties associated with altered 
aromatic acid biosynthesis in the JRMT12 strain. The other strain, P. multocida 
A:3 and M. haemolytica A:1 adhered to EBL cells at a similar rate to JRMT12 
(Table 11). These findings correspond to all previous studies mentioned above. 
However, experiments here were not extended to investigate host-interaction 
receptors between mammalian cells and P. multocida B:2 strains. In further 
experiments, it would be of interest to determine the effect of Fn on the 
adherence of these strains to mammalian cells. 
A variety of pathogenic bacterial species adhere to non-phagocytic mammalian 
cells but not all bacteria-host cell interactions result in cellular entry. Avian 
serogroup A strains of P. multocida have been reported to invade cultured 
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mammalian cells (Al-haj Ali et al., 2004) as have P. multocida serotype B strains 
when investigated for their ability to adhere to and invade bovine aortic 
endothelial cells (BAEC) (Galdiero et al., 2001). Preliminary data (Tabatabaei, 
2000; Merza, 2008) showed that P. multocida B:2 can enter and survive within 
mouse macrophage-like cells, J774.2 and bovine lymphoma cells, BL-3. In the 
host, survival within leukocytes may be a feature that facilitates rapid systemic 
infection.  
Our study showed that P. multocida B:2 has the ability to invade J774.2, BL-3 
and EBL cells at MOI 100:1. At lower MOIs, invasion was less pronounced and at 
higher MOIs little enhancement of invasion was seen (Tables 7 & 9). Much of the 
knowledge regarding bacterial internalisation and intracellular survival has been 
gained from studies using in vitro assay in which cultured mammalian cells are 
infected with bacteria for a pre-determined time. Bacteria recovered after 
antibiotic treatment to kill extracellular bacteria are presumed to be 
internalised within the cells. A combination of gentamicin and polymyxin B 
antibiotics at 50 µg/ml of each reduced the number of viable P. multocida B:2 
JRMT12 by > 99.9% after 30 min incubation and essentially killed all bacteria 
after incubation for 60 min.  Both P. multocida B:2 strains were found to be 
internalised in J774.2, BL-3 and EBL cells at 3 h post-invasion (Tables 5, 6, 8 & 
9). It was mentioned above that all other Pasteurella strains tested in this study 
were able to adhere to EBL cells; however very low number of them were found 
intracellularly. The same results were observed when J774.2 cells were infected 
with either P. multocida A:3 or E. coli XL-1 Blue, very low number of these 
strains were internalised by the phagocytic cell lines (Table 7). 
P. multocida B:2 JRMT12 was found to survive intracellularly for at least 7 h with 
a slow decrease with time in the number of viable internal bacteria. An EBL 
monolayer was exposed to JRMT12 in the standard invasion assay for 3 h and this 
was followed by prolonged incubation for 5 or 7 h, either with gentamicin and 
polymyxin B each at 10 µg/ml or 50 µg/ml or in the absence of antibiotic. These 
conditions were created in order to eliminate the possibility of any extracellular 
bacteria replicating if there was no antibiotics present in the assay. Antibiotics 
at 50 µg/ml were maintained in the assay to eliminate extracellular bacteria but 
ingestion of the assay medium by mammalian cells might result in the possibility 
of killing of intracellular bacteria. Hence, in parallel, a lower level of antibiotics 
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(10 µg/ml) was added, sufficient to prevent replication of any remaining 
extracellular bacteria but at the same time, ingestion of assay medium by the 
cell would be less likely to result in short-term killing of intracellular bacteria. 
However, the data obtained showed no significance difference in bacterial 
numbers recovered, either with or without the presence of antibiotics (Table 
12). A previous study had shown an apparent increase of bacterial counts 6 h 
post-infection by P. multocida B:2 strains of J774.2 cells but fewer bacteria 
were recovered when the assay was done in the presence of antibiotics at a low 
level (Merza, 2008). This could be due to the fact that the cell line used was 
actively phagocytic. Thus the possibility of medium ingestion would be more 
likely when compared to EBL cells used in our study. 
As mentioned above, infection of BAEC with P. multocida B at MOI 100:1 found 
the bacteria to be internalized at 4 h post-infection (Galdiero et al., 2001). They 
also found that bacterial internalization was dependent on microfilament and 
microtubule stability. The study used cytochalasin D, an inhibitor of actin 
polymerization, colchicine and nocodazole, inhibitors of microtubule formation, 
and taxol, which stabilizes the microtubules, to determine the involvement of 
microfilaments and microtubules in these processes. In the presence of 
cytochalasin D, invasion was reduced by 60%; it was reduced by 3% in the 
presence of colchicine and by 5% in the presence of nocodazole (Galdiero et al., 
2001). Thus, P. multocida invasion was principally dependent on actin filament 
formation. 
In an invasion inhibition assay in the present study, EBL monolayers were pre-
incubated with 1, 2, 4 and 8 µg/ml of cytochalasin D (CD) for 1 h. After infection 
of 3 h with the JRMT12 strain, CD was active at 1 µg/ml in completely 
preventing invasion. The assay was repeated with pre-incubation of the EBL 
monolayer with 1 µg/ml of CD but the monolayer was washed three times with 
PBS before adding the bacteria at MOI 100:1. Incubation was then followed as for 
the standard invasion assay but also prolonged as for the intracellular survival 
assay (total 7 h). Table 13 shows that the effect of CD was not reversible, at 
least during the 2 h period when washed EBL cells were incubated with bacteria 
prior to antibiotic treatment. In comparison with the above study by Galdiero et 
al. (2001) which showed only 60% of inhibition during invasion of BAEC by P. 
multocida, invasion was totally inhibited in this study when CD was pre-exposed 
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to the EBL cells before bacterial infection. Nevertheless, all data concur that 
entry of P. multocida B:2 into mammalian cells might be by actin-dependent 
phagocytosis.  
A summary of Pasteurella adherence to and invasion of mammalian cells is listed 
below in Table 15. 
Table 15. Summary of Pasteurella interactions with mammalian cells. 
Pathogen Properties Cells Reference 
P. multocida A:3 Adherence mucosal epithelium of rabbit  
nasopharynges and HeLa 
cells 
Glorioso et al., 
1982 
P. multocida A Adherence alveolar macrophages (from 
rabbits, mice, cattle and 
horses) and HeLa cells 
Esslinger et al., 
1994 
P. multocida A:3 
(capsulated) 
Adherence air sac macrophage of turkey Pruimboom et 
al., 1996 
P. multocida A:3 
P. multocida D:1 
Adherence 
Adherence 
explants of tracheal mucosa, 
lung and aorta from rabbit 
Al-Haddawi et 
al., 2000 
P. multocida B:2 Adherence 
& Invasion 
Mouse macrophage-like 
J774.2 cells  
Tabatabaei, 
2000 
M. haemolytica A:1 
P. multocida B 
Adherence 
Adherence 
& Invasion 
Bovine aortic endothelial 
(BAEC) cells  
Galdiero et al., 
2001 
M. haemolytica A Adherence Bovine upper respiratory 
tract tissues 
Clarke et al., 
2001 
M. haemolytica Adherence Mardin-Darby bovine kidney 
(MDBK) cells  
Galdiero et al., 
2002 
P. multocida A Invasion Chicken embryo fibroblast 
(CEF) cells 
Al-haj Ali et al., 
2004 
M. haemolytica 
(isolates from ovine 
mastitis) 
Adherence Ovine mammary epithelium Vilela et al., 
2004 
P. multocida B:2 Adherence 
& Invasion 
Mouse macrophage-like 
J774.2 cells and bovine 
lymphoma (BL-3) cells 
Merza, 2008 
M. haemolytica A:1 Adherence Bovine bronchial epithelial 
cells 
Kisiela & 
Czuprynski, 
2009 
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Localization of internalized bacteria was determined by TEM examination of an 
infected EBL monolayer. In previous studies the appearance of vacuoles has been 
observed in phagocytic cells such as macrophages, in the presence of the 
intracellular pathogen (Shah et al., 1996). In J774.2 cells, extensive vacuolation 
was seen after infection with P. multocida B:2 (Merza, 2008). Both of these 
studies showed dramatic effects on the appearance and viability of macrophages 
after infection with P. multocida B:2. In the present study, in order to 
determine bacterial cytotoxic activity towards mouse macrophage-like J774.2 
cells and EBL cells (which are not normally considered phagocytic), trypan blue 
exclusion staining was used to distinguish between live and dead cells. Staining 
was done before and after exposure of the cells to bacteria. The data showed no 
toxic effects of any of the bacterial strains used for either J774.2 or EBL cells. 
Galdiero et al. (2001) assessed cytotoxicity by measuring the release of lactic 
dehydrogenase from BAEC cells and their findings were in agreement with our 
study, as they reported little or no cytotoxicity of their B serotype strain. TEM 
micrographs in the present study showed pre-existing vacuoles in non-infected 
EBL cells and exposure to bacterial strains did not extensively alter their 
morphologies. Thus the vacuolating effect of P. multocida B:2 noted above may 
be restricted to professional phagocytes. 
A micrograph prepared from a sample taken 2 h post-infection demonstrated 
JRMT12 bacteria in the process of being taken up by an EBL. Protruding arms 
(pseudopod-like elongations) extending from the EBL cell to surround the 
bacteria were found in this micrograph agreeing with earlier data which 
indicated that bacteria enter through phagocytosis. Observation of filamentous 
structures on the bacterial periphery might be indication of adherence 
mechanisms. At 3 h post-infection, electron-dense P. multocida B:2 JRMT12 
were observed individually inside tight membrane bound cytoplasmic vacuoles, 
but rarely (if ever) free in the cytoplasm of EBL cells, although the vacuole 
membrane were sometime difficult to see.  
Micrographs on other Pasteurella strains demonstrated bacteria adhering to EBL 
cells or existing extracellularly at 2 h post-infection. M. haemolytica A:1 
adherence to these cells appeared to be low even compared to P. multocida A:3. 
Neither of these strains was found intracellulary even at 3 h post-infection, 
agreeing with the data of the previous invasion assays (section 3.2.4.3). These 
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data also agree with the previous literature mentioned earlier, indicating that 
both P. multocida A:3 and M. haemolytica A:1 adhere to mammalian cells but 
were not found intracellularly. 
The morphological assessment by TEM showed bacteria co-localising in a low 
percentage of mammalian cells rather than being invasive for the majority of 
mammalian cells. These results raise the question of whether the differentiation 
or proliferation states of the mammalian cells modify their susceptibility to P. 
multocida B:2. Enteropathogenic E. coli (EPEC) pathogenesis was dependent on 
cell differentiation states (Gabastou et al., 1995). Infection of Caco-2 cells with 
EPEC provided evidence that intestinal cell differentiation could alter EPEC 
pathogenesis. The study found that EPEC:cell clusters increased as a function of 
the epithelial cell differentiation while efficient cell entry by EPEC bacteria 
occurred in Caco-2 cells where differentiation had recently been initiated and 
decreased when the cells were fully differentiated. Thus, the mature cell up-
regulates intestinal colonization but down-regulates intestinal cell invasion by 
EPEC (Gabastou et al., 1995). Another study, with Listeria monocytogenes, 
showed that entry into intestinal cell lines did not involve mammalian cell 
metabolism. The observation shows that L. monocytogenes entry escalated 
during the mammalian cell proliferation process rather than during the 
differentiation state of the cells (Velge et al., 1997). In our study, P. multocida 
B:2 was found to invade selective cells after monolayer infection. Assessment of 
target cell conditions during infection would be worth investigating. Experiments 
could recruit carboxyfluorescein diacetate succinimidyl ester (CFDA-SE) to 
monitor the extent of mammalian cell proliferation (Fuller et al., 2001) 
simultaneously with fluorescent dyes such as acetomethoxy derivate of calcein 
(calcein-AM) to measure cell viability by determining functionality of 
intracellular esterases (Calvinho & Oliver, 1998). Both of these stains could 
evaluate the growth stages of cells during bacterial invasion. 
In this section, the capacity of P. multocida B:2 strains to be internalized and 
persist in mammalian cells has been discussed. The P. multocida A:3 strain and 
the M. haemolytica A:1 strain showed a capacity to adhere to EBL cells, but only 
the B:2 strain was found intracellularly. The pathogenesis of HS strains is very 
complex and further investigations are necessary to improve our understanding 
of this process. However, the recognition that the B:2 strain expresses the 
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capacity to adhere to and invade mammalian cells suggests that molecular 
studies to identify the components involved in these processes and the relevance 
of target cell cycle to pathogenesis may help to improve our understanding of 
the pathogenicity of HS. Moreover, the collective data also serves as important 
preliminary work that established that the JRMT12 strain could act as a suitable 
carrier vehicle for bacteria-mediated gene transfer (bactofection), the 
transkingdom transfer of DNA from bacteria to other organisms.  
4.2 Construction of a Pasteurella eukaryotic expression 
plasmid 
Bactofection uses bacteria as a vehicle for DNA vaccination. Generally, the 
vector bacterium will carry a plasmid able to express heterologous gene(s) under 
the control of a eukaryotic promoter. After entry of the bacterium into the 
mammalian cell, progressive destruction of the bacterium will release the 
plasmid into the mammalian cell cytosol where the heterologous gene can then 
be expressed. Such a delivery system has many benefits such as the ability to 
target sites of the immune system open only to intracellular pathogens. One of 
the most important components in bacteria-mediated gene transfer is the 
suitability of the eukaryotic expression plasmid to the carrier bacterium and to 
the target host cells.  
The eukaryotic expression plasmid pCMV-sCRIPT is a pUC-based plasmid designed 
to allow replication in E. coli together with replication and protein expression in 
mammalian systems. It was found in this study that the plasmid failed to 
propogate in P. multocida B:2 after electroporation. The inability of Pasteurella 
(Mannheimia) strains to maintain other plasmids with different origins of 
replication has been shown in previous studies. Non-Pasteurella broad-host-
range plasmids such as pRK290 and pSa4 were transferred into M. haemolytica 
A1 of bovine origin either by conjugation or electroporation. However, none was 
found to propagate in this strain (Craig et al., 1989). The study suggested that 
M. haemolytica possessed an active DNA restriction system that might prevent 
the function of a non-suitable plasmid in the bacterium. It was later found that 
M. haemolytica A1 harbours a type I restriction enzyme, phaI, and a type II 
restriction enzyme hsdM (Hill & Lainson, 2003). Another study on P. multocida 
type D found a restriction-modification system in the toxigenic strain, LFB3 
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(Hoskins, 1997). Plasmid DNA transformed in this strain was resistant to PstI, and 
sensitive to DpnI digestion. Since the discovery of DNA restriction systems in 
Pasteurellaceae, researchers have needed to develop a plasmid that can be 
delivered between members of Pasteurellaceae family and to other Gram-
negative bacteria, such as E. coli, to facilitate genetic studies (Azad et al., 
1994; Wood et al., 1995). 
As outlined in Figure 12, Chapter 3, two plasmids were selected in order to 
develop a Pasteurella eukaryotic expression plasmid. Plasmid pAKA16, 
developed in this laboratory (Azad et al., 1994) was derived from a plasmid 
isolated from a bovine M. haemolytica A:1 strain and was selected for its 
stability and ready amplification in P. multocida B:2 and also in E. coli. The 
commercial E. coli eukaryotic expression vector pCMV-sCRIPT was selected 
based on its size and properties. The proposed strategy illustrated in Figure 12 
showed the isolation of the Pasteurella origin of replication from plasmid 
pAKA16 to replace the ColE1 origin of replication on plasmid pCMV-sCRIPT. The 
origin of replication from plasmid pAKA16 (oriP) was identified and sequenced 
(Figure 15). The sequence had two open reading frames (ORF). The first ORF was 
located downstream of a set of genes recognized as the putative oriP gene; 51 
bp of the sequence within this gene was highly matched with several native 
Pasteurellaceae plasmids, pJR1 (from P. multocida), pD70 (from M. 
haemolytica), pIG1 (from P. multocida) and pAB2 (from M. haemolytica), and 
was located in the replication origin in each of these plasmids. Short 16 bp 
direct repeats were found within the 51 bp homologous sequence. Direct repeats 
and inverted repeats are common characteristics found within the region 
involved in replication in native Pasteurellaceae plasmids. One study showed 
that plasmid pIG1, isolated from P. multocida serotype D, harboured three 
major inverted repeats of 20, 16 and 38 bp in its putative origin of replication 
gene (Wright et al., 1997). Interestingly, the authors reported that the same 16 
bp and 38 bp inverted repeats were also present in the plasmid pYFC1 (from M. 
haemolytica) and plasmid pLS88 (from H. ducreyi), while all three inverted 
repeats were found in pAB2; a plasmid isolated from M. haemolytica. In addition 
to that, the 20-bp inverted repeat is found to be associated with the bla gene in 
H. influenzae and A. pleuropneumoniae. It is located immediately downstream 
of the bla gene in these organisms which is thought to be in the terminator 
region of this gene coding for the ROB-1 ß-lactamase enzyme (Maclean et al., 
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1992). None of the inverted repeats were found in our putative oriP gene. This 
might indicate a different type of sequence for the replication origin of our 
native Pasteurella plasmid. A study of multiresistance in P. multocida isolated 
13 native plasmids from clinical strains. It was noted that none of the replication 
origin regions among these 13 plasmids were identical, although they were 
highly similar (San Millan et al., 2009). This might suggest that there is more 
than one pattern of oriP gene replication in native Pasteurella plasmids which 
may harbour similar direct repeats or inverted repeats, but the relevance of 
either the direct or inverted repeats to replication of these Haemophilus, 
Actinobacillus & Pasteurella (HAP) plasmids is unclear.  
The second ORF in Figure 15 was highly matched with part of the mobilization 
gene, mbeAY from plasmid pIG1 (Wright et al., 1997). From here, isolation of 
the putative oriP gene was continued as illustrated in Figure 12. Removal of the 
pUC origin of replication from plasmid pCMV-sCRIPT was done in parallel. 
However, attempts to transform the ligation mixture of the plasmid and the oriP 
gene failed due to unknown reasons. This may have been due to DNA restriction 
barriers that may not have allowed the transformed plasmid to propagate in P. 
multocida B:2. 
Another commercial pUC-based eukaryotic expression plasmid pEGFP-N1 was 
recruited for use in this study. The plasmid was derived from plasmid pUC18 and 
has an advantage when compared to the previously selected plasmid, pCMV-
sCRIPT. It harbours a reporter gene, EGFP, which encodes a red-shifted variant 
of the wild type green fluorescent protein (GFP). The EGFP gene is located 
downstream of the viral immediate early promoter of cytomegalovirus (PCMVIE). 
An ability to propagate this plasmid in P. multocida B:2 would help to monitor 
intracellular trafficking of the plasmid via GFP expression and also for future 
antigenic protein expression in mammalian cells. 
Having a similar origin of replication as plasmid pCMV-sCRIPT, plasmid pEGFP-N1 
was expected to behave similarly after electroporation into Pasteurella. 
However, plasmid pEGFP-N1 was recovered from positive transformants at 36h 
post-electroporation. The only difference from previous electroporation with 
plasmid pCMV-sCRIPT was the extended incubation time. Small colonies were 
observed only after 36h. This indicated that suppression of plasmid DNA 
propagation was overcome, with a delay in replication and ability to express the 
Discussion 
178 
antibiotic-resistance gene. As discussed above, an active DNA restriction system 
has been identified in Pasteurellaceae bacteria which acts as a defence 
mechanism against foreign DNA. In order to achieve successful transformation, it 
was proposed that DNA must be modified by phaI (Briggs et al., 1994). However, 
Hill & Lainson (2003) found that a strain of M. haemolytica A1 positive for both 
hsdM and phaI was able to be transformed with plasmid DNA extracted from E. 
coli which was contrary to the suggestion of Briggs et al. (1994) that the origin 
of plasmid DNA influences transformation efficiency. They indicated that 
plasmid DNA purified from methylase positive and negative bacteria of different 
species can be cross-transferred at the same transformation rate.  
In order to determine if there was any enzyme modification in the E. coli 
plasmid propagating in P. multocida, pEGFP-N1 purified from P. multocida after 
electroporation was re-electroporated into E. coli XL-1 BLUE and P. multocida 
B:2 JRMT12. In parallel, purified plasmid from E. coli XL-1 BLUE was also 
electroporated into P. multocida B:2 JRMT12 and E.coli XL-1 BLUE for 
comparison. Similar numbers of colonies were found after incubation for 18 h in 
E. coli XL-1 BLUE either harbouring pEGFP-N1 purified from P.multocida or from 
E. coli. After incubation for 36 h, similar numbers of colonies were found in P. 
multocida B:2 JRMT12 either harbouring pEGFP-N1 purified from P.multocida or 
E. coli. This suggested that transfer of plasmid from methylase-negative E. coli 
XL-1 BLUE to methylase-positive P. multocida B:2 is possible, showing that the 
source of genetic material is not a barrier to transformation. However, the delay 
of P. multocida strain recovery on the selective plate would suggest that the 
plasmid DNA had to undergo some adaptation in order to replicate, and this 
would need further investigation.  
Other pUC-based plasmids, pGEM-oriP and pCMV-sCRIPT, were then 
electroporated into P. multocida B:2 JRMT12. Plasmid pAKA16 was included for 
comparison. In parallel, all plasmids were also electroporated into E. coli XL-1 
BLUE. Colonies were observed on all E. coli transformants at 18 h after 
electroporation, while in P. multocida only colonies electroporated with pAKA16 
were recovered at 18 h after electroporation. However, colonies were observed 
for all other transformants after incubation for 36 h. There was no significant 
difference in the number of colonies on each individual selective plate among 
the same strain harbouring different plasmids. This showed that the effect was 
Discussion 
179 
not confined to plasmid pEGFP-N1 but that all pUC-based plasmids were capable 
of propagation in P. multocida B:2 JRMT12 when the incubation time after 
electroporation was extended to at least 36 h.    
Plasmid-containing P. multocida B:2 were able to stably maintain the pEGFP-N1™ 
plasmid for at least 14 days with the absence of an antibiotic selection. Plasmid 
purified from all strains showed no alteration in DNA size after restriction 
enzyme analysis. Comparison of growth rate between P. multocida B:2 JRMT12 
and E. coli  XL-1 BLUE whether harbouring pEGFP-N1 or not showed a similar 
pattern with no obvious difference. However, P. multocida B:2 JRMT12 
harbouring plasmid pEGFP-N1, cultured in BHI broth with kanamycin (50 µg/ml), 
entered exponential phase at a slower rate when compared to the strain 
cultured in BHI broth without antibiotic (Figure 11). Thus, the delay may have 
been caused by the time taken to express sufficient enzyme needed for 
resistance to the antibiotic. However, both strains showed insignificant 
differences in the slope of the exponential phase. When pEGFP-N1 was purified 
from both strains at the same OD600nm, the concentration of plasmid DNA 
obtained was similar from each. Thus, pEGFP-N1 was stably maintained in P. 
multocida B:2 even in the absence of antibiotic. 
4.3 Development of P. multocida B:2 bactofection model 
system 
Bactofection (bacteria-mediated expression plasmid DNA transfer) can be 
applied for genetic vaccination, gene therapy and production of therapeutic 
proteins (Liu, 2011). Delivery of naked plasmid DNA by intramuscular, 
intradermal or oral administration in genetic vaccination offers the possibility of 
both antigen presentation and immune modulation. However, this route of 
vaccination always results in low efficiency of delivery. The use of bacteria as 
carriers for mucosal applications of DNA vaccines addresses some of the 
problems of naked DNA vaccination and provides additional benefits, such as 
adjuvant effects and the ability to target inductive sites of the immune system. 
The progress in bioengineering of attenuated strains of many otherwise 
pathogenic bacteria and use of these as vaccine vectors provides a means of 
using bacteria as efficacious delivery vehicles for transporting plasmid DNA 
containing heterologous genes expressing protective antigens into mammalian 
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cells. Attenuated bacterial strains such as Listeria monocytogenes, different 
strains of Salmonella and Shigella act as bacterial vectors for transkingdom 
transfer of plasmid. For example, a protective response was observed in BALB/c 
mice against a lethal challenge with L. monocytogenes after immunization with 
attenuated Salmonella typhimurium carrying a listeriolysin-encoding expression 
plasmid (Darji et al., 2000). In another study, a diaminopimelate auxotroph 
mutant (dap-) of Shigella flexneri harbouring plasmid pCMVß, which synthesized 
ß-galactosidase under the control of a eukaryotic promoter (Sizemore et al., 
1995), was used to infect mammalian cells which showed expression of ß-
galactosidase at 48 h post-invasion. Furthermore, after intranasal infection of 
mice, both humoral and cellular anti-ß-galactosidase responses were detected, 
indicating that in vivo delivery of plasmid DNA by this strain stimulated immune 
responses to plasmid-encoded antigen. Another recent study enhanced the 
ability of Listeria to act as delivery vector. An engineered attenuated strain of 
L. monocytogenes underwent self-destruction in the cell cytosol when it 
produced a phage lysin under the control of the actA promoter, which is 
preferentially activated in the host cytosol (Yoshikawa et al., 2009). This 
demonstrated an efficient delivery strategy in transferring plasmids (after 
programmed bacterial lysis in the cytosol) from the bacteria into epithelial or 
endothelial cells.  
The success of gene therapy has been mainly hampered by the lack of efficient 
vectors that can target transgene expression to the right cells in vivo, but at the 
same time do not induce adverse effects or vector-specific immune responses. 
Bactofection is a serious alternative to counter the inability of non-replicating 
vectors to target specific tissue layers and also to facilitate cell to cell spread. 
The almost unlimited coding capacity that could be incorporated into a bacterial 
plasmid should allow the transfer of large genomic fragments and by using 
appropriate recombinant bacterial carriers, homologous recombination might 
also be possible. It has been shown that bactofection by Salmonella 
typhimurium can deliver plasmid encoding a tumor-expressed antigen that can 
lead to induction of humoral and cellular immune response in the host and 
provide a protective defence against the tumour (Xiang et al., 2000). In another 
study, treatment of malignant melanoma has been successfully achieved by 
combining classical gene therapy with Salmonella-mediated vaccination against 
murine VEGFR-2 (Lu et al., 2008). Here, synergism was achieved with oral 
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vaccination of the vaccine Salmonella strain combined with direct intratumoral 
injection of plasmid vector encoding the chemokine IP-10 (CXCL10) resulting in 
an anti-tumour effect. 
The development of bacteria as efficient transfer vehicles for the therapy of 
monogenic defects would appear to offer potential because although most of the 
bacterial therapeutic mechanisms of action are still being understood some are 
showing promising results in clinical trials. Listeria has long been considered for 
therapeutic agents using the anticancer-vaccination approach. In one study, 
safety of a live-attenuated L. monocytogenes that secreted the HPV16 E7 
antigen fused to the Listeria protein Listeriolysin O (LLO) has been demonstrated 
in a clinical phase I trial in patients with cervical cancer (Maciag et al., 2009) 
and phase II trials are in progress. This is an example of a promising future in 
implementing bactofection for anti-tumour therapy. 
The utilization of bacterial systems for therapeutic purposes is further enhanced 
by genetic modification of the vectors which makes them a very promising tool 
for targeted delivery of genes and their products. Alternative gene therapy 
(AGT) is based on bacterial protein delivery of bacterially-expressed therapeutic 
proteins to the host organism using genetically-modified bacteria. Pawelek et al. 
(1997) have shown that using hyperinvasive Salmonella can lead to accumulation 
of bacteria to high levels in individual organs and solid tumours. Furthermore, 
high levels of expression of transgenes have been observed in cells following 
plasmid transfer from bacteria (Darji et al., 2000). In AGT, bacteria persisting in 
target tissues produce the therapeutic polypeptide in situ, thus ideally providing 
a local distribution of drug without increasing its systemic levels. For this, 
primarily oncolytic or tumour-colonizing bacterial strains such as Clostridia, 
Bifidobacteria or Salmonella have been demonstrated to be useful for treatment 
(Zheng et al., 2000; Van Mellaert et al., 2006). 
In the future, a long term aim of the laboratory would be to apply bactofection 
in genetic vaccination against cattle diseases. Hence, in this study, one interest 
was to visualize intracellular trafficking of the plasmid in and out of the 
Pasteurella in the EBL cells. As mentioned in Chapter I, one of the vital 
components for bactofection is the expression plasmid. The plasmid DNA 
backbone needs to contain the requisite genes for optimal prokaryote 
propagation, selection, delivery and expression in eukaryotic cells. In order to 
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demonstrate this, the plasmid DNA must first be able to propagate in P. 
multocida B:2, second should preferably be able to express a reporter protein in 
Pasteurella and third should be able to express a reporter protein in mammalian 
cells. 
As discussed in section 4.2, the commercial eukaryotic expression plasmid, 
pEGFP-N1 was shown to replicate stably in P. multocida B:2. Transfection of 
pEGFP-N1 into an EBL monolayer showed EBL cells expressing GFP after 
incubation for 48 h (Figure 18). In addition, P. multocida B:2 JRMT12 harbouring 
this plasmid was observed to be able to release this plasmid in EBL cells in order 
to express GFP from the eukaryotic promoter. This was demonstrated when an 
infected EBL cell monolayer was shown to express GFP at 24 h post-invasion 
(Figure 19). According to the invasion data reported in section 3.2, bacteria 
were found intracellulary in EBL cells at 3 h post-invasion. TEM micrographs 
(Figure 11) showed P. multocida B:2 JRMT12 to reside in the vacuoles of the EBL 
cells. To visualize the fate of P. multocida B:2 JRMT12 pEGFP-N1+ in EBL cells, a 
reporter protein expressed by Pasteurella from a prokaryotic promoter was 
needed to be incorporated into the plasmid backbone. Hence, the strategy used 
was to recruit another Pasteurella promoter and prokaryote reporter gene into 
plasmid pEGFP-N1, in order to allow visualization of the bacterial strain 
intracellularly. 
Plasmid pMK-Express (Bossé et al., 2009) is a broad-host range plasmid that can 
propagate in HAP (Haemophilus, Actinobacillus & Pasteurella) bacteria. An A. 
pleuropneumoniae promoter, sodC, was incorporated into plasmid pMK-Express 
downstream of the gfpmut3 gene coding for GFP. It was found that this 
constitutive promoter was active and able to express the GFP protein from this 
promoter in Pasteurella (Bossé et al., 2009). Section 3.4.2.1 showed that the 
plasmid, pMK-Express, after electroporation into our strain, JRMT12, was stably 
propagated and that expression of GFP was visualized from P. multocida B:2 
JRMT12 pMK-Express+ when viewed under fluorescence microscopy (FM) (Figure 
21). The strategy in Figure 22 was used to recruit another prokaryotic reporter 
protein, in this case red fluorescent protein (RFP), to help differentiate 
prokaryotic and eukaryotic expression. Plasmid pMK-Express and plasmid 
pDsRed-Monomer were exploited to develop plasmid pMK-RED. After 
electroporation, P. multocida B:2 JRMT12 pMK-RED+ was observed to express RFP 
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by fluorimetry and also after FM viewing (Figures 23 & 24). FM imaging also 
shows localization of the bacteria after invasion of EBL monolayer (Figure 25). 
This confirmed the ability of P. multocida B:2 JRMT12 pMK-RED+ to utilize the 
prokaryotic sodC promoter to express rfp protein from the DsRed.M1 gene. 
In developing attenuated bacteria to mediate gene delivery or bactofection, 
most studies examined bacterial behaviour after entering mammalian cells. 
Although the principal of the delivery system is generally known, there are still 
differences observed among bacterial strains especially in the hostile 
environment inside mammalian cells. Bacteria such as S. flexneri, L. 
monocytogenes or E. coli, carrying the virulence plasmid of S. flexneri, invade 
their host cells and escape from a vacuole into the cytosol. Once in the cytosol 
they die for one of three reasons; they can be auxotrophic or conditionally 
express autolysins or are killed by the addition of antibiotics to the cultures. 
This result in lysis of the bacteria and the expression plasmids are released. 
Some of these plasmids find their way into the nucleus where the open reading 
frames are expressed under the control of the eukaryotic transcription elements 
(Grillot-Courvalin et al., 1998; Anderson et al., 2000; Darji et al., 2000; Hense 
et al., 2001). Bacteria such as S. typhimurium, S. typhi or E. coli expressing the 
invasion gene, inv of Y. pseudotuberculosis invade their host cells and remain in 
the vacuole. There they die due to metabolic attenuation and release their 
expression plasmids. By an unknown mechanism, these plasmids cross the 
vesicular membrane and reach the cell nucleus of the host cells where they are 
expressed (Leung & Finlay 1991; Grillot-Courvalin et al., 1998; Fennelly et al., 
1999). This technology has not only been demonstrated in mammalian cells. A 
plant pathogen, Agrobacterium tumefaciens, adheres tightly to its host cells via 
cellulose fibrils and contains a plasmid that encodes most of the apparatus that 
is necessary for transfer of an expression cassette also encoded by the plasmid. 
Although wounded plants are its natural targets, plasmid transfer by A. 
tumafaciens has also been demonstrated to yeast and fungi. In vitro, it can also 
target human cell lines (Kunik et al., 2001). This clearly demonstrated bacterial 
versatility as delivery vectors. 
The mechanism of Pasteurella entry into mammalian cells has thus far not been 
studied in detail. In order to help understand this in the vaccine strain, JRMT12, 
development of a plasmid with both prokaryotic and eukaryotic expression 
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systems using different reporter genes was developed as indicated in Figure 26. 
The “traffic light plasmid” termed pSRG was specifically developed to have the 
Pasteurella promoter, sodC, downstream of a DsRed.M1 gene coding for RFP 
together with the virally derived promoter, PCMVIE, for optimal expression in a 
eukaryote, downstream of the EGFP gene coding for GFP. The plasmid, pSRG, at 
5700 bp was successfully propagated and maintained stably in the vaccine strain, 
JRMT12, for at least 14 days without the present of selective antibiotic. 
Sequence confirmation of the sodRED fragment from pSRG is shown in Figure 32. 
Assessment of RFP expression through the bacterial growth curve showed that 
JRMT12, harbouring pSRG, expressed RFP at its maximum during the early 
exponential phase. 
Visualization of P. multocida B:2 JRMT12 pSRG+ was undertaken (section 
3.4.2.1). The 3D image showed P. multocida B:2 JRMT12 pSRG+ expressing RFP 
from individual bacteria and the counterstain with Cy5 Dye indicated the outline 
of the bacterial cells. All images demonstrated the ability of the mutant strain 
to express RFP from the sodC promoter. It was also observed that the majority 
of the bacteria were expressing RFP at this stage.   
Transfection of plasmid pSRG into an EBL monolayer promoted expression of GFP 
at 24 h post-transfection (Figure 35). After 24 h, only 67% cells were observed to 
express GFP, but more cells (up to 15% more) were observed to express GFP 
after 48 h. 3D images of the monolayer shows selected EBL cells with expressed 
GFP in the cytoplasm after the cell barrier was counterstained with Cell Mask™ 
plasma membrane stain. The images showed that there were areas within the 
cell barrier without GFP that can be presumed to be the nuclear compartment. 
This indicated that GFP expression only occured in the cytoplasm of the 
mammalian cells. It would be of interest to counterstain the nuclear 
compartment to confirm this and also to determine the duration of expression of 
the GFP in the EBL cells. 
The data discussed above showed the functionality of both the prokaryotic and 
eukaryotic promoters in the construct, pSRG, in two separate experiments. An 
invasion assay utilizing P. multocida B:2 JRMT12 pSRG+ was then done to monitor 
bacterial entry, plasmid release and protein expression within the mammalian 
cells after the standard 3 h invasion time and also at 5 h post-invasion (Figure 
36). At 3 h post-invasion bacteria were seen intracellularly when RFP expression 
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was detected below the cell surface. Fluorescence intensity increased as the 
sectioning moved deeper into the cell and decreased as it got nearer to the 
bottom surface of the EBL cell. This co-localization of RFP was again clearly 
demonstrated in the 3D-images. In some cells, localization of green fluorescence 
was shown to occur but only in the cytoplasm of the EBL cell and not in the 
nucleus. Thus, FM images suggested that, at 3 h post-invasion, RFP-expressing 
bacteria were found intracellulary in EBL cells. Some of these cells were 
expressing GFP indicating bacterial lysis and free plasmid being delivered into 
the cytoplasm. At this stage, 44% of the EBL cells analyzed were found to 
harbour rfp-expressing P. multocida B:2 JRMT12 pSRG+ but only 17% were 
expressing gfp. 
Images captured at 5 h post-invasion showed EBL cells to have a positive 
response in all fluorescent light paths. At this stage, it was very interesting still 
to see viable P. multocida B:2 JRMT12 pSRG+ in the EBL cells. This confirmed the 
data on intracellular survival of the bacteria which found that viable 
intracellular bacteria could still be detected from 3 h to 7 h post-invasion (Table 
12). However, this did not suggest that the bacteria were replicating in the 
vacuoles as the data in the table showed a gradual decrease in the number of 
viable bacteria in the EBL cells at 3 h to 7 h post-invasion. Also at this stage, 
some EBL cells with viable P. multocida B:2 JRMT12 pSRG+ were expressing GFP, 
an indicator of bacterial lysis and the presence of pSRG in the EBL cell 
cytoplasm. The 3D images created a better visualization of the model system to 
demonstrate localization of expression of each fluorescent protein.  
Other EBL cells captured at 5 h post-invasion responded negatively under the 
filter light path which detected RFP expression. Such cells were thus found to be 
Pasteurella-negative yet were expressing GFP. This suggested that all the 
internal bacteria were lysed and free plasmid DNA was delivered outside of the 
vacuoles. From 60 analyzed EBL cells at 5 h post-invasion, 53% were found to be 
expressing GFP yet 20% of those cells still harboured viable P. multocida B:2 
JRMT12 pSRG+ because they also expressed RFP. The 3D images showed 
localization of eukaryotic GFP expression in the cytosol of the EBL cell.            
A clear observation after standard invasion time (3 h) was that infected cells 
that expressed GFP could still harbour viable P. multocida B:2 JRMT12 pSRG+ 
expressing RFP. The phenomenon was also observed at 5 h post-invasion, but at 
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this stage the majority of the gfp expressing cells were Pasteurella-negative. 
This suggested that there was killing of the bacteria from an early stage of 
infection. As this continued, plasmid DNA was released and transferred from the 
vacuoles into the cytoplasm and then, presumably, delivered to the nuclear 
compartment by an unknown mechanism.  
Vacuolar compartments contain many enzymes that could degrade bacterial cells 
and constituents. Prevention of intravacuolar growth probably results from a 
combination of inhibitory factors including the acidic pH of the vacuole, the 
presence of lysosomal enzymes and the limited availability of nutrients such as 
iron (Byrd & Horwitz, 1989). The adaptation of other facultative intracellular 
pathogens to the vacuolar environment has been widely studied, especially for 
L. monocytogenes, S. flexneri and S. typhimurium. While Listeria and Shigella 
destroy or exit the initial membrane-bound vacuole and replicate in host cell 
cytoplasm, Salmonella is known to remain in the vacuole after entry into the 
host cell. Salmonella used for bactofection then die due to metabolic 
attenuation and release their expression plasmid into the host cytoplasm. It has 
also been shown that many of the bacterial pathogens which have evolved to 
grow within a vacuole manage to activate mechanisms to prevent acidification 
of the vacuole and/or the fusion of the vacuole with lysosomes (Falkow et al., 
1992).  
It is probable that, instead of replicating, Pasteurella JRMT12 was lysed in the 
vacuole compartment. Bacterial components might then be subjected to 
degradation by lysosomal enzymes and eventually processed for presentation to 
APCs to trigger an immune response. As with Salmonella, after lysis of P. 
multocida B:2 JRMT12 pSRG+, plasmid DNA was presumably transferred from the 
vacuolar compartment into the cytoplasm. FM observation showed infected EBL 
cells expressing GFP from plasmid pSRG at 3 h and 5 h post-invasion. 
Intriguingly, it will be interesting to understand the mechanism by which free 
plasmid DNA is excluded from degradation by lysosomal nuclease, DNase II, an 
acidic endonuclease that cleaves the phosphodiester bonds between the 
nucleotide subunits of nucleic acids. One study showed that plasmid DNA 
protection in a lysosomal compartment could be achieved by the presence of a 
bacterial acid nuclease inhibitor. Purified DMI-2, a polyketide metabolite of a 
Streptomyces strain that inhibits acid DNAse, was used in a transfection process. 
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It was found that DMI-2 conferred protection to the plasmid DNA from lysosomal 
hydrolysis after transfection into a lung adenocarcinoma cell line (Ross et al., 
1998). This suggests a possibility for Pasteurella to express acid nuclease 
inhibitors in vivo for protection against nuclease degradation. It would be 
interesting to study the response of Pasteurella bacterial components towards 
lysosomal enzymes in vitro.  
 A study with a diaminopimelate auxotroph mutant (dap-) of Shigella, or the 
same mutation in invasive E. coli, demonstrated the suicidal fate of the bacteria 
upon host-entry caused by their inability to synthesize cell wall (Sizemore et al., 
1997). The bacterial vectors harboured a eukaryotic expression plasmid, pCMVß, 
which synthesizes ß-galactosidase. More than one percent of invaded mammalian 
cells were found expressing transfected ß-galactosidase after 48 h of infection. 
Furthermore, introducing these bacterial strains intranasally into mice allowed 
detection of both humoral and cellular anti-ß-galactosidase responses. This study 
indicated that in vivo delivery of plasmid DNA by these bacterial strains 
stimulated immune responses to plasmid-encoded antigen. Yet, the transfer 
mechanism of plasmid DNA to the nucleus after bacterial cell lysis remains 
unexplained.  
Despite the ability of plasmid DNA to express antigen in mammalian cells, it 
apparently occurs in only a low percentage of cells. Employing a gene that 
mediates bacterial exit from the entry vesicle, such as the hly gene coding for 
listeriolysin O (LLO), could increase the number of plasmid DNA molecules 
released into the cytoplasm. In a recent study, a dap auxotroph strain of E. coli 
with a low-copy-number plasmid pGB2 which expressed the inv (Yersinia 
invasion) gene and the hly gene were transformed with a eukaryotic expression 
vector with a GFP reporter gene (Grillot-Courvalin, 2011). The bacteria, made 
invasive by possession of the inv gene, entered non-phagocytic cells expressing 
ß1-integrins and expression of LLO from the hly gene enabled the dap auxotroph 
strain of E. coli to escape the entry vesicle. 20% of infected HeLa, CHO and COS-
1 cells showed GFP expression by 48 h post-invasion. Bacteria were shown to 
localize in the cell phagolysosomes within 1-3 h, but viable intracellular bacteria 
were found to be completely eliminated at 72 h post-invasion. This study 
indicated that the genes incorporated in the low-copy-number plasmid pGB2 
showed functionality by increasing the number of eukaryotic expression plasmid 
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molecules delivered to the cytoplasm demonstrated by the percentage 
increment of GFP-expressing cells. It would be of interest to determine the 
optimal copy number of a plasmid DNA needed for maximum transcription and 
protein expression of heterologous proteins in the mammalian cells. It is a 
question as to whether the transfer of plasmid DNA from the cytoplasm to the 
nuclear compartment is a matter of hit and miss or whether the presence of 
multiple copies of the DNA would lead to biological pressure forcing the nucleus 
to take up more and more plasmid DNA. 
Future work on this project may want to improve visualization of Pasteurella 
after bactofection, from the entry mechanism up to bacteriolysis in the vacuoles 
and then the fate of plasmid DNA giving rise to protein expression. An obvious 
possibilitiy is via live-cell imaging. For FM live-imaging, an environmental 
chamber is attached to the microscope stage, providing a mechanism for viewing 
and imaging living cells on the stage while at the same time keeping the culture 
very close to the optimum growth conditions for extended periods of time. 
Recent availability of fluorescent protein dyes that can be visualized at various 
wavelengths and used simultaneously would certainly improve monitoring of 
cellular processes in living systems. Thus, microscopic imaging coupled with the 
advancing technology of fluorescent proteins as optical markers should provide 
ease of viewing during host-pathogen interactions. This is important in 
understanding the progression of a disease such as HS where bacteria must cross 
the epithelial cell layer to reach the blood stream. 
In order to visualize the attachment/adhesion process or the entry state of the 
fluorescence-expressing bacteria during in vitro infection of mammalian cells, 
the membrane can be labelled with plasma membrane stain and the 
cytoskeleton can be immunolabeled with fluorescent phalloidin such as Alexa 
Fluor 594-conjugated phalloidin (Kraning-Rush et al., 2011). Once the bacteria 
have been internalized in the cell, fusion of the lysosome with the vacuoles 
containing bacteria (bacterial compartment) can be detected when the lysosome 
is labelled with NBD-labeled calix[4]arene (NBDCalAm) (Mueller et al., 2011). 
Here, the period after invasion up to bacterial lysis can be followed. At the same 
time, the experiment could also recruit 4'-6-Diamidino-2-phenylindole (DAPI) 
stain which forms fluorescent complexes with natural double-stranded DNA. This 
would help to visualize the nuclear compartment of the mammalian cell. The 
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transfer mechanism of plasmid DNA from the vacuoles to the nucleus is 
uncertain and the possibility of tracking this is very intriguing. Employing a 
plasmid DNA stain such as Label IT® Tracker™ (Mirus Bio, USA) might allow the 
plasmid DNA movement when it is in the bacteria and its fate after bacterial cell 
lysis to be tracked. Two studies have visualized plasmid DNA during transfection 
before and after mammalian cell entry (Cohen et al., 2009; Watt et al., 2002). 
Manipulation of all the current technologies in fluorescence microscopy to 
enhance live-cell imaging would certainly make it possible to develop a better 
understanding of P. multocida B:2 infection.  
Other than that, the duration of bacterial invasion required to allow protein 
expression by mammalian cells could be monitored concurrently with the above 
experiments. Application of flow-cytometry for example, could provide data 
such as the concentration of plasmid DNA needed in the nuclear compartment to 
trigger mammalian target protein expression and concentration of the target 
protein expressed by the mammalian cells. Data such as this could also provide 
information on dosage-response of various tissues of the host towards the 
invading pathogen by determining the concentration of heterologous antigenic 
protein expression needed to trigger mammalian cell activation and to recruit 
APCs during the development of immune responses. 
4.4 Development of bacterial DNA vaccines 
Triggering immune responses for an effective vaccine or therapy will likely 
require humoral as well as cellular immunity. In that case, while a major 
impetus for the development of DNA vaccines has been to find a means to 
generate cellular immunity, any vaccine technology will also need to be able to 
generate T-cell help and a humoral response. Thus, it is essential to develop 
innate responses that activate the adaptive response for vaccine purposes (Liu, 
2011). The use of live attenuated bacteria as carriers for DNA vaccines 
(bactofection) shows a very promising approach. It has encountered major 
bottlenecks, such as difficulties in antigen expression, lack of post-translational 
modifications and batch-to-batch variability. Nevertheless, it possesses 
advantages such as built-in immune stimulatory properties which stimulate all 
three arms of adaptive immunity (antibodies, helper T cells and cytolytic T-
lymphocytes), allows specific targeting of plasmid to APCs, and amenability for 
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mucosal administration (Becker & Guzmán, 2008; Loessner et al., 2008; Liu, 
2011). Indeed, live-attenuated bacterial vaccine (LBV) may have features such as 
cellular tropism, cell-to-cell spread and dissemination within the body and these 
properties are controllable. Reviews on current LBV show that attenuation, with 
a deletion in a gene that is essential for metabolism, will not allow them to 
overcome the immune system of the host (Loessner et al., 2008). Methods such 
as nutrient deficiency, use of common antibiotics or inducible suicide genes 
could be introduced into the host for further control of the bacterium used 
(Curtiss, 2002). 
A successful carrier for a prophylactic vaccine requires certain criteria in order 
to elicit sufficient protection in vivo. Most of them have been mentioned above 
but added to these is the strength of antigen expression in the host. Although 
most eukaryote promoters have been codon optimized, antigen-encoding genes 
may also be modified to produce a protein that is secreted, membrane-bound, 
cytosolic or associated with an organelle (Haddad et al., 1997; Ashok & 
Rangarajan, 2002). Furthermore, in order to strengthen the end production of 
the LBV-bactofection (LBV-B) system, accommodating potential molecules with 
immunomodulatory properties (such as cytokines or chemokines) can augment 
the elicited immune responses against a plasmid encoded-antigen. One improved 
technology for the LBV-B system recruited interference RNA (RNAi) for gene 
silencing to induce vigorous cell apoptosis (Li et al., 2007) which could stimulate 
cell-mediated immune responses and/or divert them from the optimal response 
pattern. Another novel strategy to enhance the LBV-B system was shown to 
employ a direct translation system for RNA. This elegant approach was based on 
the genetic fusion, at the 5’-end of the mRNA, of an internal ribosome entry 
site, IRESEMCV element. A self-destructing L. monocytogenes used this system to 
directly deliver translation-competent mRNA into the cytosol which showed an 
earlier translation than when DNA plasmid alone was delivered (Loeffler et al., 
2006). Cytoplasmic delivery in vivo could also be enhanced with a helper plasmid 
DNA encoding several genes which enhance bacterial infection and intracellular 
lysis (refer to section 4.3). 
Thus, the transkingdom transfer of plasmid DNA has been systematically studied 
within the last two decades. The easy manipulation of DNA plasmids makes them 
rapid to construct and able to express critical attributes for making vaccines 
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against many emerging pandemic threats (Becker et al., 2008; Liu, 2011). In 
many research areas, LBV-B combining multiple components from various origins 
have been used to optimize such a system and, perhaps in the future, it is only a 
matter of pick-and-use in order to fulfil all requirements in tailoring an ideal 
vaccine or therapeutic carrier. However, rapid development of the LBV-B mostly 
accommodates the need for vaccine therapy for human diseases, and not many 
have been developed in the veterinary field especially for bovine diseases. Table 
15 below shows some licensed DNA vaccines employing DNA plasmids to elicit 
protection (Liu, 2011). These licensed vaccines include those for a viral disease 
in fish, a viral disease in horses, and an immunotherapeutic vaccine for cancer in 
dogs, as well as delivery of growth hormone to pigs. Proven efficacy of these 
DNA plasmids and their acceptance as licensed products together with a better 
understanding of why the plasmids are effective in these animals will, it is 
hoped, guide efforts to make DNA vaccines effective for bovine diseases.  
Table 16. Licensed veterinary products employing DNA plasmids. 
Year Label Company Indication Species Gene(s) 
encoded 
2005 West Nile-
Innovator® 
 
Fort Dodge 
Animal Health, 
Fort Dodge, IA, 
USA 
West Nile 
virus 
Horses PreM-E 
2005 Apex-IHN® Novartis Animal 
Health, Basel, 
Switzerland 
Infectious 
haematopoiet
ic necrosis 
virus 
Salmonid 
fish 
Glycoprotein 
2008 LifeTide® 
SW 5 
VGX™ Animal 
Health Inc., 
The 
Woodlands, TX, 
USA 
Increase litter 
survival 
Breeding 
sows 
Growth 
hormone 
releasing 
hormone 
2010 Oncept™ Merial, Lyon, 
France 
Melanoma Dogs Human 
tyrosinase 
Table based on the review by Liu, 2011. 
 
In order for the LBV-B system to find use for treatment of HS and other bovine 
diseases, some roadblocks should be overcome. It is essential to elucidate the 
underlying molecular events leading to DNA transfer from the bacteria to the 
cytosol and to the nucleus. This study has developed a tool to allow visualization 
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of P. multocida B:2 JRMT12 during and after mammalian cell invasion. Plasmid 
pSRG, constructed in this study, enabled tracking of protein expression and 
further use of modern synthetic molecule component such as fluorescent 
markers or DNA staining will promote further understanding on the fate of 
plasmid DNA after bacterial lysis. Analyzing further a possible P. multocida B:2 
immunosuppressive effect will help in understanding bacterial physiology during 
infection. It could be that this unique feature of the B:2 bacteria, to persist 
longer in vivo due to an immunosuppressive effect, might actually play a role in 
eliciting efficient expression of other immune responses in the host as suggested 
above. Finally, recruiting several immunomodulatory components or functional 
antigen molecules to combine into a Pasteurella LBV-B system would enhance its 
application as a versatile vaccine and provide a major contribution to veterinary 
science. 
The ultimate aim of the laboratory is to develop a DNA vaccine, via the LBV-B 
system, expressing heterologous protective antigen(s) from other bovine 
pathogens. Our interest would include vaccines that at present can only control 
but fail to eradicate the disease, for example, against Brucella abortus, a 
zoonotic Gram-negative pathogen that causes abortion and infertility in 
ruminants. It causes serious medical problems and severe economic losses for 
livestock producers. The ability of Brucella to maintain long-term residence 
intracellularly is associated with chronic infection (Gyles et al., 2010). It is not a 
commensal pathogen, thus maintenance of brucellosis in an animal requires 
continual infection of susceptible hosts. As a facultative intracellular parasite, 
Brucella remains enclosed in the phagosomal compartment. To survive in this 
hostile environment, the bacteria have developed a successful system for 
intracellular adaptation. Vaccination has proved to be an effective tool in 
controlling brucellosis but vaccination alone has not been effective in 
eradicating the disease (Nicoletti, 1990; Schurig et al., 2002). Current vaccines 
used live attenuated bacteria, including the B. abortus B19 strain, against 
bovine brucellosis and this has been shown to induce high levels of protection in 
cattle (Baldi et al., 1996). However this vaccine has several disadvantages: 
immune responses to the vaccine can interfere with diagnosis; it may result in 
abortions when administered to pregnant animals; it can be infectious for 
humans and has weak immunogenic properties (Schurig et al., 2002; Ashford et 
al., 2004; Shumilov et al., 2010). 
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Beside Brucella, another bovine pathogen of interest is Mycobacterium bovis. Its 
infection causes bovine tuberculosis which poses financial burdens and health 
risks for the cattle industry throughout the world. Studies have indicated that 
mycobacteria have evolved as pathogens to survive in macrophages and to 
overcome multifactorial hostile innate and acquired host immune mechanisms, 
so they can survive and eventually multiply and transmit to other animals 
(Schlesinger et al., 1990; Bartow & McMurray, 1998). The M. bovis Bacillus 
Calmette-Guerin (BCG) vaccine has been demonstrated to provide widely 
unpredictable efficacy in cattle (Buddle, 2001).  The inconsistencies suggested 
that protection conferred by BCG against bovine tuberculosis is influenced by 
the exposure of animals to environmental mycobacteria which interfere with the 
acquisition of full immunity after vaccination (Brandt et al., 2002). Vaccination 
against mycobacterium diseases enables a reduction in clinical signs and limits 
the spread of bacteria but is not sufficient to eliminate the infection (Buddle, 
2001). 
Studies have shown that BCG combined with certain subunit vaccines enhanced 
protection in animals when compared with BCG alone (Skinner et al., 2003; 
Wedlock et al., 2008). Several DNA vaccines have also been developed for these 
purposes. One was reported that by combining BCG with antigens expressed 
from a DNA vaccine, higher levels of protection against tuberculosis were 
induced than with BCG alone in a mouse model when the animals were 
sensitized to environmental mycobacteria before vaccination (Donnelly et al., 
2005). Another study of interest used a single combined DNA vaccine expressing 
antigens from B. abortus and M. bovis which elicited protective immunity in 
cattle against these two infectious diseases (Hu et al., 2009). In this study, 
plasmid DNA, pJW4303, incorporated coding regions from mycobacterial antigens 
(Ag85B, MPT64 and MPT83) and Brucella antigens (BCSP31, SOD and L7/L12) 
amplified from M. tuberculosis H37Rv and B. abortus strain 544 chromosomal 
DNA. BCSP31 is a 31 kDa protein; SOD is a Cu-Zn superoxide dismutase; and 
L7/L12 is a ribosomal protein. It was previously demonstrated that using these 
combined antigens in a DNA vaccine conferred protective immune responses in 
mice against B. abortus infections (Yu et al., 2007). AG85B is an antigen 
complex including 85A, B and C recognized by T-cells; MPT64 is antigen 
restricted to strains of M. tuberculosis and is found to stimulate T-cell 
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responses; and MPT83 is lipoylated and glycosylated protein that remains 
attached to the cell surface with exposure of some epitopes (Cai et al., 2005). 
It would be of interest to incorporate some or all these antigens addressing both 
diseases caused by these pathogens into our P. multocida system. Each gene 
would be amplified by PCR and cloned into pSRG to replace the GFP gene, 
placing these bacterial genes under the control of the eukaryotic promoter. It 
would need to be established initially that the antigen(s) were expressed in, for 
example, EBL cells by antibody detection before attempting to use the P. 
multocida B:2 JRMT12 carrier system to deliver plasmid DNA in mouse model of 
infection. If this was successful, our expectations would be for the model system 
to elicit protection in cattle against challenge with P. multocida B:2, M. bovis 
and/or B. abortus with a single vaccine. 
4.5 Possible immunosuppressive effect of P. multocida 
B:2 infection 
Bacterial pathogens, by definition, have acquired some ability to overcome host 
defence mechanisms (Brunham et al., 1993). A variety of bacterial components 
and products play different roles in modulating host immune reactions, most of 
them are stimulatory but a minority are inhibitory. It has been suggested that 
every component of bacteria with adjuvant activity can also impose suppressive 
effects on the immune system depending on timing, dose and selection of 
antigen (Schwab, 1975). Virulent Gram-negative bacteria (e.g. Salmonella, 
Shigella, Pseudomonas aeruginosa), which are able to cause septicaemia and 
endotoxaemia, affect the immune system by the suppression of phagocytosis and 
cell-mediated immunity (Vorob’ev et al., 2001). The in vitro immunomodulatory 
effects of P. multocida serotype D (the causative agent of atrophic rhinitis) was 
investigated in a study on mouse splenocytes. This study showed treatment of 
splenocytes with either purified porin or LPS stimulated IL-1α, IL-6, TNF-α, IFN-γ 
and IL-12 mRNA while no effect was detected on IL-4 and IL-10. It was concluded 
that these P. multocida components were able to modulate immunological 
responses by affecting the release of different cytokines (Iovane et al., 1998). 
The immunosuppressive properties of P. multocida D were also shown in another 
study where intranasal challenge of pigs and mice with a toxigenic strain or its 
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cell free extract (CFE) reduced the IgG response of these animals (Jordan et al., 
2003). 
It has been shown that outer membrane protein (OMP) preparation of P. 
multocida B:2 is antiphagocytic as it was able to interfere with phagocytosis of 
opsonised Candida albicans by murine peritoneal cells in vivo. It was suggested 
that the antiphagocytic mechanisms induced by OMP enhanced the virulence of 
the organism (Srivastava, 1998). The immunosuppressive effects of Yersinia, 
which is close taxonomically to Pasteurella, have been extensively studied and 
the mechanisms involved in T cell suppression have been revealed (Sing et al., 
2002). Yersinia pseudotuberculosis (the causative agent of gastroenteritis and 
lymphadenitis in humans) is likely to be in contact with lymphocytes in the 
intestinal Peyer’s patches, lymph nodes, spleen and liver in which the organism 
colonises and multiplies. Preliminary studies reported that T cells transiently 
exposed to Yersinia were suppressed for TCR (T cell receptor) stimulation (Yao 
et al., 1999). Further in vitro studies showed that YopH (Yersinia outer protein 
H), which was known as being antiphagocytic and had protein tyrosine kinase 
activity (Sing et al., 2002), specifically suppressed T cells by inhibiting the 
adaptor molecules LAT (linker for activation T cells) and SLP-76 (SH2-domain-
containing leukocyte protein of 76 kDa) (Gerke et al., 2005).  
Prior to the present study, Ataei (2007) investigated a possible contributory role 
of cellular immunity against HS in calves given single IM dose of 108 CFU on the 
JRMT12 vaccine strain and after challenge with the wild type P. multocida B:2 
strain 85020. Also, in lymphocyte stimulation assay, the effects of P. multocida 
infection on PBMC isolated from calves at different times after challenge were 
assessed. He observed a possible immunosuppressive effect of the challenge with 
P. multocida B:2 on the proliferation responses of calf PBMC to ConA. This 
observation does not appear to have been reported previously since the 
immunomodulatory effects of P. multocida B:2 have not been well studied.  In 
addition, Ataei (2007) assessed the possible immunomodulatory effect in vitro 
using a cell-free extract (CFE) from P. multocida B:2 85020. He demonstrated 
that 2 µg/ml was the optimal concentration of CFE in which peripheral blood 
mononuclear cells (PBMC) (5 x 104/ml) grew normally but where the proliferative 
response to concanavalin A (ConA) was suppressed. He also observed that ConA 
at 0.2 µg/ml was the optimum concentration with which PBMC were able to 
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proliferate strongly and the suppressive effect of CFE was also observed. In his 
experiments, it was shown that the proliferative response of normal PBMC to 
ConA was 60-100 times that of non-stimulated control cells and that it was 
markedly suppressed when PBMC were pre-incubated with the optimal 
concentration of CFE of P. multocida B:2 85020 for 1 h before adding the ConA. 
The addition of 85020 (wild-type) CFE caused a 3-5 fold decrease in the 
proliferative response of PBMC to ConA. Suppressive effects on PBMC were also 
tested with other strains of Pasteurella, Staphylococcus aureus and E. coli. Only 
CFE from P. multocida serotype D and A3 (causative agent of pneumonia in 
cattle) suppressed the PBMC proliferation response to ConA. However, the effect 
were less marked than that of the CFE from the B:2 strain. Ataei (2007) also 
suggested that the active part of the suppressive agent(s) was likely to be 
protein, as he showed that heating the CFE at 80°C for 5 min completely 
destroyed the suppressive properties. An OMP preparation of P. multocida B:2 
85020 markedly suppressed the proliferative response of PBMC to ConA. 
Furthermore, suppressive effects were not altered even after dialysis of the CFE 
at 10 000 Da cut-off.  
Based on previous data obtained in the laboratory by Ataei (2007), 
immunosuppression was a concern, especially in the development of JRMT12 as a 
potential vaccine strain. Hence, in this study, the vaccine strain, P. multocida 
B:2 JRMT12, as well as the parent strain, 85020, were used to assess their 
possible immunosuppressant effect on PBMC obtained from calves. In the first 
assay, CFE of JRMT12 was compared with CFE of 85020 which had been used 
previously by Ataei (2007). In agreement with Ataei (2007), it was shown that in 
the absence of CFE, PBMC showed a similar high proliferation to all three 
concentrations of ConA, whereas little proliferation was observed without ConA. 
This mitogen, ConA, belongs to the family of lectins (carbohydrate-binding 
proteins derived from plants and bacteria). It has potent T-cell mitogenic 
activity and has been extensively used to study the in vitro lymphocyte response 
(Mukherjee et al., 2005). However, the exact mechanism involved of T cell 
proliferation in vitro by ConA is poorly understood. A dose-dependent 
suppression of PBMC proliferation was observed when PBMC were pre-exposed to 
different concentration of CFE from JRMT12. This showed that attenuation of 
this mutant strain did not alter the presence of component(s) responsible for 
suppressing PBMC proliferation. The parent strain 85020 was reported to harbour 
Discussion 
197 
major immunogenic proteins of 37 and 50 kDa (predicted to be OmpA and OmpH 
respectively) in an outer membrane protein (OMP) preparation (Ataei et al., 
2009) which corroborated to other studies reporting similar results on 
immunogenic proteins of P. multocida B:2 (Pati et al., 1996; Verma & Jaiswal, 
1997; Malik & Monga, 2002).  
The strain JRMT12 has been reported to act as an effective live-attenuated 
vaccine strain to protect calves against challenge with the virulent parent strain, 
85020. Protection against experimental HS was observed when two doses 
intramuscularly were given to the animal at 4 weeks apart (Hodgson et al., 2005; 
Dagleish et al., 2007). In these studies, they found out that, after primary 
vaccination with the JRMT12 strain, an acute phase protein response and an 
increase in rectal temperature were observed, indicating that the bacteria 
persisted long enough to promote an inflammatory response. These data indicate 
that the vaccine strain had immunogenic proteins equivalent to those of the 
parent strain sufficient for it to promote protection after challenge. It would be 
interesting to verify the existence of OmpA and OmpH in JRMT12, as OMP in 
Yersinia have been shown to have immunosuppressive effects on T cells which 
could account for the resistance of the bacterium to immunity elements in the 
host (Yao et al., 1999; Sing et al., 2002; Gerke et al., 2005). This observation of 
immunosuppressive effects of OMP of P. multocida may be applicable to 
understanding the pathogenicity of this organism and the development of the 
immune response during infection.    
However, in the present study, many discrepancies between experiments were 
observed. During the initial assay, CFE of the mutant strain, JRMT12 was 
assessed in parallel with CFE of the wild-type, 85020 which had been used 
previously by Ataei (2007) in his study and stored at -80°C. The results obtained 
showed an unclear pattern of dose-dependence for the CFE of 85020 in inhibiting 
PBMC proliferation. There was an inconsistent suppression of PBMC proliferation, 
especially after pre-incubation with CFE at 20 µg/ml. Even at 10 µg/ml, PBMC 
proliferation was not highly suppressed as was observed with the CFE from the 
mutant strain or as reported by Ataei (2007). It was concluded, that putative 
active components responsible for proliferation inhibition in the CFE might be 
labile and subject to deterioration with time and conditions of storage. Thus 
assessments were continued using freshly prepared CFE from the wild-type and 
Discussion 
198 
the vaccine strains. Again, consistent results were not obtained. One repeat 
assay  showed a dose-dependant suppression of lymphocyte proliferation in 
response to ConA by CFE from JRMT12, similar to the first assay, but CFE from 
85020 still did not show a clear suppressive effect. The inconsistency of the data 
was disappointing and further work is required to understand the reasons why 
the active component(s) of CFE apparently vary in concentration or activity. 
Difficulties in obtaining fresh blood from calves prevented further investigation 
of this phenomenon. If the reported immunosuppression of P. multocida and its 
component is a real effect not an artefact, the mechanism of this process 
requires further investigation. One possible approach would be to assess the 
interaction of live P. multocida B:2 bacteria with PBMC, as demonstrated earlier 
in this study with other mammalian cells. 
Immunosuppression of PBMC by CFE in vitro could probably be an artefact of 
disruption in relation to the receptor binding between the PBMC with ConA that 
trigger and accelerate proliferation. Ataei (2007) suggested that CFE suppressive 
properties in vitro are more likely to be clinically reflected as a chronic 
manifestation, yet in HS, the disease is usually acute. Although P. multocida B:2 
is known as the causative agent of HS, the organism exists in the tonsils and 
nasopharynx of some apparently healthy carrier cattle and buffaloes (De Alwis, 
1999). Carrier status is actually a chronic infection with the bacterium but how 
the organism survives in the carrier host tonsils, which are in close contact with 
lymphatic organs, is not yet understood. In this and the Ataei (2007) study, in 
vitro experiments showed that P. multocida contains a component(s) with the 
potential to inhibit PBMC. The suppressive properties of the organism would be a 
possible explanation of its survival in carrier animals. Other possible 
consequences of immunosuppression can be in converting a latent carrier to an 
active carrier. In the active carriers, the bacterium is present in the nasopharynx 
and, from this site, is shed in nasal secretions. Latent carriers harbour the 
organism in tonsils in which the bacterium is believed to multiply and 
intermittently spill over into nasopharynx (De Alwis, 1990). The mechanisms 
involved in converting a latent carrier to an active carrier have not been 
revealed. It was shown that stressful conditions and even administration of 
immunosuppressive preparations (dexamethasone and methylprednisolone 
acetate) were not able to cause latent carriers to shed the organism in their 
nasal secretions (De Alwis, 1999).   
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Ataei (2007) went on to examine the specific suppression of B cell and T cell 
subpopulations (CD4+, CD8+ and γδ+) in normal calf PBMC using fluorescence 
activated cell sorter (FACS) analysis. Cell populations were identified by indirect 
immunofluorescence staining of corresponding cell markers using mouse 
monoclonal antibodies against them as primary antibody and FITC-conjugated 
goat antibodies specific for the mouse Ig isotype as the secondary antibody. This 
experiment revealed the proliferative status of each population by assessing the 
ratio of proliferating and non-proliferating fractions. From this analysis, Ataei 
(2007) found that CD4+ and CD8+ T cells were the principal cells which 
proliferated in response to ConA and whose proliferation was suppressed by a 
CFE of P. multocida B:2. ConA increased the percentage of proliferating CD4+ T 
cells by 10-fold compared to the control cells, but CFE treatment before 
addition of ConA allowed only a 3-fold increase. Yet, the suppression of CD4+ T 
cells was not due to an adverse toxic effect of CFE on the cells, as CFE alone did 
not decrease the number of these cells. Mitogen stimulation of lymphocytes in 
vitro is believed to mimic stimulation by specific antigens fairly closely. 
Stimulation of T cell receptors with ConA induces a signal transduction pathway 
which stimulates IL-2 secretion and up-regulation of the α subunit of the IL-2 
receptor, CD25 (the ß and γ subunits are constitutively expressed). Secreted IL-2 
functions in an autocrine and paracrine manner by binding to the full receptor 
(α, ß and γ subunits) to initiate proliferation of stimulated lymphocytes (Peltier 
et al., 2008). IL-2 is a crucial element in cell-mediated immune responses both 
in vivo and in vitro; in cattle, IL-2 levels can be used to measure specific cellular 
immune responses (Miller-edge & Splitter, 1986). Stimulation of bovine lymph 
node cells with ConA causes a biphasic IL-2 secretion. The first phase of IL-2 
production occurs after 3 h and the second phase between 10 and 16 h. This 
study also showed the accumulation of IL-2 mRNA before each phase of IL-2 
secretion (Weinberg et al., 1988). In the 2-signal model of mitogen activation of 
T cells, the first signal occurs with mitogen and monocytes (another population 
of cells in PBMC) which cause the production of the second signal that is IL-2 
(Gelfand et al., 1985). IL-1, which is secreted by monocytes, acts as the first 
signal and induces the expression of IL-2 receptors in a subpopulation of T cells 
which, after activation by IL-2, culminates in DNA synthesis and proliferation of 
these cells (Conti 1991; Conti et al., 1991). In vitro experiments on bovine PBMC 
have indicated that monocytes are necessary for optimum stimulation of T cells 
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(Pontarollo et al., 2002). According to the 2-signal model of T cell activation, 
suppression could be at the point of IL-2 secretion and/or induction of CD25. The 
mechanism of suppression by ovine uterine serpin (OvUs; an immunosuppressive 
protein secreted by the ewe uterus during pregnancy) on the proliferative 
response of PBMC has been investigated. This study showed that OvUs inhibited 
ConA-induced expression of CD25 in γδ- cells but not γδ+ T cells. The study also 
revealed that OvUs suppressed lymphocyte proliferation by blocking CD25 
expression. It was also suggested that the lack of suppressive effect of OvUs on 
ConA stimulated CD25 expression in γδ+ T cells may indicate a different 
mechanism of activation of these cells or insensitivity to inhibition by OvUs 
(Peltier et al., 2008). This study supports a role for CD25 in the suppression 
observed in the Ataei (2007) in vitro experiments, where P. multocida CFE was 
shown to inhibit the proliferative response in γδ- T cells (including CD4+ and CD8+ 
T cells) but not γδ+ T cells. 
Interactions between host cells and pathogens are extremely complex and the 
involvement of multiple inter-dependent pathways in signalling and regulatory 
systems has made it very difficult to study these interactions. Therefore, it is 
difficult to predict the combined behaviour by just investigating the interactions 
between bacteria and individual components of the immune system. However, 
further investigation in this area could be informative and helpful in 
understanding the process of disease development by providing information on 
mechanisms that the pathogen uses to overcome or escape the host immune 
system. It would also be useful to know if the immunosuppressive effects of P. 
multocida B:2 CFE and OMP were reproducible because they could have a 
bearing on the efficacy of an attenuated B:2 aroA strain inducing rapid and 
sustained immune responses. Thus observations make this area of study 
important but the inconsistency in the data obtained needs to be investigated 
further. In this regard, it should be noted that Hodgson et al. (2005) observed 
only a low antibody response after primary vaccination of calves with P. 
multocida B:2 JRMT12 and only after a secondary booster vaccination, 4 weeks 
later, was a high IgG response obtained. This delay in response to vaccination 
(with P. multocida) had been noted previously (Chandrasekaran et al., 1994; 
Shah & Graaf, 1997) and may be related to the possible immunosuppressive 
effects of P. multocida B:2. The corollary of any immunosuppressive effect is 
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that it may allow the attenuated strain to persist longer in the host and thus 
allow more time for a protective immune response to eventually develop. 
4.6 Summary and conclusions 
Both P. multocida B:2 strains were capable of adhering to and invading J774.2, 
BL-3 and EBL cells. All of the Pasteurella and Mannheimia strains tested were 
able to adhere to EBL cells but only B:2 strains were taken up intracellularly in 
significant numbers. The vaccine strain, JRMT12, was found to survive 
intracellularly in EBL cells for at least 7 hours and the invasion inhibition assay 
suggested that its entry into the cells was by an actin-dependent process. 
Transmission electron micrographs showed that JRMT12 resided in the vacuolar 
compartments of the EBL cells.  
A novel ‘traffic light’ expression plasmid, pSRG, was created. P. multocida B:2 
JRMT12 was shown by fluorescence microscopy to be able to express the 
reporter protein, red fluorescent protein, from the prokaryotic expression 
system of this plasmid and this was used to monitor the viability and 
intracellular location of the bacterium. Expression of green fluorescent protein 
from the eukaryotic expression system of pSRG demonstrated the ability of the 
plasmid to be delivered from the intracellular environment of the bacterium into 
the intracellular environment of the eukaryotic cell. This, in principal, has 
shown a potential use of the vaccine strain as a vehicle for the intracellular 
delivery of protective antigens (bactofection).  
A reported immunosuppressive effect of P. multocida B:2 on lymphocyte 
proliferation was investigated because of its relevance to any future use of the 
JRMT12 strain for immunization purposes. However, the results were not 
consistently reproducible and further investigation in this area would be 
desirable.  
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APPENDIX 
Appendix 1 
Media composition 
Brain Heart Infusion (BHI) broth or agar 
1 litre 
Brain Heart Infusion, dehydrated (Oxoid) 37.0 g 
Distilled water     to 1 litre 
Autoclaved at 15 p.s.i. for 15 min. For solid medium, 1.2% (w/v) micro agar 
(Technical No. 3, OXOID) was added before autoclaving. 
 
Luria Bertani broth (LB) or agar 
1 litre          
Tryptone (Duchefa Biochemie)     10 g   
Yeast extract (Duchefa Biochemie)     5 g 
Sodium chloride (Analar, BDH)     10 g 
Add 1.2% micro agar (Duchefa Biochemie) for making solid media and then 
autoclaved at 15 p.s.i. for 15 min. 
 
Preparation of LB-X-Gal-IPTG plated 
20 mg of X-Gal (5-bromo-4-chloro-3-indolyl-ß-D-galactosidase, Sigma) was 
dissolved per ml in dimethyl formamide (DMSO, Sigma) and stored at –20°C. 
200 mg of IPTG (isopropyl-ß-D-thiogalactopyranoside, Sigma) was dissolved per 
ml in distilled water and stored at –20°C 
One ml of X-Gal and 100 µl of IPTG stock solution (it give 100 µg/ml final 
concentration of each) were added to 200 ml of melted LB agar, mixed by gentle 
rotation or inversion of the bottle and poured into petri dishes. 
 
Terrific broth or agar 
A) Basal medium 
To 900 ml of distilled water were added: 
Tryptone   12 g 
Yeast extract  24 g 
Glycerol    4 ml 
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For solid medium, 1.2% (w/v) agar (Technical No. 3, OXOID) was added before 
autoclaving. 
B) Additive 
To 100 ml of distilled water were added: 
KH2PO4    2.31 g 
K2HPO4  12.54 g 
Both basal medium and additive were made up separately, sterilised at 15 p.s.i 
for 15 minutes. They were mixed together just before use. 
 
SOC medium 
1 litre 
Tryptone (Duchefa Biochemie)     10 g 
Yeast extract (Duchefa Biochemie)     5 g 
Salt I (250 mM KCl, 1M NaCl)     10 ml 
After autoclaving at 15 p.s.i, add 10 ml of 2M sterile glucose and 10 ml of Salt II 
(1M MgCl2.6H2O, 1M MgSO4.7H2O) 
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Appendix 2 
 
Preparation of antibiotic solutions 
Stock solutions of antibiotics were made at the following concentrations (% w/v): 
ampicillin (1%), kanamycin (1%) and chloramphemicol (1%). Chloramphenicol was 
dissolved in ethanol. All other antibiotics were dissolved in distilled water and 
filter sterilised by passing the solution through an Acrodisc of 0.45 µm pore size 
(Milipore). All antibiotic solutions were stored at -20°C 
 
 
Phosphate-buffered saline (PBS) 
Sodium chloride     128 mM 
Potassium chloride     2.7 mM 
Potassium di-hydrogen orthophosphate  1.5 mM 
di-potassium hydrogen phosphate  5.0 mM 
 
 
Tris-Borate-EDTA (TBE) buffer 
(5 x stock solution) 
1 litre 
Tris-base      54 g 
Boric acid      27.5 g 
EDTA (0.5 M stock) pH 8.0    20 ml 
 
 
DNA loading buffer 
(6 x stock solution) 
Tris       60 mM 
EDTA       6 mM 
Sucrose      40% 
Bromophenol blue     0.25% 
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DNA ladder 
Quick-Load™ 1 kb DNA Ladder   Quick-Load™ 100 bp DNA Ladder  
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Appendix 3 
QIAprep® Spin Miniprep Kit for plasmid DNA purification. 
The kit (cat. nos. 27104 and 27106) can be stored at room temperature (15–
25°C) for up to 12 months. More information in QIAprep Miniprep Handbook, 
December 2006 at www.qiagen.com/handbooks. All centrifugation steps are 
carried out at 13,000 rpm in a conventional table-top centrifuge. 
1. Pellet 1–5 ml bacterial overnight culture by centrifugation at >8000 rpm (6800 
x g) for 3 min at room temperature (15–25°C). 
2. Resuspend pelleted bacterial cells in 250 µl Buffer P1 and transfer to a 
microcentrifuge tube. 
3. Add 250 µl Buffer P2 and mix thoroughly by inverting the tube 4–6 times until 
the solution becomes clear. Do not allow the lysis reaction to proceed for 
more than 5 min. If using LyseBlue reagent, the solution will turn blue. 
4. Add 350 µl Buffer N3 and mix immediately and thoroughly by inverting the 
tube 4–6 times. If using LyseBlue reagent, the solution will turn colorless. 
5. Centrifuge for 10 min at 13,000 rpm (~17,900 x g). 
6. Apply the supernatant from step 5 to the QIAprep spin column by decanting or 
pipetting. Centrifuge for 30–60 s and discard the flow-through. 
7. Recommended: Wash the QIAprep spin column by adding 0.5 ml Buffer PB. 
Centrifuge for 30–60 s and discard the flow-through. 
8. Wash the QIAprep spin column by adding 0.75 ml Buffer PE. Centrifuge for 30–
60 s and discard the flow-through. Transfer the QIAprep spin column to the 
collection tube. 
9. Centrifuge for 1 min to remove residual wash buffer. 
10. Place the QIAprep column in a clean 1.5 ml microcentrifuge tube. To elute 
DNA, add 50 µl Buffer EB (10 mM TrisCl, pH 8.5) or water to the center of 
the QIAprep spin column, let stand for 1 min, and centrifuge for 1 min. 
11. Plasmid DNA is stored in -20°C till further used. 
 
QIAquick® Gel Extraction Kit for purification of DNA from agarose gel. 
The QIAquick Gel Extraction Kit (cat. nos. 28704 and 28706) can be stored at 
room temperature (15–25°C) for up to 12 months. More information in QIAquick 
Spin Handbook, March 2008 at www.qiagen.com/handbooks. All centrifugation 
steps are carried out at 17,900 x g (13,000 rpm) in a conventional table-top 
centrifuge. 
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1. Excise the DNA fragment from the agarose gel with a clean, sharp scalpel. 
2. Weigh the gel slice in a colorless tube. Add 3 volumes Buffer QG to 1 volume 
gel (100 mg ~ 100 µl). For >2% agarose gels, add 6 volumes Buffer QG. 
3. Incubate at 50°C for 10 min (or until the gel slice has completely dissolved). 
Vortex the tube every 2–3 min to help dissolve gel. 
4. After the gel slice has dissolved completely, check that the color of the 
mixture is yellow If the color of the mixture is orange or violet, add 10 µl 3 M 
sodium acetate, pH 5.0, and mix. The color of the mixture will turn yellow. 
5. Add 1 gel volume of isopropanol to the sample and mix. 
6. Place a QIAquick spin column in a provided 2 ml collection. 
7. To bind DNA, apply the sample to the QIAquick column and centrifuge for 1 
min. Discard flow-through and place the QIAquick column back into the 
tube. 
8. If the DNA will subsequently be used for sequencing, add 0.5 ml Buffer QG to 
the QIAquick column and centrifuge for 1 min. Discard flow-through and 
place the QIAquick column back into the same tube. 
9. To wash, add 0.75 ml Buffer PE to QIAquick column and centrifuge for 1 min. 
Discard flow-through and place the QIAquick column back into the tube. 
10. Centrifuge the QIAquick column once more in the provided 2 ml collection 
tube for 1 min at 17,900 x g (13,000 rpm) to remove residual wash buffer. 
11. Place QIAquick column into a clean 1.5 ml microcentrifuge tube. 
12. To elute DNA, add 50 µl Buffer EB (10 mM TrisCl, pH 8.5) or water to the 
center of the QIAquick membrane and centrifuge the column for 1 min. For 
increased DNA concentration, add 30 µl Buffer EB to the center of the 
QIAquick membrane, let the column stand for 4 min, and then centrifuge for 
1 min. 
QIAquick® PCR Purification Kit for cleaning up DNA after PCR. 
The QIAquick PCR Purification Kit (cat. nos. 28104 and 28106) can be stored at 
room temperature (15–25°C) for up to 12 months. More information in QIAquick 
Spin Handbook, March 2008 at www.qiagen.com/handbooks. All centrifugation 
steps are carried out at 17,900 x g (13,000 rpm) in a conventional table-top 
centrifuge at room temperature. 
1. Add 5 volumes Buffer PB to 1 volume of the PCR reaction and mix. If the color 
of the mixture is orange or violet, add 10 µl 3 M sodium acetate, pH 5.0, and 
mix. The color of the mixture will turn yellow. 
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2. Place a QIAquick column in a provided 2 ml collection. 
3. To bind DNA, apply the sample to the QIAquick column and centrifuge for 30–
60 s. Discard flow-through and place the QIAquick column back in the tube. 
4. To wash, add 0.75 ml Buffer PE to the QIAquick column centrifuge for 30–60 s. 
Discard flow-through and place the QIAquick column back in the tube. 
5. Centrifuge the QIAquick column once more in the provided 2 ml collection 
tube for 1 min to remove residual wash buffer. 
6. Place each QIAquick column in a clean 1.5 ml microcentrifuge tube. 
7. To elute DNA, add 50 µl Buffer EB (10 mM TrisCl, pH 8.5) or water (pH 7.0–
8.5) to the center of the QIAquick membrane and centrifuge the column for 1 
min. For increased DNA concentration, add 30 µl elution buffer to the center 
of the QIAquick membrane, let the column stand for 1 min, and then 
centrifuge. 
 
MinElute® Reaction Cleanup Kit for cleaning DNA after enzymatic reactions. 
The MinElute Reaction Cleanup Kit (cat. nos. 28204 and 28206) can be stored at 
room temperature (15–25°C) for up to 12 months. Store spin columns at 2–8°C 
upon arrival. More information in the MinElute Handbook which can be found at 
www.qiagen.com/handbooks. This protocol is for cleanup of up to 5 µg DNA (70 
bp to 4 kb) from enzymatic reactions. All centrifugation steps are carried out at 
17,900 x g (13,000 rpm) in a conventional table-top centrifuge at room 
temperature (15–25°C). 
1. Add 300 µl Buffer ERC to the enzymatic reaction (sample volume 20–100 µl) 
and mix. If the enzymatic reaction is in a volume of <20 µl, adjust the volume 
to 20 µl. If the enzymatic reaction exceeds 100 µl, split your reaction, add 
300 µl Buffer ERC to each aliquot, and use the appropriate number of 
MinElute columns. 
2. Check that the color of the mixture is yellow (similar to Buffer ERC without 
the enzymatic reaction). If the color of the mixture is orange or violet, add 10 
µl 3 M sodium acetate, pH 5.0, and mix. The color of the mixture will turn to 
yellow. 
3. Place a MinElute column in a provided 2 ml collection tube. 
4. Apply sample to the MinElute column and centrifuge for 1 min. Discard flow-
through and place the MinElute column back into the tube. 
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5. Add 750 µl Buffer PE to the MinElute column and centrifuge for 1. Discard 
flow-through and place the MinElute column back into the same collection 
tube. 
6. Centrifuge the column in a 2 ml collection tube (provided) for 1 min. Residual 
ethanol from Buffer PE will not be completely removed unless the flow-
through is discarded before this additional centrifugation. 
7. Place each MinElute column into a clean 1.5 ml microcentrifuge tube. 
8. To elute DNA, add 10 µl Buffer EB (10 mM TrisCl, pH 8.5) or water to the 
center of the MinElute membrane. (Ensure that the elution buffer is dispensed 
directly onto the membrane for complete elution of bound DNA.) Let the 
column stand for 1 min, and then centrifuge the column for 1 min. 
 
PROMEGA pGEM®-T Easy Vector Systems 
Cloning PCR Products with pGEM®-T Easy Vectors 
Ligation Using 2X Rapid Ligation Buffer 
1. Briefly centrifuge the pGEM®-T Easy Vectors and Control Insert DNA tubes to 
collect contents at the bottom of the tube. 
2. Set up ligation reactions as described below. Vortex the 2X Rapid Ligation 
Buffer vigorously before each use. Use 0.5 ml tubes known to have low DNA 
binding capacity. 
 
3. Mix the reactions by pipetting. Incubate the reactions 1 hour at room 
temperature. Alternatively, incubate the reactions overnight at 4°C for the 
maximum number of transformants. 
Transformation into High Efficiency Competent E. coli Cells 
1. Prepare LB/ampicillin/IPTG/X-Gal plates. 
2. Centrifuge the ligation reactions briefly. Add 2 µl of each ligation reaction to 
a sterile 1.5 ml tube on ice. Prepare a control tube with 0.1 ng of uncut 
plasmid. 
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3. Place the High Efficiency Competent E. coli Cells in an ice bath until just 
thawed (5 minutes). Mix cells by gently flicking the tube. 
4. Carefully transfer 50 µl of cells to the ligation reaction tubes from Step 2. Use 
100 µl of cells for the uncut DNA control tube. Gently flick the tubes and 
incubate on ice for 20 min. 
5. Heat-shock the cells for 45–50 seconds in water bath at exactly 42°C. DO NOT 
SHAKE. Immediately return the tubes to ice for 2 minutes. 
6. Add 950 µl room temperature SOC medium to the ligation reaction 
transformations and 900 µl to the uncut DNA control tube. Incubate for 1.5 
hours at 37°C with shaking (~150 rpm). 
7. Plate 100 µl of each transformation culture onto duplicate 
LB/ampicillin/IPTG/X-Gal plates. For the uncut DNA control, a 1:10 dilution 
with SOC is recommended.  
8. Incubate plates overnight at 37°C. Select white colonies. 
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Appendix 4 
Cell culture 
J774.2 or BL-3 complete medium 
Heat-inactivated FBS (Sigma, UK)            10% (v/v) 
L-glutamine (Gibco, UK)             1% (v/v) 
Penicillin/Streptomycin (Sigma, UK)     1% (v/v) 
Fungizone (Amphotericin B) (Gibco, UK)     1% (v/v) 
Add RPMI (1640) medium (Sigma, UK)    up to 200 ml 
J774.2 or BL-3 assay medium 
As above but without antibiotics and fungizone.  
 
EBL complete medium 
Heat-inactivated FBS (Sigma, UK)            10% (v/v) 
L-glutamine (Gibco, UK)             1% (v/v) 
Penicillin/Streptomycin (Sigma, UK)     1% (v/v) 
Fungizone (Amphotericin B) (Gibco, UK)     1% (v/v) 
Add MEM (M2279) medium (Sigma, UK)     up to 200 ml 
EBL assay medium 
As above but without antibiotics and fungizone. 
 
Cell counting using a haemocytometer  
As manufacturer’s instructions (www.abcam.com/technical). 
Preparing haemocytometer  
1. Ensure the haemocytometer is clean using 70% ethanol.  
2. Moisten the shoulders of the haemocytometer and affix the coverslip using 
gentle pressure and small circular motions. The phenomenon of Newton’s 
rings can be observed when the coverslip is correctly affixed, thus the depth 
of the chamber is ensured.  
Preparing cell suspension  
1. Make sure the cell suspension to be counted is well mixed by either gentle 
agitation of the flask containing the cells (or other appropriate container).  A 
serological pipette may be used if required. 
2. Before the cells have a chance to settle take out about 1 ml of cell suspension 
using a serological pipette and place in an eppendorf tube.  
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3. Using a 100 µl pipette, mix the cells in this sample again (gently to avoid 
lysing them). Take out 100 µl and place into a new eppendorf, add 100 µl 
trypan blue and mix gently again.  
Cell counting  
1. Using the pipette, draw up some cell suspension containing trypan blue.  
Carefully fill the haemocytometer by gently resting the end of the pipette tip 
at the edge of the chambers.  Take care not to overfill the chamber.  Allow 
the sample to be drawn out of the pipette by capillary action, the fluid should 
run to the edges of the grooves only. 
2. Focus on the grid lines of the haemocytometer using the x10 objective of the 
microscope. Focus on one set of 16 corner squares (shown below). 
 
3. Using a hand tally counter, count the number of cells in this area of 16 
squares. When counting, always count only live cells that look healthy 
(unstained by Trypan Blue). Count cells that are within the square and any 
positioned on the right hand or bottom boundary line. Dead cells stained blue 
with trypan blue can be counted separately for a viability count. 
4. Move the haemocytometer to another set of 16 corner squares and carry on 
counting until all 4 sets of 16 corner squares are counted. 
5. The haemocytometer is designed so that the number of cells in one set of 16 
corner squares is equivalent to the number of cells x 104 /ml 
    Therefore, to obtain the count: 
The total count from 4 sets of 16 corner =  
[(cells/ml x104) X 4 squares from one haemocytometer grid] 
Divide the count by 4, and then multiply by 2 to adjust for the 1:2 dilutions in 
trypan blue. These two steps are equivalent to dividing the cell count by 2. 
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Viability 
1. The trypan blue is used to stain any dead cells. Cells looking faint or dark blue 
within the grid being counted are counted as dead cells. To check the viability 
of the cells requires: 
• Live cell count (not including trypan blue cells) 
• Total cell count including those stained with trypan blue. 
Live cell count    = % Viability 
            Total cell count 
 
Concanavalin A (ConA) 
ConA (Sigma, UK)        5 mg 
RPMI 1640 (Sigma, UK)               10 ml 
Aliquot of 200 µl kept in -20°C. Before use, mixed with 800 µl of RPMI 1640. 
 
Red blood cell (RBS) lysis buffer 
(10 x stock solution), pH 7.4 
NH4Cl                   1.5 M 
NaHCO3                  0.1 M 
diNaEDTA                  1 mM 
dH2O                   900 ml 
Wash buffer  
FBS            2% 
Penicillin/Streptomycin         1% 
Hank’s balance salt solution (HBSS) (Sigma, UK)     98 ml 
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Appendix 5 
 
Plasmid DNA 
 
pAKA 16 (Azad et al., 1994) 
 
 
 
pDsRed-Monomer (ClonTech, USA) 
 
 
pMK-Express (Bossé et al., 2010) 
 
 
 
pMC-Express (Bossé et al., 2010) 
 
 
pCMV-sCRIPT (Stratagene, UK) 
 
 
pEGFP-N1 (ClonTech, USA) 
 
 
 
pMK-Express 
7299 bp 
pMC-Express 
7299 bp 
